<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Pharm Sin B</journal-id><journal-id journal-id-type="iso-abbrev">Acta Pharm Sin B</journal-id><journal-id journal-id-type="pmc-domain-id">2814</journal-id><journal-id journal-id-type="pmc-domain">apsb</journal-id><journal-title-group><journal-title>Acta Pharmaceutica Sinica. B</journal-title></journal-title-group><issn pub-type="ppub">2211-3835</issn><issn pub-type="epub">2211-3843</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12750178</article-id><article-id pub-id-type="pmcid-ver">PMC12750178.1</article-id><article-id pub-id-type="pmcaid">12750178</article-id><article-id pub-id-type="pmcaiid">12750178</article-id><article-id pub-id-type="pmid">41477324</article-id><article-id pub-id-type="doi">10.1016/j.apsb.2025.09.043</article-id><article-id pub-id-type="pii">S2211-3835(25)00654-9</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Ferroptosis meets cancer immunotherapy: Overcoming the crosstalk challenges through advanced drug delivery strategies</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Gan</surname><given-names initials="L">Lu</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Lin</surname><given-names initials="X">Xincheng</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Zhong</surname><given-names initials="Z">Ziqiao</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Zheng</surname><given-names initials="Y">Yichun</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xinyi</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Chen</surname><given-names initials="J">Jun</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Yue</surname><given-names initials="X">Xiao</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yingshan</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Pan</surname><given-names initials="X">Xin</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Wu</surname><given-names initials="C">Chuanbin</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Ying</given-names></name><email>huangy2007@163.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Wang</surname><given-names initials="W">Wenhao</given-names></name><email>whwang97@yeah.net</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>a</label>State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Jinan University, Guangzhou 511443, China</aff><aff id="aff2"><label>b</label>College of Pharmacy, Jinan University, Guangzhou 511443, China</aff><aff id="aff3"><label>c</label>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China</aff><aff id="aff4"><label>d</label>Jiangmen Wuyi Hospital of Traditional Chinese Medicine, Affiliated Jiangmen Traditional Chinese Medicine Hospital of Jinan University, Jiangmen 529031, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding authors. <email>huangy2007@163.com</email><email>whwang97@yeah.net</email></corresp><fn id="fn1"><label>&#8224;</label><p id="ntpara0010">These authors made equal contributions to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>03</day><month>10</month><year>2025</year></pub-date><volume>15</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">503376</issue-id><fpage>6307</fpage><lpage>6341</lpage><history><date date-type="received"><day>27</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>16</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>31</day><month>12</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-01 09:25:13.190"><day>01</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>The integration of ferroptosis induction with cancer immunotherapy has emerged as a promising approach in oncology, offering dual mechanisms to overcome therapeutic resistance and tumor heterogeneity. Nevertheless, the dynamic and complicated crosstalk between ferroptosis processes and immune regulation in tumor microenvironments presents both opportunities and challenges. By inducing lipid peroxidation in tumor tissues, ferroptotic tumor cell death can stimulate immunogenicity. Nevertheless, excessive lipid peroxidation may paradoxically impair the functionality of multiple immune cells, thereby presenting crosstalk challenges in therapeutic strategies. To address these crosstalk challenges, several advanced drug delivery strategies have been proposed, such as immunostimulatory active pharmaceutical ingredients co-delivery, tumor-targeted delivery, and stimuli-responsive delivery. These drug delivery strategies demonstrate dual therapeutic efficacy by synergistically potentiating ferroptosis induction in malignant cells while concurrently mitigating immunotoxicity and even augmenting antitumor immunity. This review offers detailed insights into the crosstalk between ferroptosis and tumor immunity, along with a guiding overview of the three delivery strategies. The current obstacles and translational potential were thoroughly analyzed, providing valuable perspectives for future research.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p>Three advanced drug delivery strategies, including ISAPIs co-delivery, tumor targeted delivery, and stimuli-responsive delivery strategies for overcoming the crosstalk challenges of ferroptosis and cancer immunotherapy are summarized.<fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>Cancer</kwd><kwd>Ferroptosis</kwd><kwd>Immunotherapy</kwd><kwd>Immune cells</kwd><kwd>Crosstalk challenges</kwd><kwd>Tumor targeted delivery</kwd><kwd>Immunostimulatory active pharmaceutical ingredients co-delivery</kwd><kwd>Stimuli-responsive delivery</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Cancer is a class of diseases characterized by uncontrolled cellular proliferation and dysregulated differentiation, leading to the formation of localized masses, invasion of adjacent tissues, and metastasis to distant organs <italic toggle="yes">via</italic> the bloodstream or lymphatic system<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref>. According to the latest data from the International Agency for Research on Cancer, approximately 20 million new cancer cases and nearly 10 million cancer-related deaths were reported globally in 2022, with lung, breast, colorectal, and prostate cancers being the most prevalent types<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref>. Current therapeutic approaches encompass surgical resection, radiotherapy, chemotherapy, and immunotherapy. Among these, immunotherapy has emerged as a revolutionized approach due to its advantages in immune persistence, specificity, broad applicability, and synergistic potential, distinguishing it from conventional treatments<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>.</p><p id="p0015">Specifically, immunotherapy operates by modulating or enhancing the patient's immune system to recognize and eliminate malignant cells. Key mechanisms of immunotherapy include alleviating immunosuppression (<italic toggle="yes">e.g.</italic>, blockade of immune checkpoints such as PD-1/PD-L1 and CTLA-4), activating immune effector cells, and remodeling the tumor microenvironment (<italic toggle="yes">e.g.</italic>, targeting regulatory T cells or tumor-associated macrophages)<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref>. Current immunotherapeutic strategies include immune checkpoint inhibitors (<italic toggle="yes">e.g.</italic>, pembrolizumab and ipilimumab), adoptive cell therapies (<italic toggle="yes">e.g.</italic>, CAR-T and tumor-infiltrating lymphocyte therapy), cytokines (<italic toggle="yes">e.g.</italic>, IL-2 and IFN-<italic toggle="yes">&#945;</italic>), bispecific antibodies, and cancer vaccines<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref>. Recent advancements have introduced novel approaches such as T-cell immunoreceptors with Ig and ITIM domains inhibitors and personalized neoantigen vaccines into clinical trials<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref>.</p><p id="p0020">The high specificity of cancer immunotherapy arises from immune recognition of tumor-specific antigens, necessitating antigen release to stimulate immune cell maturation and differentiation<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref>. Therefore, to amplify therapeutic efficacy, combination strategies integrating tumor ablation with immunotherapy have been proposed, such as chemo-immunotherapy, radio-immunotherapy, photo-immunotherapy, and ferroptosis-immunotherapy. While chemo-immunotherapy leverages chemotherapeutic agents to enhance tumor antigen release and immune activation, radio- and photo-immunotherapy employ physical modalities (radiation or laser ablation) to achieve similar effects<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>. These therapies possess distinct advantages and have made significant contributions to the ongoing fight against cancer in humans.</p><p id="p0025">In recent years, ferroptosis-immunotherapy has emerged as a promising strategy to address therapeutic resistance and tumor heterogeneity in malignant cancers. Ferroptosis, an iron-dependent form of regulated cell death, is characterized by lipid peroxide (LPO) accumulation and suppression of glutathione peroxidase 4 (GPX4) activity<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref>. Ferroptosis-immunotherapy combines ferroptosis inducers with immunotherapeutic agents to simultaneously trigger tumor cell ferroptosis and potentiate antitumor immune responses<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>. The core mechanism involves ferroptosis-induced tumor cell lysis, which releases tumor-associated antigens and damage-associated molecular patterns (DAMPs), thereby eliciting immunogenic cell death (ICD) and synergizing with immunotherapeutic agents such as immune checkpoint inhibitors or cellular therapies to achieve durable antitumor effects<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>. For instance, representative agents such as Erastin (Er)<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>, Sorafenib<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref>, and the GPX4 inhibitor RSL3<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> induce lipid peroxidation through mechanisms involving glutathione (GSH) depletion and GPX4 activity inhibition. Meanwhile, pharmacological agents, including Artesunate<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref>, statins<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref>, and ammonium ferric citrate, promote ferroptosis by disrupting intracellular iron homeostasis to facilitate ROS generation <italic toggle="yes">via</italic> the Fenton reaction. Besides, IFN-<italic toggle="yes">&#947;</italic> released by CD8<sup>+</sup> T cells during the anti-tumor immune response induces ferroptosis in tumor cells, demonstrating the interaction and mutual influence between ferroptosis and immune responses<xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>. Unlike apoptosis induced by chemotherapy or radiotherapy, ferroptosis circumvents apoptotic resistance mechanisms and effectively eliminates therapy-resistant cancer stem cells, which are often drivers of recurrence and metastasis<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref>. Moreover, ferroptosis inducers exhibit selectivity for tumor cells with dysregulated lipid metabolism or elevated iron-related protein expression, minimizing off-target toxicity<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref>. Critically, ferroptosis-induced ICD activates dendritic cells (DCs), enhances antigen presentation, and synergizes with immunotherapy to amplify systemic antitumor immunity, positioning ferroptosis-immunotherapy as a highly promising therapeutic paradigm.</p><p id="p0030">However, although ferroptosis-immunotherapy demonstrates significant therapeutic potential, the interplay between ferroptosis and immune responses is complex and bidirectional. On one hand, ferroptosis in tumor cells stimulates immune activation, while ferroptosis in immune cells has been demonstrated to impair immunological responses<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>. Conversely, immune cells can modulate tumor cell sensitivity to ferroptosis through either enhancement or suppression mechanisms, thereby influencing therapeutic outcomes of ferroptosis-immunotherapy<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref>. Consequently, precision drug delivery strategies can selectively enhance ferroptosis in tumor cells while minimizing potential damage to immune cells, which constitutes a prerequisite for optimizing the efficacy of combined ferroptosis-immunotherapy regimens. Current research has documented multiple drug delivery strategies for ferroptosis-immunotherapy, primarily including immunostimulatory active pharmaceutical ingredients (ISAPIs) co-delivery, tumor-targeted delivery, and stimuli-responsive delivery. These strategies have demonstrated remarkable anti-tumor efficacy through distinct mechanisms. Immune-stimulating API co-delivery enables immunomodulatory targeting through coordinated delivery of ferroptosis inducers and immune-activating agents, facilitating tumor eradication and sustained anti-tumor immunity. Tumor-targeted delivery achieves preferential tumor accumulation <italic toggle="yes">via</italic> either enhanced permeability and retention (passive targeting) or ligand-receptor interactions (active targeting), effectively inhibiting tumor progression. Stimuli-responsive delivery utilizes endogenous/exogenous physical triggers (<italic toggle="yes">e.g.</italic>, pH, redox, ion, or light) to achieve spatiotemporal control of drug release, thereby minimizing systemic toxicity while enhancing therapeutic precision. Each strategy exhibits unique advantages in oncology applications. This review will provide a comprehensive analysis of their mechanisms, clinical applications, and future development directions in ferroptosis-immunotherapy.</p><p id="p0035">To investigate the development of ferroptosis-immunotherapy and its drug delivery strategies, a literature survey was conducted based on the Web of Science by the search query, &#8220;ferroptosis AND immunity AND drug delivery systems&#8221;. The results revealed that approximately 321 publications in this field were published over the past 6 years. The first paper in this field was published in 2019, indicating that the field is emerging and gaining significant attention. Notably, the year 2024 was the peak of the number of publications, and &#8220;article&#8221; was the main publication type. The number of citations related to ferroptosis-immunotherapy and its drug delivery strategies has been steadily increasing in recent years, with a count of nearly 3981 citations for the year 2024. The papers published by the researchers from China accounted for 291. Additionally, the top 5 journals that have published papers on ferroptosis-immunotherapy and its drug delivery strategies include <italic toggle="yes">Chemical Engineering Journal</italic>, <italic toggle="yes">Advanced Healthcare Materials</italic>, <italic toggle="yes">ACS Nano</italic>, <italic toggle="yes">Advanced Science</italic> and <italic toggle="yes">Journal of Nanobiotechnology</italic>. A majority of these journals pertain to the field of materials science, likely since numerous ongoing studies are centered on the development of novel materials for constructing drug delivery systems aimed at ferroptosis-immunotherapy. This observation signifies a growing emphasis and interest in this field. Thus, it is necessary to summarize and analyze the current publications on ferroptosis-immunotherapy and its drug delivery strategies, enabling the scientific community to gain the latest development direction and research focus in this field.</p></sec><sec id="sec2"><label>2</label><title>The interplay between ferroptosis and tumor immunity</title><p id="p0040">Ferroptosis differs from apoptosis, necrosis and autophagy in morphology, biochemistry and genetics. It cannot be inhibited by inhibitors of apoptosis, pyroptosis, or autophagy, but can be inhibited by iron chelators and antioxidants<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref>. In addition, ferroptotic cells also typically display hallmark features including decreased cell volume, mitochondrial shrinkage, and compromised cell membrane integrity. Besides, it's noteworthy that ferroptosis inducers exhibit better selectivity compared to chemotherapy drugs capable of inducing ICD in tumor cells to activate immune responses. These inducers can overcome drug resistance and hold potential for synergistic therapeutic strategies. Ferroptosis inducers typically target tumor cells selectively, as these cells are characterized by high fatty acid content and increased sensitivity to ferroptosis<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref>. In contrast, their impact on normal cells is relatively minimal, thereby reducing collateral damage to healthy tissues. Additionally, certain tumor cells develop resistance to conventional chemotherapeutic agents, such as apoptosis inducers. However, ferroptosis inducers may circumvent this resistance through alternative signaling mechanisms, including the inhibition of GPX4<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref>. Furthermore, the combination of ferroptosis inducers with immune-stimulatory agents, such as immune checkpoint inhibitors, can markedly potentiate anti-tumor immune responses. Representative ferroptosis inducers and their therapeutic mechanisms are summarized in <xref rid="tbl1" ref-type="table">Table 1</xref><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref>, <xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref>.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Ferroptosis inducers and their therapeutic mechanisms.</p></caption><alt-text id="alttext0065">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Type of ferroptosis inducers</th><th colspan="1" rowspan="1">Representative drug</th><th colspan="1" rowspan="1">The therapeutic mechanism</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="5" colspan="1">Micromolecule</td><td colspan="1" rowspan="1">Erastin and its derivatives, sorafenib, sulfasalazine</td><td colspan="1" rowspan="1">Decrease intracellular GSH levels by inhibiting the key protein SLC7A11 of the system Xc<sup>&#8722;</sup>, blocking the uptake of cystine, thereby weakening the antioxidant activity of GPX4 and eventually triggering lipid peroxidation</td><td colspan="1" rowspan="1"><xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref></td></tr><tr><td colspan="1" rowspan="1">RSL3, dGPX4, FIN56, ML162, ML210, cisplatin</td><td colspan="1" rowspan="1">Inhibit or degrade GPX4 to make it inactive or reduce its content, leading to the inability to reduce lipid peroxides, thereby triggering lipid peroxidation of cell membranes</td><td colspan="1" rowspan="1"><xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref></td></tr><tr><td colspan="1" rowspan="1">iFSP1</td><td colspan="1" rowspan="1">Inhibit FSP1 activity and reduce coenzyme Q10 production</td><td colspan="1" rowspan="1"><xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref></td></tr><tr><td colspan="1" rowspan="1">Artemisinin, Artesunate, Palatinib, FINO2, tBOOH</td><td colspan="1" rowspan="1">Induction of lipid peroxidation <italic toggle="yes">via</italic> iron or PUFA overload</td><td colspan="1" rowspan="1"><xref rid="bib49" ref-type="bibr">49</xref>,<xref rid="bib50" ref-type="bibr">50</xref></td></tr><tr><td colspan="1" rowspan="1">Fentomycin-1</td><td colspan="1" rowspan="1">Activation of lysosomal iron leading to phospholipid oxidative degradation</td><td colspan="1" rowspan="1"><xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref></td></tr><tr><td colspan="1" rowspan="1">Macromolecule</td><td colspan="1" rowspan="1">Lipoxygenase</td><td colspan="1" rowspan="1">Direct oxidation of PUFA generating lipid peroxides</td><td colspan="1" rowspan="1"><xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref></td></tr><tr><td rowspan="4" colspan="1">Nano-composites</td><td colspan="1" rowspan="1">High-density lipoprotein-like nanoparticles</td><td colspan="1" rowspan="1">Reduce TXNRD1 expression and the cells' utilization of selenium to diminish the synthesis of selenoproteins such as GPX4. Enhance ACSL4-dependent PUFA membrane phospholipid synthesis to provide critical substrates for ferroptosis</td><td colspan="1" rowspan="1"><xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref></td></tr><tr><td colspan="1" rowspan="1">Ruthenosomes</td><td colspan="1" rowspan="1">Targeting mitochondria and inducing ferritin autophagy to release iron ions, driving lipid peroxidation and ferroptosis</td><td colspan="1" rowspan="1"><xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref></td></tr><tr><td colspan="1" rowspan="1">Iron nanoparticles</td><td colspan="1" rowspan="1">Direct induction of lipid peroxidation through surface catalysis</td><td colspan="1" rowspan="1"><xref rid="bib52" ref-type="bibr">52</xref>,<xref rid="bib53" ref-type="bibr">53</xref></td></tr><tr><td colspan="1" rowspan="1">Gold nanoparticles</td><td colspan="1" rowspan="1">Generate local high heat through surface plasmon resonance effect, or produce ROS through surface catalysis, thereby indirectly promoting ferroptosis</td><td colspan="1" rowspan="1"><xref rid="bib54" ref-type="bibr">54</xref>,<xref rid="bib55" ref-type="bibr">55</xref></td></tr></tbody></table><table-wrap-foot><fn><p>GPX4, glutathione peroxidase 4; PUFA, polyunsaturated-fatty-acid; ACSL4, long-chain-fatty-acid-CoA ligase 4.</p></fn></table-wrap-foot></table-wrap></p><p id="p0045">Ferroptosis is a form of regulated cell death induced by iron-dependent lipid peroxidation<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref>. Its defining characteristic is the abnormal accumulation of intracellular iron ions, particularly Fe<sup>2+</sup>, along with excessive production of LPO, which ultimately leads to structural damage of the cell membrane and subsequent cell death<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref>. The System&#8211;GSH&#8211;GPX4 signaling axis plays a central role in this process (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). System Xc<sup>&#8722;</sup>, also known as the cystine/glutamate antiporter, facilitates the cellular uptake of cystine, which is essential for the synthesis of GSH. GSH serves as a crucial cofactor for GPX4, an enzyme that protects cells from oxidative stress by neutralizing LPO. Inhibition of System Xc<sup>&#8722;</sup>, such as by erastin, results in reduced GSH levels and impaired GPX4 activity, thereby promoting LPO and initiating ferroptosis<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref>. Additionally, iron overload is a key driver of ferroptosis. Iron enters the cell <italic toggle="yes">via</italic> transferrin receptor-mediated uptake and is subsequently reduced to Fe<sup>2+</sup>
<italic toggle="yes">in vivo</italic>. Fe<sup>2+</sup> catalyzes the conversion of hydrogen peroxide into highly reactive hydroxyl radicals through the Fenton reaction, further accelerating lipid peroxidation. Moreover, the degradation of iron storage proteins, such as ferritin, <italic toggle="yes">via</italic> a selective autophagic process termed ferritinophagy, contributes to elevated Fe<sup>2+</sup> levels, thereby enhancing ferroptotic cell death<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).<fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>The top section illustrates the molecular mechanism underlying ferroptosis. The bottom-left section shows ferroptosis involved in antitumor immunity. And the bottom-right section depicts ferroptosis involved in immunosuppression.</p></caption><alt-text id="alttext0015">Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0050">The tumor microenvironment (TME) constitutes a multifaceted ecosystem consisting of tumor cells, immune cells, stroma cells, and other cells. These components not only coexist but also engage in intricate interactions that significantly influence tumor growth and progression<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref><sup>,</sup><xref rid="bib61" ref-type="bibr"><sup>61</sup></xref>. Compared with apoptosis, necrosis and autophagy, ferroptosis exerts a more complex influence on immune regulation, exhibiting a bidirectional interaction with the immune system. On one hand, ferroptosis in cancer cells may initiate or modulate immune responses in the TME (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). On the other hand, the susceptibility of immune cells in the TME to ferroptosis varies significantly, and different immune cell types can either promote or suppress ferroptosis in cancer cells<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). This distinct characteristic highlights the unique role of ferroptosis in immune regulation as compared to apoptosis, necrosis and autophagy. Subsequently, we would classify the interaction between tumor ferroptosis and immune cells to elucidate this intricate relationship more comprehensively.</p><sec id="sec2.1"><label>2.1</label><title>The effect of tumor ferroptosis on immune cells</title><p id="p0055">The impact of tumor ferroptosis on the immune system is highly complex, with even contradictory research findings reported. Ferroptosis may serve as a form of ICD, which is driven by stress stimuli and can induce adaptive immunity against dead cell antigens<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref>. Not only do cell death-related antigens activate immune responses, but ICD is also accompanied by the release of a multitude of DAMPs during ferroptosis. These DAMPs, including calreticulin exposed on the cell surface, high-mobility group protein 1 (HMGB1) secreted by tumor cells, adenosine triphosphate (ATP) released by cells, and heat shock proteins (such as HSP70 and HSP90), among others, can bind to pattern recognition receptors on antigen-presenting cells (APCs) and enhance the efficiency of macrophage phagocytosis of ferroptotic cancer cells, thereby activating immune responses<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="bib62" ref-type="bibr"><sup>62</sup></xref>. In addition to the aforementioned conventional DAMPs, ferroptosis tumor cells further release a subset of their characteristic DAMPs. For instance, the oxidized phospholipids (PL), such as 1-stearoyl-2-15-HpETE-<italic toggle="yes">sn</italic>-glycero-3-PE, located on the cell surface of ferroptotic cancer cells, can be recognized by Toll-like receptor 2 (TLR2) on macrophages, promoting their engulfment<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref>. Wen et al.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> investigated the HMGB1 release mechanism of ferroptotic cancer cells, where HMGB1 was a DAMP that could be released by ferroptotic cells in an autophagy-dependent manner. Mechanistically, inhibition of autophagy-mediated histone deacetylase promoted HMGB1 acetylation, leading to HMGB1 release during ferroptosis. HMGB1 induced macrophage inflammation and released TNF through the AGER pathway. Additionally, it was reported that HMGB1 could upregulate cyclooxygenase 2 (COX2) and transferrin expression <italic toggle="yes">via</italic> the RAS&#8211;JNK/p38 pathway, promoting erastin-induced ferroptosis<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref>. These interactions not only drive macrophages to polarize towards the M1 phenotype but also promote T-cell infiltration and activity within tumors. They can even trigger vaccine-like responses, activating antitumor immunity<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref>. Conversely, inhibiting ferroptosis results in reduced T cell infiltration and activity in the TME, ultimately dampening T cell-mediated antitumor responses.</p><p id="p0060">However, it is noteworthy that some studies have suggested that ferroptotic cancer cells may hinder DCs maturation, thereby affecting their antigen-presenting capacity<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref>. PL peroxidation products generated by the 12/15-lipoxygenase reaction in ferroptotic cancer cells, or other lipid peroxidation by-products, such as 4-hydroxynonenal, appear to impair DCs maturation and function<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref>. The interaction between ferroptotic cancer cells and DCs may depend on the stage of ferroptosis. It has been reported that during the early stages of ferroptosis, cancer cells trigger DC maturation; however, in the later stages, although DCs can effectively engulf these late-stage ferroptosis cells, their ability to promote DC maturation is reduced<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref>. Overall, the impact of ferroptosis on antitumor immune responses is dual-edged. While it exhibits characteristics of ICD by releasing DAMPs to induce immune cell maturation, it also affects immune cell function and immune responses due to its unique properties, such as the production of PL peroxidation products.</p></sec><sec id="sec2.2"><label>2.2</label><title>The effect of immune cells on tumor ferroptosis</title><p id="p0065">Immune cells within the TME can influence the sensitivity of cancer cells to ferroptosis by enhancing or inhibiting it. For instance, Wang et al.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> discovered that activated CD8<sup>+</sup> T cells during tumor immunotherapy could enhance ferroptosis-specific lipid peroxidation levels within tumor cells, thereby increasing their sensitivity to ferroptosis. Further research revealed that the Interferon-gamma (IFN-<italic toggle="yes">&#947;</italic>) released by CD8<sup>+</sup> T cells has a dual impact on cancer cell ferroptosis. On one hand, IFN-<italic toggle="yes">&#947;</italic> downregulates the expression of solute carrier family 3 member 2 (SLC3A2) and solute carrier family 7 member 11 (SLC7A11) on the tumor cell surface through the JAK&#8211;STAT1 pathway. SLC3A2 and SLC7A11 are two subunits of the glutamate&#8211;cysteine antiporter System Xc<sup>&#8210;</sup>, which impairs tumor cell cystine uptake, thereby enhancing lipid peroxidation and ferroptosis<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref>. On the other hand, IFN-<italic toggle="yes">&#947;</italic> upregulates the expression of long-chain-fatty-acid-CoA ligase 4 (ACSL4), promoting the synthesis of ACSL4-mediated polyunsaturated-fatty-acid-PL (PUFA-PL) (especially those containing arachidonic acid). Therefore, IFN-<italic toggle="yes">&#947;</italic> promotes ferroptosis by inhibiting the cell's defense against it and amplifying the metabolic activities driving the process. However, despite IFN-<italic toggle="yes">&#947;</italic> enhancing tumor cell ferroptosis, studies have also shown that it promotes tumor dormancy, and edits tumor cell immunosuppression, leading to tumor evasion and recurrence<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref>.</p><p id="p0070">In the TME, tumor-associated macrophages (TAMs) primarily exhibit an immunosuppressive M2 phenotype<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref>. An extensive tumor immunological study aims to clear M2 TAMs and/or convert them into a more anti-tumor M1 phenotype. Recent studies have shown that M1 TAMs exhibit greater resistance to ferroptosis compared to M2 TAMs<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref>. The elevated levels of inducible nitric oxide synthase in M1 TAMs can produce more nitric oxide radicals (NO&#183;), which can inhibit 15-lipoxygenase, resulting in a resistance to ferroptosis comparable to GPX4<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref>. Additionally, NO&#183; has membrane diffusibility, which can confer ferroptosis resistance to cells surrounding M1 macrophages<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref>. Exosomes secreted by adipose tissue macrophages containing miR-140-5p can target SLC7A11 in cardiomyocytes, inhibiting reduced glutathione synthesis and inducing ferroptosis in cardiomyocytes, providing a new therapeutic strategy for obesity-induced cardiac damage<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref><sup>,</sup><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref>. Furthermore, studies have found that TAM-secreted TGF-<italic toggle="yes">&#946;</italic>1 regulates the expression of hepatic leukemia factor in triple-negative breast cancer through SMAD3, which transactivates gamma-glutamyl transferase 1 (GGT1)<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref>. GGT1 catalyzes the decomposition of extracellular glutathione, providing cysteine for intracellular glutathione synthesis, enhancing GPX4 activity and the tumor cell's resistance to ferroptosis.</p><p id="p0075">Moreover, other immune cells also have a significant impact on ferroptosis. For example, in a glioblastoma mouse model driven by PDZ-binding motifs, neutrophils transfer myeloperoxidase (MPO) into tumor cells through direct cell contact or close contact, inducing tumor cell lipid peroxidation and promoting ferroptosis<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref>.</p><p id="p0080">In summary, ferroptosis and the immune response in the TME have complex interactions, which can both enhance anti-tumor immunity and suppress immune reactions. In practical therapeutic applications, how to utilize the positive effects of ferroptosis on the immune response while avoiding its negative impacts has become an important topic in tumor cell ferroptosis therapy.</p></sec></sec><sec id="sec3"><label>3</label><title>Delivery strategies for ferroptosis-immunotherapy therapy</title><p id="p0085">The analysis above shows that ferroptosis has a complex interaction with the immune response in the TME. It is crucial for tumor treatment to enhance the synergy between ferroptosis therapy and immunotherapy, avoiding the interference of ferroptosis with the immune response. It is of great importance to develop drug delivery strategies for the combination of ferroptosis and immunotherapy.</p><p id="p0090">Therefore, many drug delivery strategies loaded with ferroptosis inducers have been developed, and ISAPIs co-delivery strategy, tumor targeted delivery strategy and stimuli-responsive delivery strategy have become mainstream.</p><sec id="sec3.1"><label>3.1</label><title>ISAPIs co-delivery</title><p id="p0095">As previously discussed, several studies have manifested that inducing ferroptosis is capable of activating the anti-tumor innate immune response and further augmenting the therapeutic efficacy of ferroptosis<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref><sup>,</sup><xref rid="bib76" ref-type="bibr"><sup>76</sup></xref>. However, as research advances, it has become increasingly evident that ferroptosis may not only be inadequate in activating innate immunity in the early stage of ferroptosis (characterized by the intact membrane) but could also potentially impair immune cells to a certain extent. For example, CD8<sup>+</sup> T cells are susceptible to ferroptosis, and the IFN-<italic toggle="yes">&#947;</italic> released by them may upregulate PD-L1 expression in tumor cells and induce inflammatory immunosuppression. Consequently, to compensate for the insufficiency of the immune system in ferroptosis-immune therapy, one of the most straightforward and simplistic strategies is to incorporate ISAPIs into the ferroptosis induction system, thereby positively eliciting an effective, long-lasting, and profound anti-tumor immune response<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref>.</p><p id="p0100">To achieve that end, an increasing number of immune-stimulating agents have emerged, effectively enhancing the immune activation effect induced by ferroptosis: (1) Augment the innate immune response. During the advanced stage of ferroptosis, antigen presentation was insufficient. To overcome this deficiency, agonists of STING and TLR, as well as blockers of indoleamine 2,3-dioxygenase (IDO) and CD73, among others, can be encapsulated to enhance the intensity of the anti-tumor immune response by strengthening the functions of macrophages, DCs, or natural killer (NK) cells<xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref>. (2) Enhance adaptive immunity: The direct or indirect negative impacts of ferroptosis on tumor-specific effector T cells can be counterbalanced by the addition of T-cell-associated immune checkpoint inhibitors (such as PD-1 monoclonal antibodies or CTLA-4 antibodies)<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref>. (3) Inhibit the formation of immunosuppressive microenvironment: IDO blockers, TGF-<italic toggle="yes">&#946;</italic> blockers and COX2/PEG inhibitors are employed to block immunosuppressive signals, inhibit tumor fibrosis, angiogenesis and alleviate hypoxia to improve the immune microenvironment<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref> (<xref rid="fig2" ref-type="fig">Fig. 2</xref>).<fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Classification of ISAPIs.</p></caption><alt-text id="alttext0020">Figure 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0105">However, in recent years, with the advancement of ferroptosis-immunotherapy, the uncontrolled release and long-term stability of ISAPIs have gradually emerged as crucial issues. Although a simple injection of ISAPI can exert an immediate effect, it frequently leads to a series of side effects, such as pain at the injection site and an inflammatory factor storm due to the instantaneous high concentration. For instance, after the TLR agonist TLR-7/8 is injected into the body, it can rapidly disseminate from the blood throughout the entire body, thereby causing potent side effects<xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref>, <xref rid="bib85" ref-type="bibr">85</xref>. In addition, the majority of the ISAPIs under investigation are proteins or nucleic acids, which are prone to degradation and clearance by the internal environment, further restricting the persistence of their efficacy. Hence, the development of delivery systems capable of achieving the stable release of ISAPIs has emerged as a research focus. The drug delivery system can optimize the druggability of ISAPIs and broaden the range of disease applications. At present, the development of delivery systems for the co-delivery of ferroptosis inducers and ISAPIs has manifested the following significant characteristics: (1) Synergistically augment anti-tumor effects: Integrating a ferroptosis inducer and an ISAPI into a single drug delivery system enables more precise control and synergistic effects compared to two separate injections. (2) Enhance the efficiency of antigen delivery: By designing the size, shape, and spatial structure of the delivery system to simulate the traits of pathogens, it can effectively enhance the antigen uptake capacity of APCs, thereby laying a foundation for further improving the efficacy of immunotherapy<xref rid="bib86" ref-type="bibr"><sup>86</sup></xref>. (3) Prolonging the biological activity of immune-stimulating agents: The delivery system can provide physical or chemical protection for immune-stimulating agents, effectively counteracting the impairment to their activity caused by the complex internal environment, thereby offering more stable immune support for tumor treatment<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref>. Based on the mechanism of ISAPIs in the drug delivery system, we have classified them into two types: cargoes with immune-stimulating effects and vectors with intrinsic immune activation functions. We systematically review the structural characteristics, mechanisms, and applications of these two types of delivery systems in tumor therapy.</p><sec id="sec3.1.1"><label>3.1.1</label><title>Cargoes with immune-stimulating effects</title><p id="p0110">Firstly, it is feasible to design the immunostimulatory materials as the cargoes within the drug delivery system, encapsulate them along with ferroptosis inducers, and precisely deliver them to the TME. Based on numerous studies, the cargoes with immune-stimulating effects can be categorized into two major types: macromolecules (such as proteins, nucleic acids, etc.) and small-molecule drugs. Subsequently, we will expound on the mechanism of such ISAPIs and explore the crucial role of the drug delivery system in optimizing their therapeutic efficacy, both of which are summarized in <xref rid="tbl2" ref-type="table">Table 2</xref><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib88" ref-type="bibr">88</xref>, <xref rid="bib89" ref-type="bibr">89</xref>, <xref rid="bib90" ref-type="bibr">90</xref>, <xref rid="bib91" ref-type="bibr">91</xref>, <xref rid="bib92" ref-type="bibr">92</xref>, <xref rid="bib93" ref-type="bibr">93</xref>, <xref rid="bib94" ref-type="bibr">94</xref>, <xref rid="bib95" ref-type="bibr">95</xref>, <xref rid="bib96" ref-type="bibr">96</xref>.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Immune-stimulating cargoes and their application.</p></caption><alt-text id="alttext0070">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Immune-stimulating cargo</th><th colspan="1" rowspan="1">Ferroptosis inducer</th><th colspan="1" rowspan="1">Drug delivery system</th><th colspan="1" rowspan="1">Tumor model</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">aPD-1</td><td colspan="1" rowspan="1">Withaferin A</td><td colspan="1" rowspan="1">Hydrogel</td><td colspan="1" rowspan="1">Melanoma</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref></td></tr><tr><td rowspan="2" colspan="1">aPD-L1</td><td colspan="1" rowspan="1">Fe<sup>3+</sup></td><td colspan="1" rowspan="1">Metal nanocomplex</td><td colspan="1" rowspan="1">Lymphoma</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref></td></tr><tr><td colspan="1" rowspan="1">Ultrasmall iron nanoparticles</td><td colspan="1" rowspan="1">Ultrasmall iron nanoparticles</td><td colspan="1" rowspan="1">Breast cancer</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref></td></tr><tr><td colspan="1" rowspan="1">aTGF-<italic toggle="yes">&#946;</italic></td><td colspan="1" rowspan="1">Sorafenib</td><td colspan="1" rowspan="1">Hybrid metal nanoparticles</td><td colspan="1" rowspan="1">Colon tumor</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref></td></tr><tr><td colspan="1" rowspan="1">PEP20 (CD47 inhibitory peptide)</td><td colspan="1" rowspan="1">Hemin (H)</td><td colspan="1" rowspan="1">Biomimetic nanoparticles</td><td colspan="1" rowspan="1">Breast cancer</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref></td></tr><tr><td colspan="1" rowspan="1">Pol (I:C) (TLR3 agonists)</td><td colspan="1" rowspan="1">AIEgens</td><td colspan="1" rowspan="1">Polymer nanoparticle</td><td colspan="1" rowspan="1">Breast cancer</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref></td></tr><tr><td colspan="1" rowspan="1">Indoximod (Ido blocker)</td><td colspan="1" rowspan="1">Quinone methide and Fe<sup>3+</sup></td><td colspan="1" rowspan="1">Polymer nanoparticle</td><td colspan="1" rowspan="1">Breast cancer</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref></td></tr><tr><td colspan="1" rowspan="1">DNA (STING agonists)</td><td colspan="1" rowspan="1">DHA</td><td colspan="1" rowspan="1">Iron-based metal&#8211;organic framework</td><td colspan="1" rowspan="1">Lewis lung cancer</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref></td></tr><tr><td colspan="1" rowspan="1">Mn<sup>2+</sup> (STING agonists)</td><td colspan="1" rowspan="1">MnO<sub>2,</sub> GOx</td><td colspan="1" rowspan="1">Hybrid metal nanoparticles</td><td colspan="1" rowspan="1">Breast cancer</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref></td></tr><tr><td colspan="1" rowspan="1">R848 (TLR7/8 agonists)</td><td colspan="1" rowspan="1">Fe-TCPP</td><td colspan="1" rowspan="1">Iron-based metal&#8211;organic framework</td><td colspan="1" rowspan="1">Melanoma</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref></td></tr></tbody></table><table-wrap-foot><fn><p>IDO, indoleamine 2, 3-dioxygenase; DHA, dihydroartemisinin; GOx, glucose oxidase; TLR, Toll-like receptor.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec3.1.1.1"><label>3.1.1.1</label><title>Protein and nucleic acid macromolecular immune-stimulating cargoes</title><p id="p0115">Protein ISAPIs are predominantly monoclonal antibodies targeting immune checkpoints, which are a set of molecules expressed on immune cells or cancer cells and regulate immune activation, playing a crucial role in preventing the occurrence of autoimmune reactions<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref>. For example, immune checkpoints such as the typical protein ISAPIs can be classified into activated and suppressed ones. It is well-known that numerous tumor cells employ suppressed immune checkpoints, including PD-1, PD-L1/2, CTLA-4, CD73 and so on, to achieve the effect of tumor immune escape<xref rid="bib98" ref-type="bibr">98</xref>, <xref rid="bib99" ref-type="bibr">99</xref>, <xref rid="bib100" ref-type="bibr">100</xref>, <xref rid="bib101" ref-type="bibr">101</xref>, <xref rid="bib102" ref-type="bibr">102</xref>, <xref rid="bib103" ref-type="bibr">103</xref>. Owing to their high specificity, a substantial number of clinically validated pharmaceutical products have been successfully developed and commercialized. Such as PD-1 antibodies, namely nivolumab, Pembrolizumab, Cemiplimab, Toripalimab, and Carfilzomib; PD-L1 antibodies, including Atezolizumab, Avelumab, and Durvalumab; and CTLA-4 monoclonal antibodies, for instance, ipilimumab, etc<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref><sup>,</sup><xref rid="bib104" ref-type="bibr"><sup>104</sup></xref><sup>,</sup><xref rid="bib105" ref-type="bibr"><sup>105</sup></xref>. In addition, CD73 is also a classical immune checkpoint. CD73, as Ecto-5&#8242;-Nucleotidase, is the critical enzyme that catalyzes adenosine monophosphate (AMP) to generate extracellular adenosine<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref><sup>,</sup><xref rid="bib107" ref-type="bibr"><sup>107</sup></xref>. However, adenosine is an immunosuppressive molecule that influences both innate and adaptive immunity, as well as the TME<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref><sup>,</sup><xref rid="bib109" ref-type="bibr"><sup>109</sup></xref>. Consequently, aCD73, as an emerging star of immune checkpoint monoclonal antibodies, has been extensively developed, such as oleclumab developed by AstraZeneca and uliledlimab developed by Celestia, both which are in the clinical stage.</p><p id="p0120">In addition to immune checkpoint monoclonal antibodies, there are other immunotherapy protein drugs, such as anti-TGF-<italic toggle="yes">&#946;</italic> and anti-CD47 antibodies, as ISAPIs. TGF-<italic toggle="yes">&#946;</italic> exerted negative impacts on the innate and adaptive immune system, as well as the TME<xref rid="bib110" ref-type="bibr">110</xref>, <xref rid="bib111" ref-type="bibr">111</xref>, <xref rid="bib112" ref-type="bibr">112</xref>, <xref rid="bib113" ref-type="bibr">113</xref>, <xref rid="bib114" ref-type="bibr">114</xref>. Luspatercept is a drug targeting TGF-<italic toggle="yes">&#946;</italic> and has received marketing approval for addressing the pathological processes associated with TGF-<italic toggle="yes">&#946;</italic>. CD47, also known as integrin-associated protein I (IAP), is the "self" marker of almost all tumor cells, representing the "don't eat me" signal. CD47 can bind to the SIRP<italic toggle="yes">&#945;</italic> on the surface of macrophages, effectively avoiding macrophage phagocytosis<xref rid="bib115" ref-type="bibr"><sup>115</sup></xref><sup>,</sup><xref rid="bib116" ref-type="bibr"><sup>116</sup></xref>. Hence, multiple CD47-targeting antibodies have advanced into late-stage clinical trials as well.</p><p id="p0125">Although a wide range of antibody-based ISAPIs continues to emerge as one of the most promising frontiers in new drug development, their therapeutic potential is often hindered by inadequate stability issues such as denaturation, fragmentation, and enzymatic hydrolysis. These limitations are further exacerbated by suboptimal controlled-release properties, which reduce therapeutic efficacy and increase the risk of systemic toxicity<xref rid="bib117" ref-type="bibr"><sup>117</sup></xref><sup>,</sup><xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>. For instance, intravenous administration of monoclonal antibodies yields low response rates (overall response rate &lt;30%) in most cancer patients, largely due to inefficient delivery<xref rid="bib119" ref-type="bibr"><sup>119</sup></xref>. Consequently, the pharmacological activity of biologic drugs critically depends on developing safe and efficient delivery systems&#8212;such as hydrogels, metal nanoparticles, and biomimetic nanoparticles&#8212;to overcome these challenges.</p><p id="p0130">Hydrogel is a high-molecular system that contains a considerable quantity of water and has a three-dimensional network structure, which has been employed for the delivery of protein drugs. It is reported that hydrogel formed through cross-linking hyaluronic acid and dextran is capable of maintaining the therapeutic concentration of bevacizumab for at least three months<xref rid="bib120" ref-type="bibr"><sup>120</sup></xref>. Cheng et al.<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref> developed an injectable hydrogel (Gel@WA-cRGD + aPD-L1) based on <italic toggle="yes">&#946;</italic>-cyclodextrin, Ca<sup>2+</sup>, and oxidized sodium alginate. The porous network of the hydrogel was designed to deliver both aPD-L1 and the ferroptosis-inducing prodrug WA-cRGD (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A&#8210;C). The prodrug conjugation of cRGD ligands could facilitate the preferential uptake by tumor cells while preventing their accidental uptake by immune cells, so as to lower the cytotoxic impact on splenic immune cells. <italic toggle="yes">In vivo</italic> imaging of Cy5-loaded hydrogels in mice demonstrated prolonged fluorescence retention compared to free Cy5, indicating the hydrogel's potential for controlled drug release (<xref rid="fig3" ref-type="fig">Fig. 3</xref>D). In a bilateral B16F10 postoperative tumor model, the treatment significantly inhibited tumor growth over 60 days and markedly enhanced the infiltration of mature DCs and M1 macrophages in distant tumors, both with a 21% increase compared to the control group.<fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Protein and nucleic acid macromolecular immune-stimulating cargoes and their application in ferroptosis-immunotherapy. (A) Schematic illustration of the synthesis procedure for Gel@WA-cRGD + aPD-L1, a carrier designed for co-delivering aPD-L1and WA-cRGD. (B) SEM image of hydrogel with a porous network. Scale bar = 100 &#956;m. (C) Rheology behavior of Gel and Gel@WA-cRGD + aPD-L. (D) Fluorescence imaging showing the different drug release behavior between free Cy5 and Gel@Cy5 <italic toggle="yes">in vivo</italic>. The unit of fluorescence intensity is a.u. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 Elsevier. (E) Tumor weight, and (F) survival rate of mice from each treatment group. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 American Chemical Society. (G) Schematic illustration of MP@CH/BSA coupled with PEP20 peptide and co-loaded with Ce6 and heme. (H) TEM images of MP@CH/BSA. Scale bar = 0.3 &#956;m. (I) Laser-triggered release of hemin from MP@CH/BSA NP. (J) Representative bio-TEM images of 4T1 cells treated with fresh medium, MP@CH/BSA NP or MP@CH/BSA NP (L+). Scale bar = 1.2 &#956;m in original view above and 0.6 &#956;m in enlarged view below. (K) A heat map showing concentrations of IFN-<italic toggle="yes">&#947;</italic>, TNF-<italic toggle="yes">&#945;</italic>, and IL-6 in 4T1 tumor-bearing mice subjected to different treatment regimens. The unit of concentration intensity is pg/mL. (L) Percentages of M1 macrophages in tumors. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2022 Elsevier. (M) Illustration of the synthesis procedure for M@P. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2025 Springer Nature.</p></caption><alt-text id="alttext0025">Figure 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0135">In ferroptosis therapy, metal nanoparticles are widely utilized, often incorporating iron and other elements to enhance the therapeutic efficacy of ferroptosis. This "self-supplying iron/self-inducing ferroptosis" feature bypasses complex drug-loading processes, significantly streamlining nanocarrier fabrication while controlling iron ion release through a TME-responsive strategy. Furthermore, antibodies can be engineered through various modification and functionalization strategies, enabling their self-assembly into nanostructured particles with enhanced stability and controlled release properties. Nie et al.<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref> fabricated aPD-L1 to spermidine-grafted glucan (APP-SPM-DEX) through the EDC/NHS reaction, and subsequently complexed it with sodium tripolyphosphate and Fe<sup>3+</sup> nanomorph, ultimately constructing a spermidine-immune peptide&#8211;metal nanocomplex (APP-Fe NC) for regulating the TME. They discovered that aPD-L1-Fe NC induced more significant cytotoxicity to mouse lymphoma cells than aPD-L1-SPM-DEX and free Fe<sup>3+</sup>. Similarly, in the <italic toggle="yes">in vivo</italic> anti-lymphoma experiments, the tumor weight was decreased by 25.4%, 35.8%, and 73.6%, respectively, in the aPD-L1-SPM-DEX, free Fe<sup>3+</sup>, and aPD-L1-Fe NC groups compared to the control group (<xref rid="fig3" ref-type="fig">Fig. 3</xref>E). All these imply that immunotherapy drugs alone might not yield a significant therapeutic effect, while the combination of ferroptosis and immunotherapy will achieve the optimal anti-tumor effect (<xref rid="fig3" ref-type="fig">Fig. 3</xref>F). Similarly, Shen et al.<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref> implemented <sup>131</sup>I modification on aPD-L1 to acquire <sup>131</sup>I-APD-L1, which was co-assembled with the ultrasmall iron nanoparticles (USINPs) functionalized with fluorobenoborate. These nanoparticles not only serve as direct ferroptosis inducers but also prolong blood circulation time and enhance tumor accumulation, offering significant advantages. The combined ferroptosis-immune-radiation therapy effectively inhibits the progression of breast cancer. Zhou et al.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> loaded the ferroptosis inducer sorafenib and aTGF-<italic toggle="yes">&#946;</italic> onto Fe<sub>3</sub>O<sub>4</sub>/Gd<sub>2</sub>O<sub>3</sub> hybrid nanoparticles. aTGF-<italic toggle="yes">&#946;</italic> could be specifically released in tumor tissues and synergize with iron particles and sorafenib to mediate ferroptosis, thereby promoting DCs maturation, M1 macrophage infiltration, and T cell activation to remodel the TME.</p><p id="p0140">Leveraging their cell-membrane-mimicking structures, biomimetic nanoparticles have emerged as strategic vectors for the co-delivery of ferroptosis inducers and ISAPIs, where the nanoparticles&#8217; natural tropism enhances tumor accumulation while their biomimetic cloak minimizes immune clearance, thereby creating a synergistic platform for dual-modality therapy. He et al.<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref> employed BSA coated with the M1 macrophage cell membrane as a delivery carrier (MP@CH/BSA NP), loaded Ce6 as a photosensitizer, and heme as well (<xref rid="fig3" ref-type="fig">Fig. 3</xref>G and H). They aimed to upregulate the expression of heme oxidase-1, thereby inducing heme degradation and Fe<sup>2+</sup> release, promoting the Fenton reaction and ferroptosis. Interestingly, the study revealed that laser irradiation significantly enhances hemin release, achieving rates twice as high as those measured under unirradiated conditions (<xref rid="fig3" ref-type="fig">Fig. 3</xref>I). The CD47 inhibitory peptide PEP20 was recoupled to the macrophage cell membrane, which was expected to block the CD47&#8211;SIRRP<italic toggle="yes">&#945;</italic> interaction in the TME. Additionally, after drug treatment, the secretion of IFN-<italic toggle="yes">&#947;</italic> in the tumor could be significantly increased, thus down-regulating the expression of Xc<sup>&#8210;</sup> in the system, which could significantly sensitize ferroptosis (<xref rid="fig3" ref-type="fig">Fig. 3</xref>J&#8210;L).</p><p id="p0145">While protein-based ISAPIs dominate current ferroptosis-immunotherapy paradigms, nucleic acid ISAPIs have also gradually gained a position due to their distinctive immune regulatory function. Nevertheless, because of its susceptibility to degradation by nuclease in serum and electrostatic repulsion with the cell membrane, its cellular uptake efficiency is low, thereby restricting its practical application<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref><sup>,</sup><xref rid="bib122" ref-type="bibr"><sup>122</sup></xref>. Currently, one of the most prevalent nucleic acid ISAPIs is polyinosinolate Poly(I:C), which is a TLR agonist. Poly(I:C) is a synthetic double-stranded RNA molecule. Since its structure is similar to that of viral double-stranded RNA, it can simulate the natural immune response of the host induced by viral infection and is regarded as a potent interferon inducer<xref rid="bib123" ref-type="bibr">123</xref>, <xref rid="bib124" ref-type="bibr">124</xref>, <xref rid="bib125" ref-type="bibr">125</xref>. Nucleic acid-based immune stimulants typically have a short half-life. According to reports, loading the nucleic acid immune stimulant CpG ODN into a nanodelivery system can significantly extend its elimination half-life by approximately 7 h. Moreover, this approach enhances its ability to promote the maturation of BMDCs and boost the secretion of TNF-<italic toggle="yes">&#945;</italic> and IL-6<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref>. Wang et al.<xref rid="bib92" ref-type="bibr"><sup>92</sup></xref> developed a nanoplatform through a self-assembly strategy by complexing negatively charged Poly(I:C) with positively charged aggregation-induced emission luminogens (AIEgens) MTCN-3. The resulting complex was further encapsulated in the amphiphilic polymer DSPE-Hyd-PEG-Folate, denoted as M@P (<xref rid="fig3" ref-type="fig">Fig. 3</xref>M). Upon light irradiation, MTCN-3 generated ROS and heat, leading to lysosomal dysfunction and subsequently triggering pyroptosis and ferroptosis in tumor cells. Following M@P injection, the nanoplatform actively targeted the tumor site in mice within 6 h and continued to accumulate for up to 24 h. In a breast cancer mouse model, treatment significantly increased the proportion of mature DCs cells from 26.4% to 45.3%, while the levels of pro-inflammatory cytokines, including IL-6, IL-18, IL-1<italic toggle="yes">&#945;</italic>, IL-1<italic toggle="yes">&#946;</italic>, TNF-<italic toggle="yes">&#945;</italic>, and IFN-<italic toggle="yes">&#947;</italic>, were markedly elevated.</p><p id="p0150">In recent years, RNA interference (RNAi) technology based on small interfering RNA (siRNA) has shown significant advantages in the field of anti-tumor therapy. While siRNA is not traditionally considered an ISAPI, it can exhibit adjuvant-like effects under certain conditions<xref rid="bib127" ref-type="bibr"><sup>127</sup></xref>. siRNA specifically degrades target mRNA and precisely regulates gene expression at the post-transcriptional level. Studies have demonstrated the successful development of various siRNA-based delivery systems, including liposomes, polymeric micelles, dendritic macromolecules, and other carriers, to achieve the downregulation of PD-L1, VEGF, or TGF-<italic toggle="yes">&#946;</italic><xref rid="bib128" ref-type="bibr">128</xref>, <xref rid="bib129" ref-type="bibr">129</xref>, <xref rid="bib130" ref-type="bibr">130</xref>, <xref rid="bib131" ref-type="bibr">131</xref>. These systems have effectively inhibited tumor growth and metastasis. Although research on siRNA technology in ferroptosis-related immunotherapy has not yet been reported, its precise gene regulation capabilities and promising therapeutic effects provide new insights for the development of novel ferroptosis-immunotherapy combination strategies.</p><p id="p0155">Although antibody and nucleic acid ISAPIs show strong therapeutic potential in immunotherapy because of their highly specific immune activation ability, which can accurately identify specific targets through antibody&#8211;antigen and other reactions. However, due to its macromolecular structure, the development of such ISAPI faces many challenges, such as: (1) Complex and costly development and production: complex structure and strict quality control requirements lead to high production costs. (2) Poor stability: easy to be affected by environmental conditions (such as temperature, pH), needs to be stored at low temperatures, which increases the difficulty of transportation and storage<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref>. These factors limit the clinical transformation and wide application of such ISAPIs. In contrast, small molecule ISAPI is similar to a large molecule in immune response mechanism, but its simple structure and stronger stability make it more flexible and operable in clinical application, and provide a broader prospect for the popularization and development of immunotherapy.</p></sec><sec id="sec3.1.1.2"><label>3.1.1.2</label><title>Small-molecule ISAPIs</title><p id="p0160">In recent years, small-molecule immunomodulators have made significant progress in the field of immunotherapy. These drugs target specific immune regulatory sites, such as IDO, Cyclic GMP&#8211;AMP synthase (cGAS)-stimulator of interferon genes (STING), and TLR, allowing for precise modulation of immune responses and thereby exerting therapeutic effects. Next, we will classify small-molecule immunomodulators based on their mechanisms, with a focus on the mechanisms of IDO inhibitors, STING agonists, and TLR agonists, as well as their remarkable efficacy in ferroptosis-immunotherapy delivery systems.</p><p id="p0165">Studies have demonstrated that the enhancement of tryptophan&#8211;kynurenine (Trp&#8211;Kyn) metabolic pathway activity is associated with local immunosuppression in the TME, facilitating the immune escape of cancer cells<xref rid="bib133" ref-type="bibr">133</xref>, <xref rid="bib134" ref-type="bibr">134</xref>, <xref rid="bib135" ref-type="bibr">135</xref>. Small molecule inhibitors targeting IDO, governing the Trp&#8211;Kyn metabolic axis, have emerged as promising immunotherapeutic agents, given IDO's pivotal role in tumor immune evasion through local tryptophan depletion and kynurenine-mediated immunosuppressive signaling. Hence, targeting IDO <italic toggle="yes">via</italic> small molecules might be a potential protocol for cancer therapy. Huang et al.<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> fabricated a multifunctional nanoplatform featuring self-driven release of IDO inhibitor, indoximod (IND), and enhancement of oxidative stress. They initially devised an IND prodrug based on the release of ROS and esterase in response and chelated it with Fe<sup>3+</sup> and polydopamine to form nanoparticles (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A and B). In a tumor-specific high-ROS microenvironment, the IND prodrug undergoes activation to generate IND, thereby inhibiting the conversion of Trp into Tyn and concomitantly generating quinone (QM) as a by-product (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C). QM further augments oxidative stress by elevating ROS and depleting GSH, and collaborates with iron ions to facilitate the ferroptosis process (<xref rid="fig4" ref-type="fig">Fig. 4</xref>D). Additionally, the intensification of oxidative stress significantly expedited the self-driven release of the prodrug, achieving efficient drug delivery. This design amplifies the therapeutic effect through multiple mechanisms, offering an innovative strategy for the combination of ferroptosis and immunotherapy.<fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Small molecule immune-stimulating cargoes and their application in ferroptosis-immunotherapy. (A) TEM image of nanoparticles. Scale bar = 100 nm. (B) Release profile of IND under different conditions. H<sub>2</sub>O<sub>2</sub>: 100 &#956;mol/L, esterase: 100 U/mL. (C) Kyn inhibition rate in 4T1 cells after different treatments. (D) The GSH level in 4T1 cells after different treatments. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 Elsevier. (E) TEM images of DHA@MIL-101. Scale bar = 100 nm. (F) The uptake of DHA@MIL-101-ICG in TAM and lung cancer cells (LLC). The unit of fluorescence intensity is a.u. (G) The LPO generation in TAM was observed with laser confocal microscopy. Scale bar = 10 &#956;m. (H) The Kyoto Encyclopedia of Genes and Genomes functional enrichment analysis was conducted. The DEGs were mainly enriched in the ferroptosis and DNA damage-associated signaling pathways. (I) The expression of cGAS/STING was detected by WB. (J) Multiple immunofluorescence staining examined molecules of M1, GBP5. Scale bar = 20 &#956;m. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 Wiley. (K) Improved tumor enrichment of Fe-MOF-RP was monitored by fluorescence imaging <italic toggle="yes">in vivo</italic>. The unit of fluorescence intensity is a.u. (L) DC maturation expressed on CD11c<sup>+</sup> cells. (M) Proportion of CD8<sup>+</sup> T cells after different treatments. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2024 American Chemical Society.</p></caption><alt-text id="alttext0030">Figure 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0170">Within the realm of small-molecule ISAPIs, the cGAS&#8211;STING signaling axis also serves as a pivotal biosensor mechanism, orchestrating cytoplasmic surveillance of extranuclear DNA through a precisely coordinated molecular cascade. Specifically, cGAS, a DNA receptor in the cytoplasm, recognizes DNA from the nucleus or mitochondria and catalyzes the production of cyclic dinucleotides (CDNs, <italic toggle="yes">e.g.</italic>, 2&#8242;,3&#8242;-cGAMP)<xref rid="bib136" ref-type="bibr"><sup>136</sup></xref>. As a second messenger, the CDNs are capable of binding to and activating STING, a key protein in the innate immune system, that exists in the endoplasmic reticulum in the form of a symmetric dimer. The activated STING forms polymers that recruit and activate downstream molecules, TBK1 and IRF3. Subsequently, TBK1 phosphorylates IRF3, inducing the dimer to enter the nucleus and initiating the expression of type I interferons (such as IFN-<italic toggle="yes">&#946;</italic>), which triggers the interferon immune response<xref rid="bib137" ref-type="bibr"><sup>137</sup></xref>. Subsequently, the production of IFN can enhance the maturation of DCs and promote the expression of chemokines CXCL9 and CXCL10, facilitating the migration of T cells to the TME. Furthermore, the activation of STING not only polarizes TAM towards anti-tumor M1 macrophages but also reprograms M2-TAM to the M1 phenotype<xref rid="bib138" ref-type="bibr">138</xref>, <xref rid="bib139" ref-type="bibr">139</xref>, <xref rid="bib140" ref-type="bibr">140</xref>, <xref rid="bib141" ref-type="bibr">141</xref>. In conclusion, with respect to the activation of the STING pathway, not only can an increase in the release of DNA activate cGAS, but also the activation of CDNs is capable of activating STING. Hence, cGAS&#8211;STING pathway activators are often incorporated into delivery systems to enhance the efficacy of ferroptosis-based immunotherapy.</p><p id="p0175">CDNs are a natural and direct agonist for STING. However, its high molecular weight and strong polarity restrict its ability to penetrate the cell membrane. Meanwhile, its phosphodiester bond is prone to enzymatic hydrolysis, leading to poor metabolic stability and thereby limiting its clinical application<xref rid="bib142" ref-type="bibr"><sup>142</sup></xref>. To overcome these shortcomings, non-nucleotide STING agonists, including Mn<sup>2+</sup>, STING agonist-4, have emerged as a research focus. In ferroptosis-immunotherapy, ferroptosis might impact the normal functionality of immune cells, resulting in mitochondrial dysfunction and the release of intracellular DNA. Nevertheless, this process can be ingeniously exploited to further activate the STING pathway and enhance its immunogenicity, thereby offering novel concepts and potential breakthroughs for the synergistic application of ferroptosis and immunotherapy. Li et al.<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> administered an iron-based metal-organic frameworks (MOF) encapsulating Dihydroartemisinin (DHA), denoted as DHA@MIL-101, into the TAM (<xref rid="fig4" ref-type="fig">Fig. 4</xref>E). The construction of the MOF enhances the solubility and bioavailability of DHA and ingeniously exploits the disparity in the content of basic iron ions between cancer cells and macrophages to achieve the reprogramming of TAM. It has been experimentally verified that TAM can phagocytose the drug-carrying MOFs and exert a certain ferroptosis effect (<xref rid="fig4" ref-type="fig">Fig. 4</xref>F). The ROS and LPO produced will damage intracellular DNA, and their fragments mediate the activation of cGAS/STING, thereby generating an anti-lung cancer immune effect (<xref rid="fig4" ref-type="fig">Fig. 4</xref>G&#8211;I). By employing the DNA damage inhibitor Wortmannin and the ferroptosis inhibitor Fer-1, the study demonstrates that ferroptosis-induced DNA damage in TAMs is essential for activating the STING pathway, which subsequently enhances polarization and phagocytic function (<xref rid="fig4" ref-type="fig">Fig. 4</xref>J). Mn<sup>2+</sup> has also been encompassed in the studies of STING activation. Mn<sup>2+</sup>, as an essential trace element, is capable of enhancing the enzyme activity of cGAS<xref rid="bib143" ref-type="bibr"><sup>143</sup></xref>. Nevertheless, as a hydrophilic ion, Mn<sup>2+</sup> possesses a high clearance rate <italic toggle="yes">in vivo</italic> and poor membrane permeability; thus, free Mn<sup>2+</sup> injections fail to yield a curative effect<xref rid="bib144" ref-type="bibr"><sup>144</sup></xref>. Hu et al.<xref rid="bib145" ref-type="bibr"><sup>145</sup></xref> successively modified MnO<sub>2</sub> and glucose oxidase (GOx) on the Hafnium oxide (HfO<sub>2</sub>) core to form HfO<sub>2</sub>@MnO<sub>2</sub>@GOx (HMG) nanoparticles. The shell layer of MnO<sub>2</sub> can consume GSH, which not only elevates intracellular ROS content by the Fenton-like reaction of Mn<sup>2+</sup> but also directly binds to cGAS, enhances the binding affinity of cGAS to cell membrane DNA, promotes its enzymatic activity, and generates cGAMP in the presence of trace cell membrane DNA. In addition, HMG nanoparticles, whether administered intravenously or intraperitoneally, possess effective antitumor properties in tumor-bearing mice.</p><p id="p0180">TLRs, a class of evolutionarily conserved pattern recognition receptors strategically localized at plasma membranes and endolysosomal compartments, can identify pathogen-associated molecular patterns through leucine-rich repeat (LRR) domains while amplifying DAMPs signals<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref>. R848 is a small imidazoline&#8211;quinoline compound possessing dual agonist activity towards TLR7 and TLR8, which is strikingly distinct from some nucleic acid agonists (such as CpG ODN)<xref rid="bib146" ref-type="bibr">146</xref>, <xref rid="bib147" ref-type="bibr">147</xref>, <xref rid="bib148" ref-type="bibr">148</xref>. Through binding to TLR7/8, R848 is capable of triggering a MyD88-dependent signaling pathway, effectively activating DCs and significantly enhancing both innate and adaptive immune responses<xref rid="bib149" ref-type="bibr"><sup>149</sup></xref>. R848 can induce the polarization of TAM from the immunosuppressive M2 phenotype to the M1 phenotype with anti-tumor activity, subsequently promoting the secretion of pro-inflammatory cytokines (such as IL-6, IL-12) and chemokines, and enhancing the anti-tumor immune response<xref rid="bib150" ref-type="bibr"><sup>150</sup></xref>. Nevertheless, the direct administration of R848 as a free drug presents a significant issue of a sharp increase in blood concentration. Significant differences in the delivery behavior between free R848 and R848 encapsulated in nanoparticles have been well-documented. Within 4 h after administration, the serum concentration of the drug in the free group was considerably higher than that in the polylactic acid nanoparticle group, even 4&#8211;5 times greater. This concentration fluctuation might result in systemic toxicity, which could potentially restrict its clinical application<xref rid="bib151" ref-type="bibr"><sup>151</sup></xref>. Fan et al.<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref> devised a light-triggered nanozyme, namely Fe-TCPP-R848-PEG (Fe-MOF-RP). Utilizing Fe-TCPP MOF as the core architecture, the immunoagonist R848 was encapsulated within the nanozyme, and PEG was modified on the surface, thereby significantly optimizing its pharmacokinetic properties. The PEG modification not only endows Fe-MOF with excellent biocompatibility but also enhances its tumor-accumulation ability, prolongs the drug's blood circulation time, and markedly improves its selective enrichment in tumor tissues (<xref rid="fig4" ref-type="fig">Fig. 4</xref>K). In contrast to the PBS group, Fe-MOF-RP in combination with laser irradiation significantly elevated the expression levels of co-stimulatory molecules (CD80<sup>+</sup> and CD86<sup>+</sup>) and MHC I in DCs. Additionally, the proportion of CD8<sup>+</sup> T cells and memory T cells also increased significantly, indicating that it can effectively enhance the tumor-specific immune response (<xref rid="fig4" ref-type="fig">Fig. 4</xref>L and M).</p><p id="p0185">Cargoes possessing immunostimulating capacity are capable of augmenting the activity of immune cells and enhancing the immune system's response to tumors. Nevertheless, at high dosages or when employed inappropriately, these cargoes can give rise to the overactivation of immune cells, triggering cytokine storms or other toxic reactions. Hence, precise dose control and release strategies are indispensable to prevent an uncontrolled immune response or toxic accumulation, thereby guaranteeing the safety and efficacy of the treatment. Additionally, carrier design is particularly crucial when co-delivering immune-stimulating cargo along with ferroptosis inducers. A sophisticated carrier system is requisite to ensure the synergistic release of the two, guarantee the balanced release of drugs in the tumor area and avoid the unbalanced drug release influencing the therapeutic effect, so as to optimize the combined therapeutic effect of ferroptosis and immunotherapy.</p></sec></sec><sec id="sec3.1.2"><label>3.1.2</label><title>Vectors with intrinsic immune activation functions</title><p id="p0190">Vectors with intrinsic immune activation functions refer to carriers that can actively trigger immune responses without the need for additional exogenous immunostimulants. These systems leverage the intrinsic immunoactivating properties of their constituent materials, such as chitosan-based carriers or bacterial membrane vesicles, or rely on specific physicochemical characteristics, including surface charge and structural morphology, to directly activate immune cells such as DCs and macrophages or to activate key immune signaling pathways<xref rid="bib152" ref-type="bibr">152</xref>, <xref rid="bib153" ref-type="bibr">153</xref>, <xref rid="bib154" ref-type="bibr">154</xref>. In the following sections, we will provide a detailed discussion of the underlying immunoactivation mechanisms and highlight innovative applications of these systems in enhancing the immunotherapeutic synergy of ferroptosis-based cancer treatments.</p><p id="p0195">Chitosan is a type of natural polymeric material. Due to its immunomodulatory effect, chitosan has been extensively utilized in immunotherapy and ferroptosis research. Studies have indicated that highly deacetylated chitosan can induce mitochondrial stress, facilitate the generation of mitochondrial ROS and the release of DNA, activate the cGAS&#8211;STING signaling pathway and the NLRP3 inflammasome, and further promote the maturation of DCs by inducing type I interferon<xref rid="bib155" ref-type="bibr"><sup>155</sup></xref>. Moreover, it enhances the antigen-specific Th1 response in a type I IFN receptor-dependent manner<xref rid="bib156" ref-type="bibr"><sup>156</sup></xref><sup>,</sup><xref rid="bib157" ref-type="bibr"><sup>157</sup></xref>. Meng et al.<xref rid="bib158" ref-type="bibr"><sup>158</sup></xref> constructed an injectable hydrogel delivery system consisting of chitosan hydrochloride and oxidized dextran (CH-OD) for loading the FDA-approved ferroptosis inducer salazopyridine (SSZ), attaining both tumor cell elimination and anti-tumor immune activation. Experiments have manifested that both CH and CH-OD can prominently facilitate the polarization of bone marine-derived macrophages (BMDMs) towards the M1 phenotype, demonstrating their inherent immunostimulatory capacity. Moreover, the SSZ-loaded CH-OD system (CH-OD-SSZ) further significantly augments this ability. This is attributed to the fact that SSZ induces ferroptosis in H22 liver cancer cells, releasing DAMPs, thereby amplifying the immune activation effect. Nevertheless, due to the restricted immunostimulating capability of chitosan, the Day 60 survival rate after CH-OD-SSZ treatment was merely 25% in model mice. When combined with aPD-1, the survival rate of mice escalated significantly to 58%. Therefore, even though chitosan has emerged as one of the core materials in ferroptosis-immunotherapy research on account of its immunoregulatory capacity, biocompatibility, and degradability, its inherent immunostimulatory ability is inadequate and thus difficult to fulfill the requirement for sufficient activation of the immune system in complex treatment scenarios. To surmount this limitation, the introduction of an immune adjuvant as extra functional cargo based on chitosan can conspicuously enhance its immune activation effect, concurrently endowing it with greater therapeutic flexibility and efficiency<xref rid="bib159" ref-type="bibr"><sup>159</sup></xref>.</p><p id="p0200">At present, the natural membrane self-adjuvant delivery system is the most widely used carrier for such research. For example, bacterial outer membrane vesicles (OMV), which are natural nanovesicles secreted by Gram-negative bacteria with a particle size of 20 to 250 nm, are an excellent adjuvant carrier platform<xref rid="bib160" ref-type="bibr"><sup>160</sup></xref>. Because OMV contains peptidoglycan, LPS and flagellin, it is a natural TLR agonist with a strong ability to activate innate immune signaling pathways<xref rid="bib161" ref-type="bibr"><sup>161</sup></xref>. Kim et al.<xref rid="bib162" ref-type="bibr"><sup>162</sup></xref> demonstrated that OMV derived from <italic toggle="yes">Escherichia coli</italic> with the &#916;msbB mutation can effectively inhibit the growth of colon cancer, breast cancer and melanoma in mice, and significantly improve the release of anti-tumor cytokines IL-12, p40, IFN-<italic toggle="yes">&#947;</italic> and CXCL10. Moreover, due to the specific phospholipid bilayer nanostructure, similar to liposomes, OMV usually acts as a drug delivery carrier and the drugs that induce ferroptosis can be modified on the OMV surface by covalent coupling or electrostatic adsorption, or embedded in the lipid bilayer membrane by co-incubation, electroporation, etc<xref rid="bib163" ref-type="bibr"><sup>163</sup></xref>. For example, Sun et al.<xref rid="bib164" ref-type="bibr"><sup>164</sup></xref> fixed <italic toggle="yes">Escherichia coli</italic> OMV with Fe<sup>2+</sup> by electrostatic interaction and loaded with STING agonist-4, along with DSPE-PEG-FA modification, to achieve a functional design of OMV/SaFeFA. The introduction of OMV and STING agonist-4 significantly increased the maturity of DCs by 84%, while the levels of CD8<sup>+</sup> T cells and CD4<sup>+</sup> T cells were respectively elevated by twofold and 80%.</p><p id="p0205">Furthermore, researchers are vigorously investigating the crucial role of the physical and chemical properties of materials (such as surface charge, morphological characteristics, etc.) in the regulation of immune cells. For instance, by exposing positively charged primary amine groups on the surface of the carrier, it can not only effectively facilitate the maturation of DCs as an immune adjuvant, but also activate the immune response of CTLs<xref rid="bib152" ref-type="bibr"><sup>152</sup></xref>. Researchers are also endeavoring to develop novel delivery systems that control immune activation through modulation of their morphological properties. Hu et al.<xref rid="bib153" ref-type="bibr"><sup>153</sup></xref> developed an innovative, aspecific tetrapod spiky-like iron-palladium (FePd) nanocrystal, which significantly augmented the ferroptosis of cancer cells while inducing macrophages to release pro-inflammatory cytokines, further amplifying the activation effect of the immune system. In addition, He et al.<xref rid="bib154" ref-type="bibr"><sup>154</sup></xref> also endeavored to achieve more precise immune regulation by designing chiral nanocarriers to precisely regulate the phenotypic differentiation of macrophages. Looking forward, by optimizing the surface design and functional modification of materials, not only can their ability to regulate immune cells be enhanced, but also more efficient and safer immune regulatory systems can be developed. These technologies will offer a novel direction for the study of tumor therapy and other immune-related diseases and promote the further advancement of immunotherapy.</p><p id="p0210">The utilization of carrier materials possessing immune-activating capacities not only circumvents intricate ISAPI loading procedures but also simplifies carrier design. Such self-adjuvant vectors can discharge immune activation signals more uniformly and sustainably, thereby augmenting the immune response while reducing the dependence on complex controlled release mechanisms and enhancing the efficacy of therapy. Nevertheless, despite the remarkable advancements made in theory and experimentation with this approach, due to the technical demands and cost limitations of its production process, achieving large-scale industrial transformation remains challenging, which has emerged as a bottleneck in clinical application.</p><p id="p0215">Overall, compared to the traditional method of separately administering ferroptosis inducers and ISAPIs, co-encapsulating both agents within a single delivery system enables more precise control over drug spatiotemporal distribution and synergistic effects. This co-delivery strategy ensures the concurrent arrival of both drugs at the target site (<italic toggle="yes">e.g.</italic>, tumor tissue or specific cells) and their simultaneous release at the lesion site in a predetermined optimal ratio. Consequently, it maximizes the synergistic effect between ferroptosis-induced immunogenic cell death and ISAPI-activated anti-tumor immune responses, thus avoiding issues associated with separate injections, such as uneven drug distribution, temporal mismatch in action, and disproportionate dosing<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref>. However, given variations across tumor types, disease stages, and individual patients, the optimal combination of inducers and ISAPIs may require personalized selection. Therefore, implementing personalized treatment is paramount, requiring thorough evaluation of the patient's specific disease profile (<italic toggle="yes">e.g.</italic>, tumor characteristics) and physiological status (<italic toggle="yes">e.g.</italic>, immune function, organ function) to formulate a tailored therapeutic regimen.</p></sec></sec><sec id="sec3.2"><label>3.2</label><title>Tumor targeted delivery</title><p id="p0220">As a novel therapeutic approach, ferroptosis has demonstrated an indispensable role in anti-tumor treatment. Nevertheless, the non-specific distribution of ferroptosis inducers <italic toggle="yes">in vivo</italic> constitutes an important limiting factor in ferroptosis therapy. The systemic circulation of ferroptosis agents following intravenous administration may induce off-target cytotoxicity, particularly affecting critical immune components, including CD8<sup>+</sup> T cells, NK cells, and DCs. Furthermore, tumor heterogeneity often leads to reduced susceptibility to ferroptosis, while ferroptosis-inducing agents can simultaneously trigger T cell apoptosis and cause damage to non-tumor tissues, thereby constraining the therapeutic potential of ferroptosis-based cancer treatment. Consequently, enhancing tumor-specific drug targeting represents a crucial strategy for improving anti-tumor efficacy<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib165" ref-type="bibr"><sup>165</sup></xref>.</p><p id="p0225">Targeted drug delivery is an advanced technology that can achieve a more efficient accumulation of drug in the target tissues and cells through the heterogeneity of different tissues. Inspired by the targeted technology, many researchers have worked on the targeted drug delivery of ferroptosis inducers. Many targeted delivery strategies have been developed, including enhanced permeability and retention effect (EPR effect), receptor-mediated targeted and bionic materials-mediated targeted, etc.</p><p id="p0230">With the development of nanotechnology and biomaterials, nanomaterials have proved to be feasible carriers for achieving targeted delivery. On the one hand, the nanomaterial, through a suitable size, can effectively penetrate the tumor tissue and accumulate in the deep tumor cells. It is also not easy to clean up. Therefore, the application of nanomaterials improves the bioavailability of drugs<xref rid="bib166" ref-type="bibr"><sup>166</sup></xref>. On the other hand, through surface modification of nanomaterials, the targeting can be enhanced, which mediates the endocytosis of nanomaterials by tumor cells and then increases the intracellular drug concentration. All these advantages indicate that nanomaterials are excellent carriers for targeted delivery strategies<xref rid="bib167" ref-type="bibr"><sup>167</sup></xref>.</p><p id="p0235">Based on the different targeting mechanisms, drug targeting systems can be divided into passive and active targeted delivery.</p><sec id="sec3.2.1"><label>3.2.1</label><title>Passive targeted delivery</title><p id="p0240">Passive targeted drug delivery is a typical strategy in which the drug can accumulate in tumor tissues through the EPR effect. The materials widely used for passive targeting are mainly nanomaterials, including metal-based nanomaterials, liposomes, polymers, supramolecular nanoplatforms, and so on. Up to now, there are several reviews describing passive targeting-based nano-delivery systems for tumor therapy, and here we take metal-based nanomaterials as an example for a brief analysis<xref rid="bib168" ref-type="bibr">168</xref>, <xref rid="bib169" ref-type="bibr">169</xref>, <xref rid="bib170" ref-type="bibr">170</xref>.</p><p id="p0245">Metal-based nanomaterials are a class of nanoscale metal materials. Powerful catalytic, imaging, and photothermal conversion capabilities broaden their applications in tumor diagnosis and treatment. Common metal-based nanomaterials include monolithic and metal oxide nanoparticles, metal-organic frameworks (MOFs), metal-phenolic networks (MPNs), and nano-enzymes.</p><p id="p0250">For example, Huang et al.<xref rid="bib171" ref-type="bibr"><sup>171</sup></xref> reported Fe-MnO<sub>2</sub> nanosheets for loading DHA (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A), which improved the DHA targeting and therapeutic effect. DHA is an excellent ferroptosis inducer, in which the endoperoxide bridge can be broken under the catalysis of Fe<sup>2+</sup>, generating ROS to trigger ferroptosis<xref rid="bib172" ref-type="bibr"><sup>172</sup></xref><sup>,</sup><xref rid="bib173" ref-type="bibr"><sup>173</sup></xref>. However, the poor targeting ability of DHA and low Fe<sup>2+</sup> content in tumor cells limit the therapeutic effect. Therefore, the research carried out by Huang et al. suggested that the nanosheet group had stronger fluorescence in the tumor (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B and C) and an anti-tumor effect (<xref rid="fig5" ref-type="fig">Fig. 5</xref>D) compared to the free drug group. The combination of Fe-nanomaterials and DHA enhanced the accumulation of DHA while providing a source of Fe for DHA activation. Erastin also suffered the same dilemma. Erastin is an inducer that is widely applied in ferroptosis therapy. It acts by inhibiting the Xc<sup>&#8722;</sup> system, thereby reducing the cellular uptake of cystine<xref rid="bib174" ref-type="bibr"><sup>174</sup></xref>. This inhibition ultimately leads to the induction of ferroptosis and lipid peroxidation. Nevertheless, the administration of free Erastin is associated with a plethora of adverse reactions, such as cerebral infarction, glomerular abnormalities, splenomegaly, and anemia, etc<xref rid="bib175" ref-type="bibr"><sup>175</sup></xref>. To address this difficulty, Li et al.<xref rid="bib176" ref-type="bibr"><sup>176</sup></xref> reported a core-shell nanoparticle (Cu/Er NCP) for targeted delivery of erastin (<xref rid="fig5" ref-type="fig">Fig. 5</xref>E). These nanoparticles enhance the stability of Erastin. It's worth noting that the half-life of Cu/Er NCP <italic toggle="yes">in vivo</italic> is up to 8 h (<xref rid="fig5" ref-type="fig">Fig. 5</xref>F). The prolongation of systemic circulation time creates favorable conditions for the accumulation of drugs in tumors. In the <italic toggle="yes">in vivo</italic> distribution experiment, the fluorescence intensity at the tumor site was the highest. Specifically, it was 2.7 times and 4.3 times that of the spleen and kidney, respectively (<xref rid="fig5" ref-type="fig">Fig. 5</xref>G and H). These results indicated that the nanoparticles conferred the targeting ability of the drug delivery system to achieve efficient accumulation at the tumor site.<fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Passive targeted drug delivery system and its application to ferroptosis therapy. (A) Preparation process of Fe-MnO<sub>2</sub>/DHA. Tumor fluorescence images (B) and quantitative analysis (C) in the ICG group and Fe-MnO<sub>2</sub>@ICG group at different time points. The unit of fluorescence intensity is a.u. (D) Tumor growth curves in different treatment groups. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 Elsevier. (E) Schematic showing the synthesis of CuP/Er. (F) Time-dependent Ce6 fluorescence intensities in the plasma after CuP-Ce6/intravenous injection. The unit is &#215; 10<sup>8</sup> [p/s/cm<sup>2</sup>sr]/[&#956;W/cm<sup>2</sup>]. (G) Average radiant efficiency of different organs after i.v. injection of CuP-Ce6/Er to 4T1 tumor-bearing mice. The unit is &#215; 10<sup>8</sup> [p/s/cm<sup>2</sup> sr]/[&#956;W/cm<sup>2</sup>]. (H) Fluorescence intensity of tumors and major organs <italic toggle="yes">ex vivo</italic>. Color bar represents radiant efficiency([p/s/cm<sup>2</sup>/sr]/[&#956;W/cm<sup>2</sup>]). Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2024 Wiley.</p></caption><alt-text id="alttext0035">Figure 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0255">Although nanomaterials can accumulate and remain in tumor tissues through the EPR effect, there are still some challenges in their practical application: (1) Tumor factors. Tumors of different sizes have different vascular distributions and permeabilities. Large tumors often hinder the accumulation and penetration of nanoparticles due to the formation of blood clots. In addition, pericytes and extracellular matrix (ECM) form a "wall" outside the tumor blood vessels, which hinders the penetration of nanoparticles and even leads to reflux. Finally, the tumor microenvironment often has a high interstitial fluid pressure (IFP), and a high IFP reduces the pressure difference between the inside and outside of the blood vessels, reducing the driving force for the penetration of nanoparticles into the tissue and affecting drug accumulation<xref rid="bib177" ref-type="bibr"><sup>177</sup></xref>. (2) Nanomaterial factors. Particle size, charge, and surface wettability are important factors affecting tumor accumulation. Small particle size can lead to too low retention, while large particle size can cause insufficient permeability. Moreover, positively charged or hydrophobic nanoparticles are more easily cleared by the reticuloendothelial system (RES)<xref rid="bib178" ref-type="bibr"><sup>178</sup></xref>. Therefore, in view of the disadvantages of passive targeting strategies, the development of active targeting delivery systems is urgently needed.</p></sec><sec id="sec3.2.2"><label>3.2.2</label><title>Active targeted delivery</title><p id="p0260">Active targeted drug delivery entails the surface modification of nanosystems through the incorporation of specific proteins, small-molecule peptides, antibodies, and small molecules. These modifications facilitate the recognition and binding to specific molecular markers and proteins expressed on tumor cell surfaces, thereby enabling selective drug accumulation within tumor tissues. A list of common targeting materials has been provided in <xref rid="tbl3" ref-type="table">Table 3</xref><xref rid="bib179" ref-type="bibr">179</xref>, <xref rid="bib180" ref-type="bibr">180</xref>, <xref rid="bib181" ref-type="bibr">181</xref>, <xref rid="bib182" ref-type="bibr">182</xref>, <xref rid="bib183" ref-type="bibr">183</xref>, <xref rid="bib184" ref-type="bibr">184</xref>, <xref rid="bib185" ref-type="bibr">185</xref>, <xref rid="bib186" ref-type="bibr">186</xref>, <xref rid="bib187" ref-type="bibr">187</xref>, <xref rid="bib188" ref-type="bibr">188</xref>, <xref rid="bib189" ref-type="bibr">189</xref>.<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Categories of common targeting materials in active targeted delivery.</p></caption><alt-text id="alttext0075">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Strategy</th><th colspan="1" rowspan="1">Material</th><th colspan="1" rowspan="1">Advantage</th><th colspan="1" rowspan="1">Disadvantage</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">Receptor-mediated targeted delivery</td><td colspan="1" rowspan="1">CD44 targeting materials (HA)</td><td colspan="1" rowspan="1">Easy to modify, amphiphilic property, good biocompatibility, long blood circulation times, evasion of MPS clearance</td><td colspan="1" rowspan="1">Insufficient targeting capacity, tough purification process</td><td colspan="1" rowspan="1"><xref rid="bib179" ref-type="bibr">179</xref>,<xref rid="bib180" ref-type="bibr">180</xref></td></tr><tr><td colspan="1" rowspan="1">Integrin targeting materials (cRGD, iRGD and fibronectin)</td><td colspan="1" rowspan="1">Good permeability, tumor vascular inhibition</td><td colspan="1" rowspan="1">Immunogenicity, rapid blood clearance, and significant MPS accumulation</td><td colspan="1" rowspan="1"><xref rid="bib181" ref-type="bibr">181</xref>, <xref rid="bib182" ref-type="bibr">182</xref>, <xref rid="bib183" ref-type="bibr">183</xref></td></tr><tr><td colspan="1" rowspan="1">TfR targeting materials (ferritin)</td><td colspan="1" rowspan="1">Small size enhancing drug stability, ease of production and modification</td><td colspan="1" rowspan="1">Immunogenicity, low drug loading efficacy and insufficient targeting</td><td colspan="1" rowspan="1"><xref rid="bib184" ref-type="bibr">184</xref>,<xref rid="bib185" ref-type="bibr">185</xref></td></tr><tr><td colspan="1" rowspan="1">FR targeting materials (FA)</td><td colspan="1" rowspan="1">Favorable pharmacokinetic properties, convenient availability and low cost</td><td colspan="1" rowspan="1">Inconsistent folate attachment,</td><td colspan="1" rowspan="1"><xref rid="bib186" ref-type="bibr">186</xref>,<xref rid="bib187" ref-type="bibr">187</xref></td></tr><tr><td rowspan="2" colspan="1">Bionic materials-mediated targeted delivery</td><td colspan="1" rowspan="1">Tumor cell membrane</td><td colspan="1" rowspan="1">Unlimited proliferation, evasion of MPS clearance and enhancing the immune response</td><td colspan="1" rowspan="1">Difficult isolation and purification, immunogenicity, and susceptible to contamination</td><td colspan="1" rowspan="1"><xref rid="bib233" ref-type="bibr">233</xref>, <xref rid="bib234" ref-type="bibr">234</xref>, <xref rid="bib235" ref-type="bibr">235</xref></td></tr><tr><td colspan="1" rowspan="1">Immunocyte membrane</td><td colspan="1" rowspan="1">Inflammatory response, evasion of MPS clearance</td><td colspan="1" rowspan="1">Limited membrane source, susceptible to contamination</td><td colspan="1" rowspan="1"><xref rid="bib233" ref-type="bibr">233</xref>, <xref rid="bib234" ref-type="bibr">234</xref>, <xref rid="bib235" ref-type="bibr">235</xref></td></tr></tbody></table><table-wrap-foot><fn><p>HA, hyaluronic acid; MPS, mononuclear phagocyte system; cRGD, cyclic RGDs; iRGD, linear RGDs; TfR, transferrin receptor; FA, folate.</p></fn></table-wrap-foot></table-wrap></p><p id="p0265">An active targeted drug delivery system has the following advantages: 1. Higher target activity. Passive targeting realizes accumulation in tumors <italic toggle="yes">via</italic> systemic circulation and EPR effects, which tend to result in insufficient drug content in tumor cells. The long-term retention in the tumor microenvironment may cause the drug to be cleared. In contrast, active targeting improves the targeting "initiative" by recognizing and binding to specific molecules and receptors on the surface of tumor cells<xref rid="bib190" ref-type="bibr"><sup>190</sup></xref>. 2. Higher biosafety. The normal cell surface is characterized by specific receptors of low quality and quantity. Therefore, the affinity of the active targeted drug delivery system to normal cells is weak, which greatly reduces the accumulation and absorption of drugs in normal tissues, thus improving the safety of drugs. Due to the different mechanisms of active targeted drug delivery systems, they can be divided into receptor-mediated targeted delivery and cell membrane-based targeted delivery.</p><sec id="sec3.2.2.1"><label>3.2.2.1</label><title>Receptor-mediated targeted delivery</title><p id="p0270">The receptor-mediated targeted delivery is a key component of the active targeted drug delivery system. It targets a specific or overexpressed receptor on the tumor cells surface, facilitating the drug delivery to the tumor cells through the modification of the ligand and the specific reaction between the receptor and the ligand. Many receptors are often differentiated or overexpressed on the surface of the tumor cell membrane. This provides the possibility to design correlative ligands according to the structure of the receptor and implement precision therapy. CD44, integrin, transferrin receptor (TfR) and folate receptor (FR) are all typical examples of the receptor-mediated targeted delivery system.</p><p id="p0275"><italic toggle="yes">CD44</italic>: CD44 is a type-I transmembrane single-chain glycoprotein, widely distributed on the cell membrane of lymphocytes, tumor cells, endothelial cells, and other cells. It has been shown that CD44 is overexpressed on the surface of tumor cells. Based on this, many CD44-targeting drug delivery platforms have been developed. Hyaluronic acid (HA), a naturally occurring polysaccharide, binds to the hyaluronic acid-binding sites on CD44, forming a complex that is subsequently internalized by tumor cells. Consequently, HA is frequently employed as a surface coating for targeted drug delivery systems to enhance their specificity and efficacy<xref rid="bib191" ref-type="bibr"><sup>191</sup></xref>.</p><p id="p0280">Wang et al.<xref rid="bib192" ref-type="bibr"><sup>192</sup></xref> combined palmityl palmitate with cetyltrimethylammonium bromide to construct core&#8211;shell nanoparticles (PNDH) for targeted delivery of ferroptosis inducer cisplatin, while using HA as the surface coating to improve tumor targeting. In the presence of HA, the tumor recognition efficiency was enhanced approximately twofold. Chi et al.<xref rid="bib193" ref-type="bibr"><sup>193</sup></xref> reported "core-shell" magnetic nanoparticles (FMMHG/Sor) modified with HA, comprising an Fe<sub>3</sub>O<sub>4</sub> core and a mesoporous organic silica shell (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A). By loading ferroptosis inducer sorafenib into the nanoparticle, dual-pathway ferroptosis therapy was achieved. HA modification significantly promoted cell uptake, with a cellular uptake rate of 72.3%. However, after pretreatment with free HA, cell uptake was less than 20%, further demonstrating the active targeting ability of HA (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B). Thanks to the modification of HA, FMMHG/Sor exerted effective anti-tumor effects. No significant increase in tumor volume was observed at the end of the study. HA-coated targeted delivery platforms can be used not only for small-molecule drug delivery, but also for macromolecular drug delivery. For example, Fan et al.<xref rid="bib194" ref-type="bibr"><sup>194</sup></xref> assembled anti-B7-H3 antibody (biAbs), epigallocatechin-3-gallate dimer (dEGCG) and HA to form S-biAb/dEGCG@NPs for the treatment of glioblastoma (GBM) (<xref rid="fig6" ref-type="fig">Fig. 6</xref>C). The intracranial accumulation of S-biAb/dEGCG@NPs was 12.3 times higher than that of free biAb. Tumor-bearing mice in the S-biAb/dEGCG@NP group survived significantly longer due to efficient drug accumulation (<xref rid="fig6" ref-type="fig">Fig. 6</xref>D). The above results indicate that S-biAb/dEGCG@NPs have a better therapeutic effect due to their better penetration and targeting. In conclusion, the HA-coated ferroptosis inducer delivery platform effectively improves ferroptosis efficiency. However, CD44 is mentioned to be widely distributed in normal tissues. HA-mediated targeting systems inevitably lead to accumulation in normal tissues and organs. Therefore, the development of more efficient targeting ligands still needs to be explored.<fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p>CD44 and integrin-mediated active targeted delivery systems in ferroptosis therapy. (A) Schematic diagram of dual-responsive FMMHG/Sor preparation. (B) The quantified results of cellular uptake of FMMHG/Sor, FMMG/Sor, FMM/Sor and HA + FMMHG/Sor in A549 cells. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2022 Elsevier. (C) The synthesis route schematic diagram of S-biAb/dEGCG@NP. (D) Survival curves of mice given different treatments. (I) Control, (II) biAbs, (III) biAb/dEGCG complexes, (IV) biAb/dEGCG@NPs, and (V) S-biAb/dEGCG@NPs. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 American Chemical Society. (E) Changes in the GPX4 activity in B16F10 cells after different treatments, including (I) Control, (II) Gel, (III) WA, (IV) WA-cRGD, (V) Gel@WA-cRGD. (F) Flow cytometry analysis of tumor cell death after different treatments. The unit of fluorescence intensity is a.u. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 Elsevier. (G) The Schematic diagram of ferroptosis in tumor cells induced by bcc-USINPs and subsequently the anti-tumor immune reaction. (H) Cell uptake in bcc-USINPs, iRGD-bcc-USINPs and iRGD-bcc-USINPs + free iRGD. Reprinted with the permission from Ref. <xref rid="bib200" ref-type="bibr">200</xref>. Copyright &#169; 2021 American Chemical Society. (I) Relative tumor volume in tumor-bearing mice as a function of time during treatment. Reprinted with the permission from Ref. <xref rid="bib202" ref-type="bibr">202</xref>. Copyright &#169; Reproduced from 2022 American Chemical Society.</p></caption><alt-text id="alttext0040">Figure 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0285"><italic toggle="yes">Integrin</italic>: Integrins are a family of cell surface receptors that can be activated by anchoring ligands, triggering endocytosis. Moreover, it has been found that certain tumor cell membranes overexpress integrin <italic toggle="yes">&#945;</italic><sub>V</sub><italic toggle="yes">&#946;</italic><sub>3</sub>. These characteristics make the selective delivery of ferroptosis inducers possible. Integrin <italic toggle="yes">&#945;</italic><sub>V</sub><italic toggle="yes">&#946;</italic><sub>3</sub> is usually poorly expressed in most cells but can be upregulated in tumor cells and endothelial cells within the tumor microenvironment<xref rid="bib195" ref-type="bibr"><sup>195</sup></xref>. Thus, integrin <italic toggle="yes">&#945;</italic><sub>V</sub><italic toggle="yes">&#946;</italic><sub>3</sub> has a higher selectivity compared to CD44. The integrin-mediated targeted delivery system is suitable for precise delivery to tumors<xref rid="bib196" ref-type="bibr"><sup>196</sup></xref><sup>,</sup><xref rid="bib197" ref-type="bibr"><sup>197</sup></xref>. The arginine&#8211;glycine&#8211;aspartate (RGD) peptide is a three-amino acid sequence<xref rid="bib195" ref-type="bibr"><sup>195</sup></xref>. According to the different structure of RGDs, RGD peptides can be divided into linear RGDs (iRGD) and cyclic RGDs (cRGD). Kapp et al.<xref rid="bib198" ref-type="bibr"><sup>198</sup></xref> demonstrated that RGD peptides bind to <italic toggle="yes">&#945;</italic><sub>V</sub><italic toggle="yes">&#946;</italic><sub>3</sub> through a bidentate salt bridge, which is involved in the interaction of the guanidinium moiety on arginine and the <italic toggle="yes">&#945;</italic>-subunit Asp218 in <italic toggle="yes">&#945;</italic><sub>V</sub><italic toggle="yes">&#946;</italic><sub>3</sub>. Furthermore, the electrostatic interaction present between RGD and metal ions in integrins also contributes to targeting<xref rid="bib199" ref-type="bibr"><sup>199</sup></xref>. All of these characteristics set up integrin as an ideal target for cancer therapy.</p><p id="p0290">cRGD contains the thiol group, which enables it to form a disulfide bond with drugs that also possess the thiol group. Under the targeting effect of cRGD, the drug successfully entered the tumor cells, exerting its curative effect. For example, Cheng et al.<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref> reported sodium alginate hydrogels loaded with WA-cRGD and aPD-L1. After intratumoral injection, WA is internalized by B16 cells <italic toggle="yes">via</italic> the interaction with cRGD-integrin receptors and subsequently released by the cells. As shown in <xref rid="fig6" ref-type="fig">Fig. 6</xref>E, the GPX4 activity in the WA-cRGD group was 25% lower than that in the WA group, which indicates that cRGD enhances tumor endocytosis of WA and brings a more significant ferroptosis inhibition. Furthermore, flow cytometry experiment results reaffirm the necessity for WA delivery with cRGD. As shown in <xref rid="fig6" ref-type="fig">Fig. 6</xref>F, the tumor cell death rate in the WA-cRGD group was 20% higher than that in the WA group. To sum up, the modification of cRGD significantly improved the tumor targeting of WA, promoted the accumulation of WA, and induced more intense ferroptosis. In addition, the application of iRGD in tumor-targeted drug delivery also achieved promising results. Sun and his colleagues<xref rid="bib200" ref-type="bibr"><sup>200</sup></xref>prepared iRGD-modified ultrasmall single-crystal Fe nanoparticles (iRGD-bcc-USINPs). iRGD&#8211;integrin interaction promotes the iRGD bcc-USINPs, internalized by tumors, and iron single crystals were released to induce ferroptosis in the acidic tumor microenvironment (<xref rid="fig6" ref-type="fig">Fig. 6</xref>G). According to the tracking of nanoparticles <italic toggle="yes">in vivo</italic>, the modification of iRGD resulted in a doubling of cellular uptake (<xref rid="fig6" ref-type="fig">Fig. 6</xref>H).</p><p id="p0295">Except for RGD peptides, which are directly used to modify drug carriers, RGD-enriched substances can also be utilized to modify drug carriers for targeting properties. Fibronectin (FN) is a typical example. FN is an ECM protein that contains an RGD sequence<xref rid="bib201" ref-type="bibr"><sup>201</sup></xref>. Xu et al.<xref rid="bib202" ref-type="bibr"><sup>202</sup></xref> utilize this characteristic of FN to achieve targeted delivery of the metal polyphenol network. Under the interaction of FN, the metal polyphenol network enters the tumor cells and releases Fe<sup>2+</sup> to induce ferroptosis. The <italic toggle="yes">in vivo</italic> anti-tumor experiments showed that DOX-TAF@FN has a significant inhibition of tumor and has a significant difference with DOX-TAF@BSA, which reflects the excellent targeting of FN (<xref rid="fig6" ref-type="fig">Fig. 6</xref>I).</p><p id="p0300">In conclusion, constructing a delivery system including the &#8220;missiles&#8221; RGD peptides offers a new approach to the precise delivery of ferroptosis inducers. Unfortunately, cRGD-modified delivery systems were shown to be highly immunogenic<xref rid="bib182" ref-type="bibr"><sup>182</sup></xref><sup>,</sup><xref rid="bib203" ref-type="bibr"><sup>203</sup></xref>. In addition, the susceptibility degradation of RGD peptides by proteases may reduce their stability <italic toggle="yes">in vivo</italic><xref rid="bib204" ref-type="bibr"><sup>204</sup></xref>. This brings challenges to the clinical application of RGD peptides. For the development of RGD peptide-targeting systems, finding a balance between targeting ability, immunogenicity, and instability is still a challenge.</p><p id="p0305"><italic toggle="yes">TfR</italic>: TfR is a kind of surface receptor of nucleated cells, which can bind to ferritin and maintain the homeostasis of intracellular iron level<xref rid="bib205" ref-type="bibr"><sup>205</sup></xref>. However, the extreme deficiency of iron ions in the tumor limits its growth and differentiation. Several studies have shown that TfR1 is highly expressed in a wide range of tumor cells (pancreatic, rectal, lung, bladder, etc.) to improve intracellular iron ion levels<xref rid="bib205" ref-type="bibr"><sup>205</sup></xref><sup>,</sup><xref rid="bib206" ref-type="bibr"><sup>206</sup></xref>. As a result, TfR-mediated ferroptosis inducer delivery strategy progressively becomes a new trend in targeted therapy of cancer. Ferritin is a protein nanocage composed of heavy chain ferritin (HFn) and light chain ferritin. As a major iron-storage protein in the body, ferritin can bind to TfR1 on the cell surface through its heavy chain. After entering the cytoplasm, ferritin releases iron ions to promote cell growth and development<xref rid="bib184" ref-type="bibr"><sup>184</sup></xref><sup>,</sup><xref rid="bib207" ref-type="bibr"><sup>207</sup></xref><sup>,</sup><xref rid="bib208" ref-type="bibr"><sup>208</sup></xref>. In addition, ferroptosis therapy is highly dependent on the intracellular iron level in tumor cells. Based on the TfR targeting ability and abundant iron ions, ferritin is considered an excellent carrier for the targeted delivery of ferroptosis inducers.</p><p id="p0310">Cheng et al.<xref rid="bib209" ref-type="bibr"><sup>209</sup></xref> constructed murine heavy chain ferritin (mHFn) by genetic engineering for targeted delivery of the ferroptosis inducers RSL3 and iFSP1 (<xref rid="fig7" ref-type="fig">Fig. 7</xref>A). <italic toggle="yes">In vivo</italic> and <italic toggle="yes">ex vivo</italic> imaging demonstrated that the high affinity of mHFn to TfR1 allowed the delivery system to be retained in the tumor cell for a longer time after intravenous injection (<xref rid="fig7" ref-type="fig">Fig. 7</xref>B and C). The long retention improved the drug's antitumor effect. In the <italic toggle="yes">in vivo</italic> anti-tumor experiments, the tumor volume in the mHFn@RSL3/iFSP1 group was only half of that in the free RSL3/iFSP1 group (<xref rid="fig7" ref-type="fig">Fig. 7</xref>D). The encapsulation of mHFn enables RSL3/iFSP1 to improve targeting capacity while reducing the possibility of being cleared. Zuo et al.<xref rid="bib210" ref-type="bibr"><sup>210</sup></xref> reported a ferritin-coated sorafenib to achieve targeted therapy for breast cancer (<xref rid="fig7" ref-type="fig">Fig. 7</xref>E). Ferritin enhanced the uptake of sorafenib in tumor cells, and the ferritin-modified group had higher fluorescence intensity (<xref rid="fig7" ref-type="fig">Fig. 7</xref>F) and tumor inhibition (<xref rid="fig7" ref-type="fig">Fig. 7</xref>G).<fig id="fig7" position="float" orientation="portrait"><label>Figure 7</label><caption><p>TfR and FR-mediated active targeted delivery systems in ferroptosis therapy. (A) Schematic diagram for the preparation process of mHFn@RSL3/iFSP1 nanocage. (B) <italic toggle="yes">In vivo</italic> biodistribution and fluorescence intensity quantification of mHFn@Cy7 in CT26 tumor-bearing BALB/c mice in CT26 tumors at predetermined time points. The unit is &#215; 10<sup>6</sup> p/s/cm<sup>2</sup>/sr. (C) <italic toggle="yes">Ex vivo</italic> imaging of CT26 tumor-bearing BALB/c mice at 72 h post-free Cy7 or mHFn@Cy7 administration. The unit is &#215; 10<sup>6</sup> p/s/cm<sup>2</sup>/sr. (D) MC38 tumor growth curves in different treatment groups. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2024 Elsevier. (E) Scheme of <italic toggle="yes">in vivo</italic> FPBC@SN behavior and related pathways of ferritinophagy-cascade. (F) Biodistribution images of PBC@IR820 and FPBC@IR820 at different time points <italic toggle="yes">in vivo</italic>. The unit is &#215; 10<sup>9</sup> [p/sec/cm<sup>2</sup>/sr]/[&#956;W/cm<sup>2</sup>]. (G) Tumor growth curves in different treatment groups. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2021 Wiley. (H) Schematic diagram of the synthesis process of TPL@TFBF. (I) Fluorescence images of tumor-bearing mice <italic toggle="yes">in vitro</italic> after different treatments. The unit of fluorescence intensity is a.u. (J) The tumor growth curves of mice in different treatment groups. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 Springer Nature.</p></caption><alt-text id="alttext0045">Figure 7</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p><p id="p0315">In conclusion, ferritin as the ligand could target tumor cells, and after the carrier was internalized into tumor cells, the ferroptosis inducer was released and triggered ferroptosis, which is an excellent candidate for targeted delivery of ferroptosis inducers.</p><p id="p0320"><italic toggle="yes">FR</italic>: FR is a glycosylphosphatidylinositol-linked membrane glycoprotein, which is characterized by high affinity to folate (FA)<xref rid="bib211" ref-type="bibr"><sup>211</sup></xref>. However, different forms of folate have different affinities for FR. Therefore, it is necessary to make structural modifications to folic acid to improve targeting efficiency. FR-mediated targeted delivery systems combine folic acid or analogues with a ferroptosis inducer and finally form a complex. Upon binding to FR, the cytomembrane was invaginated and the intracellular inclusion was produced. Finally, the complex is released from the inclusion under the ionic pump function. Therefore, drug delivery systems targeting FR also provide new solutions for the delivery of ferroptosis drugs.</p><p id="p0325">Wang et al.<xref rid="bib212" ref-type="bibr"><sup>212</sup></xref> constructed a BSA-FA functionalized iron-containing metal-organic framework (TPL@TFBF) (<xref rid="fig7" ref-type="fig">Fig. 7</xref>H). With the help of FA, TPL@TFBF targeted melanoma cells and released Triptolide (TPL), Fe<sup>3+</sup> and TA, triggering ferroptosis and pyroptosis. In the <italic toggle="yes">ex vivo</italic> fluorescence imaging, we observed significant fluorescence from <email>TPL@TFBF-Cy5.5</email> in the tumor tissues compared to other groups (<xref rid="fig7" ref-type="fig">Fig. 7</xref>I). This result demonstrated significant tumor targeting of FA. <italic toggle="yes">In vivo</italic> anti-tumor experiments demonstrated the significant advantages of the FA-modified delivery system. TPL@TFB group showed that the tumor growth inhibition is 41.74%, whereas FA modification significantly increased the tumor inhibition of TPL@TFBF (65.58%) (<xref rid="fig7" ref-type="fig">Fig. 7</xref>J).</p><p id="p0330">Although receptor-mediated targeting preparation improves the targeting performance against tumors, there are still some challenges in clinical application and industrialization. Firstly, animal tumor model tends to be established in a short time, whereas primary tumor in humans tends to form in several years. The variability of species and formation time often leads to heterogeneity of receptors and differences in expression levels; therefore, equivalence for clinical application remains a factor to be considered<xref rid="bib213" ref-type="bibr"><sup>213</sup></xref>. In addition, the modifying proportion of the ligand is also an important factor. The lower modification often leads to limited targeting efficiency, while the higher modification may affect the release of the drug from the carrier and reduce the efficacy<xref rid="bib214" ref-type="bibr"><sup>214</sup></xref>. Finally, possible off-target effects. Although these specific receptors are overexpressed in tumor cells, they also have low expression in normal cells. Therefore, exploring the toxicity of receptor-mediated targeted delivery systems in normal cells is also a matter that needs to be addressed<xref rid="bib215" ref-type="bibr"><sup>215</sup></xref>.</p></sec><sec id="sec3.2.2.2"><label>3.2.2.2</label><title>Bionic materials-mediated targeted delivery</title><p id="p0335">With the development of bionic technology, the cytomembrane has brought a new perspective for drug delivery. The cytomembrane-mediated targeting strategy utilizes the cytomembrane to wrap and deliver drugs to tumor cells by virtue of the natural properties of the cytomembrane, such as homologous targeting, chemotaxis, adhesion and so on. Second, the cell membrane is derived from the body, which confers high biosafety and avoids recognition and clearance by the immune system. Thus, membrane-based biomimetic carriers usher in a new era for the delivery of ferroptosis inducers. Therefore, cell membrane-based biomimetic carriers bring out a new era for the delivery of iron death inducers.</p><p id="p0340">Many biomolecules on the tumor cytomembrane (such as galactan-3, calreticulin, and Thomson-Friedenlein antigen, etc.) are involved in cell communication and adhesion, which behavior promotes aggregation for tumor cell<xref rid="bib216" ref-type="bibr"><sup>216</sup></xref>. Depending on these functional biomolecules, the tumor cell membrane, as the "coat" of the drug delivery system, can effectively deliver drugs to the tumor cell. Guo et al.<xref rid="bib217" ref-type="bibr"><sup>217</sup></xref> structured a ferroptosis inducer prodrug cisplatin delivery platform, covered gastric cancer cytomembrane "coat" (CMnMPt) to target gastric cancer cells <italic toggle="yes">in vivo</italic>. <italic toggle="yes">In vivo</italic> experiments showed that CMnMPt nanoparticles at the tumor site had double fluorescence intensity compared to MnMPt nanoparticles (<xref rid="fig8" ref-type="fig">Fig. 8</xref>A) and the tumor inhibition also increased nearly 20% (<xref rid="fig8" ref-type="fig">Fig. 8</xref>B). In addition, evscaping the recognition and uptake by immune cells is also a key factor. Pan et al.<xref rid="bib218" ref-type="bibr"><sup>218</sup></xref> designed a drug delivery system (PFTT@CM), consisting of tiaprazine (TPZ), ferroptosis inducer PFT, and cancer cell membrane (<xref rid="fig8" ref-type="fig">Fig. 8</xref>C), and researched the uptake behavior of RAW 264.7 cells to the drug delivery system. The result suggested that the uptake rate of PFTT nanoparticles by RAW 264.7 cells was 3.69 times higher than PFTT@CM (<xref rid="fig8" ref-type="fig">Fig. 8</xref>D). With precise targeting, PFTT@CM completely suppressed tumor growth within 18 days (<xref rid="fig8" ref-type="fig">Fig. 8</xref>E).<fig id="fig8" position="float" orientation="portrait"><label>Figure 8</label><caption><p>Cell membrane-modified delivery systems and their application in ferroptosis treatment. (A) The MRI signal of the tumor to normal-tissue ratio at 0, 4, 8 and 12 h after being treated with MnMPt or CMnMPt. (B) The weight of excised tumors in mice treated with Control, MSN, MPt, MnM, MnMPt or CMnMPt. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 Elsevier. (C) Synthesis of the tumor cell membrane-coated drug delivery system PFTT@CM. (D) Mean fluorescence intensity analysis of RAW 264.7 after incubating with PFT, PFTT, and PFTT@CM, using RAW 264.7 without any treatment as a blank group. The unit of fluorescence intensity is a.u. (E) Tumor volume growth curves were presented in the different treatment groups. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2022 Elsevier. (F) Cellular uptake of GA/PLGA (left) and GCMNPs (right) in U937, MV4&#8211;11, HT29, Caco-2, LO-2 and BM cells after 30 min of incubation. The nucleus was stained with DAPI (blue). The GCMNPs were labeled with Nile red (red). Scale bar = 10 &#956;m. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2022 Elsevier. (G) The preparation process of CFA/PRV@MM. (H) Time-dependent cellular uptake of CFA/C6 and CFA/C6@MM in 4T1 cells and (I) fluorescence semi-quantitative analysis of C6 signal. Scale bar in (H) = 10 &#956;m. The unit of fluorescence intensity in (I) is a.u. (J) Average tumor growth curves after 14 days of different treatments. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2024 Wiley.</p></caption><alt-text id="alttext0050">Figure 8</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr8.jpg"/></fig></p><p id="p0345">Immune cells are a family of cells that are associated with the immune response, including macrophages, NK cells, leukocytes, neutrophils and others. A variety of receptors with different functions are distributed on the immune cell membrane, and these receptors provide specialized biological functions for immune cells. For example, CD47 and CD45 send out the "don't eat me" signal, while the chemokine receptor and Toll receptor have inflammatory chemotactic properties<xref rid="bib219" ref-type="bibr"><sup>219</sup></xref><sup>,</sup><xref rid="bib220" ref-type="bibr"><sup>220</sup></xref>. The inflammatory features of the tumor microenvironment provide a new insight for the application of immune cell membranes to target drug delivery. For example, Gao et al.<xref rid="bib221" ref-type="bibr"><sup>221</sup></xref> designed a macrophage membrane-encapsulated chlorella (M-Chl). The cell membrane could interact with the inflammatory factors of solid tumor tissues <italic toggle="yes">via</italic> the inflammatory cytokines-related receptors. This specific substrate recognition drives the targeted accumulation and retention of M-Chl in the tumor sites. Second, immune cell membranes inherit cell markers, such as adhesion molecules and chemokine receptors<xref rid="bib220" ref-type="bibr"><sup>220</sup></xref><sup>,</sup><xref rid="bib222" ref-type="bibr"><sup>222</sup></xref>. For bionic nanocarriers, these markers are involved in the recognition of tumors, contributing greatly to the successful delivery of drugs inside tumor cells. Li et al.<xref rid="bib223" ref-type="bibr"><sup>223</sup></xref> developed white cell membrane-encapsulated ferroptosis drug glycyrrhetinic acid (GA) nanoparticles (GCMNPs) for the treatment of leukemia and colorectal tumors. Compared to normal cells (LO-2) and bone marrow (BM) cells, GCMNPs exhibited intense red fluorescence in colorectal cancer and leukemia cells (<xref rid="fig8" ref-type="fig">Fig. 8</xref>F), demonstrating the ability of GCMNPs to selectively target tumor cells without affecting normal cells. Yang et al.<xref rid="bib224" ref-type="bibr"><sup>224</sup></xref> prepared a nanogel (chitosan-Fc polymer crosslink with sodium alginate to form CFA nanogels) for encapsulating the ferroptosis inducer pravastatin (PRV), then wrapped with macrophage membranes (MM) to form CFA/PRV@MM (<xref rid="fig8" ref-type="fig">Fig. 8</xref>G). In cellular uptake experiments, CFA/PRV@MM showed significantly higher fluorescence intensity than CFA/PRV (<xref rid="fig8" ref-type="fig">Fig. 8</xref>H and I). The enhanced cellular uptake could be attributed to MM-induced tumor accumulation and endocytosis. With the help of MM, CFA/PRV@MM demonstrated the superior tumor inhibition effect (<xref rid="fig8" ref-type="fig">Fig. 8</xref>J).</p><p id="p0350">Although the cell membrane-based targeted drug delivery system has active targeting capacity, which improves the therapeutic effect. However, bio-nanotechnology is still in its infancy, faced with certain challenges in clinical application and industrialization. The limited membrane source is the first problem to be solved. The immune cells are limited-proliferation cells. Many cultured cells are still required to obtain cell membranes, which is unrealistic for industrialization. Second, isolation and purification are still a major challenge. For cancer cell membranes, the nucleus and genetic material should be strictly removed to eliminate potential carcinogenicity<xref rid="bib225" ref-type="bibr"><sup>225</sup></xref>. In addition, the expression of major histocompatibility complex (MHC) molecules on the membranes derived from immune cells brings immunogenicity issues<xref rid="bib226" ref-type="bibr"><sup>226</sup></xref>. All these issues will bring potential risks to the subsequent clinical application. Third, membrane separation is usually achieved by fragmentation and centrifugation, but the specific conditions have not been clearly demonstrated<xref rid="bib227" ref-type="bibr"><sup>227</sup></xref><sup>,</sup><xref rid="bib228" ref-type="bibr"><sup>228</sup></xref>. Further, we also need to define standard quality control criteria for cell membranes to ensure integrity without microorganisms. Otherwise, the quality and purity of the generated cell membranes cannot be guaranteed<xref rid="bib226" ref-type="bibr"><sup>226</sup></xref>.</p></sec></sec><sec id="sec3.2.3"><label>3.2.3</label><title>Perspectives of tumor targeted delivery</title><p id="p0355">Compared to the traditional drug delivery route, the targeted drug delivery strategy significantly increases the drug deposition in tumor cells and greatly improves the drug delivery efficiency and therapeutic effect. Passive or active targeting strategies can promote the delivery of drugs to the tumor, which makes the anti-tumor effect and side effects of patients take a turn for the better. However, the targeted delivery technology is immature, and there are many existing issues that need to be solved. For example, there are limited FDA-approved targeting materials and a single method for evaluating targeting ability. In addition, the safety of the materials is an important factor that we need to evaluate. Apart from examining short-term toxicity, such as organ toxicity and routine blood analysis, the long-term toxicity of targeting materials is rarely systematically evaluated<xref rid="bib229" ref-type="bibr"><sup>229</sup></xref>. Finally, the human tumor tends to take a long time to develop compared to animal models. Therefore, the tumor and microenvironment are often more complex, which requires us to further evaluate the efficacy of the ferroptosis inducer.</p></sec></sec><sec id="sec3.3"><label>3.3</label><title>Stimuli-responsive delivery strategy</title><p id="p0360">In ferroptosis-immunotherapy, the targeting strategy of the drug delivery system elevates the effective concentration of the drug at the tumor site. However, controlled release strategies, playing a crucial role in ensuring drug safety and efficacy by preventing the premature release of ferroptosis inducers, are essential to minimize their toxicity to immune cells such as T cells and macrophages. Among these, stimuli-responsive delivery strategies have demonstrated unparalleled therapeutic function. The core objective of this controlled drug release is to precisely deliver drugs to the lesion area and precisely regulate the timing and dose of drug release through external or endogenous stimulation signals, thereby achieving the "on-off" control of drug release<xref rid="bib230" ref-type="bibr"><sup>230</sup></xref><sup>,</sup><xref rid="bib231" ref-type="bibr"><sup>231</sup></xref>. Through this strategy, it can effectively prevent the toxic side effects that might be induced by the release of large doses of drugs within a short period, reduce the frequency of administration, and enhance patient compliance<xref rid="bib232" ref-type="bibr"><sup>232</sup></xref>. Such systems can respond to endogenous (such as low pH, high concentrations of ROS and GSH in the TME, specific overexpressed enzymes, etc.) or exogenous (such as light, ultrasound, etc.) stimuli to trigger the release of drugs, thereby achieving efficient treatment in the tumor area. Hence, based on the origin of response conditions, we will categorize them into endogenous stimulus-responsive delivery strategy and exogenous stimulus-responsive delivery strategy and introduce the characteristics of corresponding delivery systems and their application in ferroptosis-immunotherapy. <xref rid="tbl4" ref-type="table">Table 4</xref><xref rid="bib233" ref-type="bibr">233</xref>, <xref rid="bib234" ref-type="bibr">234</xref>, <xref rid="bib235" ref-type="bibr">235</xref>, <xref rid="bib236" ref-type="bibr">236</xref>, <xref rid="bib237" ref-type="bibr">237</xref>, <xref rid="bib238" ref-type="bibr">238</xref>, <xref rid="bib239" ref-type="bibr">239</xref>, <xref rid="bib240" ref-type="bibr">240</xref>, <xref rid="bib241" ref-type="bibr">241</xref>, <xref rid="bib242" ref-type="bibr">242</xref>, <xref rid="bib243" ref-type="bibr">243</xref> lists the advantages and disadvantages of each stimuli-responsive delivery system.<table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>Stimuli-responsive delivery system for ferroptosis-immunotherapy.</p></caption><alt-text id="alttext0080">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="1">Stimuli-responsive delivery system</th><th colspan="1" rowspan="1">Advantage</th><th colspan="1" rowspan="1">Disadvantage</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">Endogenous</td><td colspan="1" rowspan="1">pH-stimuli-responsive</td><td colspan="1" rowspan="1">Controlled release triggered by tumor acidity;<break/>Neutralizing the acidic environment</td><td colspan="1" rowspan="1">Tumor pH heterogeneity;<break/>Acid interference from inflammation or metabolic variations</td><td colspan="1" rowspan="1"><xref rid="bib233" ref-type="bibr">233</xref>, <xref rid="bib234" ref-type="bibr">234</xref>, <xref rid="bib235" ref-type="bibr">235</xref></td></tr><tr><td colspan="1" rowspan="1">REDOX-stimuli-responsive</td><td colspan="1" rowspan="1">Disrupting the equilibrium of GSH and ROS;<break/>Enhancing ferroptosis efficiency</td><td colspan="1" rowspan="1">Limited specificity in tumors with normal redox levels;<break/>Complex synthesis of redox-sensitive linkers/carriers;<break/>Variable redox heterogeneity within tumors</td><td colspan="1" rowspan="1"><xref rid="bib236" ref-type="bibr">236</xref>,<xref rid="bib237" ref-type="bibr">237</xref></td></tr><tr><td colspan="1" rowspan="1">Enzyme-stimuli-responsive</td><td colspan="1" rowspan="1">High specificity;<break/>Rapid response by fast enzymatic catalysis</td><td colspan="1" rowspan="1">Unable to directly eliminate abnormal enzymes;<break/>Variability in enzyme activity across tumor types/individuals;<break/>Inflammation-triggered leakage</td><td colspan="1" rowspan="1"><xref rid="bib240" ref-type="bibr">240</xref>, <xref rid="bib241" ref-type="bibr">241</xref></td></tr><tr><td colspan="1" rowspan="1">Multi-stimuli-responsive</td><td colspan="1" rowspan="1">Synergistic release control;<break/>Adaptability to heterogeneity</td><td colspan="1" rowspan="1">Insufficient conditions within the TME;<break/>Design complexity;<break/>High validation costs</td><td colspan="1" rowspan="1"><xref rid="bib240" ref-type="bibr">240</xref>, <xref rid="bib241" ref-type="bibr">241</xref></td></tr><tr><td rowspan="2" colspan="1">Exogenous</td><td colspan="1" rowspan="1">Light-stimuli-responsive</td><td colspan="1" rowspan="1">Synergistic therapeutic action with PTT/PDT;<break/>Remotely controlled activation</td><td colspan="1" rowspan="1">Risks of cutaneous injury during treatment;<break/>Toxicological risks from photosensitizers</td><td colspan="1" rowspan="1"><xref rid="bib240" ref-type="bibr">240</xref>,<xref rid="bib241" ref-type="bibr">241</xref></td></tr><tr><td colspan="1" rowspan="1">Ultrasound- stimuli-responsive</td><td colspan="1" rowspan="1">Synergistic therapeutic action with SDT;<break/>Deep tissue penetration</td><td colspan="1" rowspan="1">Device reliance;<break/>Tissue damage risks;<break/>Carrier stability demands</td><td colspan="1" rowspan="1"><xref rid="bib242" ref-type="bibr">242</xref>,<xref rid="bib243" ref-type="bibr">243</xref></td></tr></tbody></table><table-wrap-foot><fn><p>GSH, glutathione; TME, tumor microenvironment; PTT, photothermal therapy; PDT, photodynamic therapy; SDT, sonodynamic therapy.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec3.3.1"><label>3.3.1</label><title>Endogenous stimuli-responsive delivery strategy</title><p id="p0365">Compared to the physiological homeostasis of normal tissues, the TME exhibits significant pathological heterogeneity. These distinct pathological features provide a strategic opportunity for the design and development of tumor-stimuli drug delivery systems.</p><p id="p0370">Endogenous stimuli-responsive delivery strategy facilitates precise drug delivery by exploiting the characteristics of the tumor-specific microenvironment<xref rid="bib244" ref-type="bibr"><sup>244</sup></xref>. These systems can be activated in response to the stimulation of specific tumor pathological markers and only exert a therapeutic effect in tumor tissue while remaining "inactive" in normal tissue, thereby ensuring biosafety<xref rid="bib245" ref-type="bibr"><sup>245</sup></xref>. Given that the specificity of the TME is closely associated with the occurrence and development of tumors, this strategy can not only alleviate the abnormal TME but also achieve the specific release of drugs, attaining the effect of "one stone, two birds" and significantly enhancing ferroptosis and immunotherapy. Based on the different abnormal characteristics of the TME, endogenous stimulus-responsive delivery systems can be classified into pH-stimuli-responsive, REDOX-stimuli-responsive, enzyme-stimuli-responsive and multi-stimuli-responsive drug delivery strategies. The following will focus on the features of the corresponding delivery systems and their application in ferroptosis and immunotherapy.</p><p id="p0375">In solid tumors, in accordance with the Warburg effect, irrespective of the availability of oxygen, tumor cells have a greater propensity to undertake energy metabolism <italic toggle="yes">via</italic> anaerobic glycolysis, namely lactic acid metabolism, which leads to the accumulation of lactic acid<xref rid="bib246" ref-type="bibr"><sup>246</sup></xref>. Simultaneously, ion exchange proteins on the tumor cell membrane are constantly transporting H<sup>+</sup> from inside the cell to the exterior to prevent self-acidosis. Consequently, the TME assumes a weakly acidic state with a pH ranging from 6 to 7<xref rid="bib247" ref-type="bibr"><sup>247</sup></xref>. This acidic milieu can impact the activity of T cells, NK cells, and DCs, thereby suppressing immune function<xref rid="bib248" ref-type="bibr"><sup>248</sup></xref><sup>,</sup><xref rid="bib249" ref-type="bibr"><sup>249</sup></xref>. The slightly acidic environment of tumors can serve as an ideal stimulus for responsive drug delivery systems, which can enhance anti-tumor therapy by precisely controlling drug release. pH-sensitive chemical bonds, such as Schiff base bonds<xref rid="bib250" ref-type="bibr"><sup>250</sup></xref>, hydrazone bonds <xref rid="bib251" ref-type="bibr"><sup>251</sup></xref><sup>,</sup><xref rid="bib252" ref-type="bibr"><sup>252</sup></xref>, amido bonds<xref rid="bib253" ref-type="bibr"><sup>253</sup></xref>, acetal bonds<xref rid="bib254" ref-type="bibr"><sup>254</sup></xref>, ester bonds<xref rid="bib255" ref-type="bibr"><sup>255</sup></xref> and so on, can typically be incorporated into the material structure to construct acid-responsive carriers<xref rid="bib256" ref-type="bibr"><sup>256</sup></xref><sup>,</sup><xref rid="bib257" ref-type="bibr"><sup>257</sup></xref>. The Schiff base bond is formed through the nucleophilic addition reaction between aldehydes and amines. In an acidic environment, C<private-char name="E00C" description="bond, double bond"><glyph-data id="pc-E00C" format="SVG" resolution="300" x-size="12" y-size="9" xml:space="preserve">

&lt;svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="20.666667pt" height="16.000000pt" viewBox="0 0 20.666667 16.000000" preserveAspectRatio="xMidYMid meet"&gt;&lt;metadata&gt;
Created by potrace 1.16, written by Peter Selinger 2001-2019
&lt;/metadata&gt;&lt;g transform="translate(1.000000,15.000000) scale(0.019444,-0.019444)" fill="currentColor" stroke="none"&gt;&lt;path d="M0 440 l0 -40 480 0 480 0 0 40 0 40 -480 0 -480 0 0 -40z M0 280 l0 -40 480 0 480 0 0 40 0 40 -480 0 -480 0 0 -40z"/&gt;&lt;/g&gt;&lt;/svg&gt;


</glyph-data></private-char>N will undergo protonation and become unstable, readily breaking, and thereby decomposing into the original carbonyl and amino groups<xref rid="bib258" ref-type="bibr"><sup>258</sup></xref>. Zhang et al.<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> employed the reaction between 1,3,5-benzenetricarboxaldehyde and <italic toggle="yes">p</italic>-phenylenediamine to polymerize a COF layer on the surface of MOF, into which arachidonic acid (AA) was subsequently loaded. In the TME solution, the COF layer was gradually dissociated and AA was gradually released. The iron-based MOF converts H<sub>2</sub>O<sub>2</sub> and O<sub>2</sub> into OH and O<sub>2</sub><sup>&#8722;</sup> with a strong oxidizing capacity through the activity of peroxidase and natural oxidase, and possesses a strong GSH scavenging ability. The occurrence of ferroptosis promotes the immune response, and CD8<sup>+</sup>T cells secrete IFN-<italic toggle="yes">&#947;</italic>, which further activates ACSL4 and promotes the phosphatidylation of AA, thereby exacerbating ferroptosis. After treatment, the survival rate of the breast cancer mice reached 100 percent within 50 days. In the design of pH-stimuli-responsive delivery systems, in addition to utilizing pH-sensitive chemical bonds, the intelligent regulation of &#8220;ionizable functional groups&#8221; has emerged as a crucial strategy. Functional groups such as amino<xref rid="bib259" ref-type="bibr"><sup>259</sup></xref>, carboxyl<xref rid="bib260" ref-type="bibr"><sup>260</sup></xref>, and sulfonic acid groups can undergo protonation/deprotonation, leading to charge reversal or hydrophilicity&#8211;hydrophobicity transitions, thereby precisely driving structural reconstruction of the carrier and controlled drug release<xref rid="bib260" ref-type="bibr"><sup>260</sup></xref>. Despite these, the imidazole group has garnered significant attention due to its unique protonation properties, enabling it to absorb protons under mildly acidic conditions (pH 6.0&#8211;6.5), thereby inducing a hydrophilicity&#8211;hydrophobicity transition<xref rid="bib261" ref-type="bibr"><sup>261</sup></xref>. Zuo et al.<xref rid="bib210" ref-type="bibr"><sup>210</sup></xref> fabricated a pH-sensitive nanoparticle FPBC@SN and loaded Sorafenib and IDO inhibitor NLG919 to inhibit breast cancer. In an acidic milieu, the benzimidazole within the nanoparticles can be protonated and subsequently transformed from hydrophobic to hydrophilic, leading to the disintegration of the nanoparticles. Sorafenib successfully upregulates the expression of nuclear receptor coactivator 4 to facilitate ferritin autophagy and promote the liberation of endogenous iron ions. Simultaneously, the application of NLG919 also effectively reduced the Kyn/Trp ratio and elicited a potent anti-tumor immune response. An increasing amount of evidence indicates that lactic acid in the TME can suppress anti-tumor immunity by impeding the function and metabolism of related immune cells, thereby playing a role in promoting tumor growth<xref rid="bib233" ref-type="bibr"><sup>233</sup></xref>. Therefore, the pH-stimuli-responsive delivery system can not only trigger drug release <italic toggle="yes">via</italic> H<sup>+</sup> protonation in the TME but also enhance the proliferation and activation of immune cells by neutralizing the acidic environment, thereby augmenting the efficacy of immunotherapy.</p><p id="p0380">The REDOX-stimuli-responsive delivery system, designed to exploit the aberrant ROS and GSH levels in tumors, can achieve controlled drug delivery while disrupting this equilibrium. Within the TME, ROS (including superoxides and H<sub>2</sub>O<sub>2</sub>) and GSH exist at high concentrations, maintaining this balance<xref rid="bib262" ref-type="bibr"><sup>262</sup></xref>. Notably, TME H<sub>2</sub>O<sub>2</sub> levels can reach &#8764;100 &#956;mol/L-100-fold higher than in normal tissues, inducing oxidative DNA damage (<italic toggle="yes">e.g.</italic>, elevated 8-OHdG). Unrepaired damage contributes to malignant transformation<xref rid="bib263" ref-type="bibr"><sup>263</sup></xref>. While ROS promotes tumor development, it can also cause cellular damage. Consequently, tumor cells upregulate antioxidant systems like the GSH/GSSG pair. GSH, a major intracellular antioxidant, neutralizes ROS to protect tumor cells from oxidative stress and enhance survival<xref rid="bib236" ref-type="bibr"><sup>236</sup></xref>. Elevated GSH levels are further linked to increased cancer cell proliferation and resistance to apoptosis<xref rid="bib237" ref-type="bibr"><sup>237</sup></xref>, allowing tumors to safeguard growth through ROS/GSH dynamics.</p><p id="p0385">ROS-stimuli-responsive delivery systems can specifically react to ROS through changes in chemical structure or physical properties. Functional groups such as thioether<xref rid="bib264" ref-type="bibr"><sup>264</sup></xref><sup>,</sup><xref rid="bib265" ref-type="bibr"><sup>265</sup></xref>, borate ester<xref rid="bib266" ref-type="bibr"><sup>266</sup></xref>, and selenide<xref rid="bib267" ref-type="bibr"><sup>267</sup></xref> play a crucial role in these transformations, making such systems widely applicable in anti-tumor ferroptosis-immunotherapy. Ma et al.<xref rid="bib266" ref-type="bibr"><sup>266</sup></xref> utilized polyvinyl alcohol (PVA) as the gel matrix and incorporated TSPBA (borate ester bonds as crosslinker/ROS-sensor) to construct a hydrogel with ROSstimuli&#8211;responsive properties (<xref rid="fig9" ref-type="fig">Fig. 9</xref>A and B). Loaded with Rhodamine B and FITC, it demonstrated H<sub>2</sub>O<sub>2</sub>&#8211;triggered sol&#8211;gel transition and drug release. After seven days, the cumulative release of Rhodamine B and FITC was approximately three times higher than that in PBS (<xref rid="fig9" ref-type="fig">Fig. 9</xref>C and D). In mouse models of breast cancer, the release of CuS nanoparticles loaded with iFSP1 inhibited GPX4 and FSP1 and enhanced LPO, thereby inducing ferroptosis (<xref rid="fig9" ref-type="fig">Fig. 9</xref>E). Simultaneously, hydrogel-loaded SSO blocked CD36 on immunosuppressive cells, remodeling the TME (<xref rid="fig9" ref-type="fig">Fig. 9</xref>F). This strategy promoted ferroptosis, DC maturation, and T-cell responses (<xref rid="fig9" ref-type="fig">Fig. 9</xref>G). The consumption of GSH is also an important strategy for enhancing ferroptosis-immunotherapy. The levels of GSH in tumor cells can reach 2&#8210;10 mol/L, approximately 100&#8211;1000 times that of the extracellular matrix (2&#8211;10 &#956;mol/L) and 7&#8211;10 times that of normal tissue<xref rid="bib268" ref-type="bibr"><sup>268</sup></xref>. GSH is capable of reducing various metal-based nanomaterials, such as MnO<sub>2</sub> and MOFs, leading to the disintegration of the carrier structure and facilitating drug release. Furthermore, as a widely studied structural motif, disulfide bonds can be reduced to thiol groups under the action of GSH. Consequently, numerous disulfide-rich carriers have been designed for responsive drug delivery systems<xref rid="bib269" ref-type="bibr"><sup>269</sup></xref><sup>,</sup><xref rid="bib270" ref-type="bibr"><sup>270</sup></xref>. Dai et al.<xref rid="bib271" ref-type="bibr"><sup>271</sup></xref> developed a nanoreactor, ssPPELap@Fe-TA, where ssPPE is a polyphosphate ester containing disulfide bonds. This nanoreactor is capable of consuming GSH, leading to the inactivation of GPX4, and simultaneously triggering the rapid release of the loaded drug, <italic toggle="yes">&#946;</italic>-lapachone. Experimental results demonstrate that, in mouse CT26 colon cancer cells, the levels of GSH and GPX4 significantly decreased following treatment. Furthermore, the therapeutic outcomes revealed that the proportion of DCs increased from 23.4% to 45.0%, and the IL-6 level was elevated by approximately 3.6-fold compared to the PBS control group. These findings highlight the promising potential of ssPPELap@Fe-TA in cancer therapy. REDOX&#8211;stimuli&#8211;responsive delivery systems sensitize ferroptosis by disrupting the equilibrium between ROS and GSH, thereby augmenting the efficacy of immunotherapy. Nevertheless, excessive REDOX reactions might result in unanticipated side effects, and this uncertainty could be a major challenge for future clinical transformation.<fig id="fig9" position="float" orientation="portrait"><label>Figure 9</label><caption><p>Endogenous stimuli-responsive delivery strategy and their application in ferroptosis-immunotherapy. (A) A scheme for the assembly of the ROS-stimuli-responsive composite hydrogel. (B) The cryo-SEM image of the composite hydrogel. Scale bar = 1 &#956;m. Cumulative releasing curves of (C) FITC and (D) RhB-CuS-M from the composite hydrogel in the absence or presence of 0.5 mmol/L H<sub>2</sub>O<sub>2</sub>. (E) The LPO levels in 4T1 cells. Scale bar = 25 &#956;m. (F) Fluorescence imaging of free fatty acid uptake by M2-TAMs in the absence or presence of SSO (300 &#956;mol/L) from Hydrogel. Scale bar = 10 &#956;m. (G) The ratios of CD40<sup>+</sup> cells, MHC-II<sup>+</sup> cells and CD8<sup>+</sup> T cells after different treatments. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 Wiley. (H) Schematic illustration showing the dissociation of Sorafenib@Hb-Ce6 under MMP2. (I) Drug release in different environments (PBS, serum, MMP2, pH 6.5). (J) Survival rates of mice in different treatment groups. Reprinted with the permission from Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2020 American Chemical Society. (K) Schematic illustration of the dual-stimuli triggered peroxidase-like activity of FeIIITA@HA. (L) Fe<sup>3+</sup> release kinetics of nanoprobes recorded under different conditions. (M) The TNF-<italic toggle="yes">&#945;</italic>/IFN-<italic toggle="yes">&#947;</italic> staining images of the tumor slices after 10 days of treatment. Scale bar = 100 &#956;m. Ref. <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>. Copyright &#169; 2023 Springer Nature.</p></caption><alt-text id="alttext0055">Figure 9</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr9.jpg"/></fig></p><p id="p0390">Enzyme-stimuli-responsive drug delivery systems are also commonly used in ferroptosis-immunotherapy. Studies have demonstrated that the pathology of the tumor is associated with the dysfunction or dysregulation of enzyme expression, matrix metalloproteinases (MMP)<xref rid="bib272" ref-type="bibr"><sup>272</sup></xref>, hyaluronidase (HAase)<xref rid="bib273" ref-type="bibr"><sup>273</sup></xref>, esterasem<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib274" ref-type="bibr"><sup>274</sup></xref>, oxidoreductase<xref rid="bib275" ref-type="bibr"><sup>275</sup></xref> and so on. Among these, the most typical is the overexpression of MMP, which can participate in numerous pathological processes related to tumor initiation, progression, invasion, and metastasis by modulating signal transduction<xref rid="bib276" ref-type="bibr"><sup>276</sup></xref>. Based on this characteristic, it is of considerable significance to utilize enzymes as a responsive point to design and develop an anti-tumor drug delivery system, which is conducive to the controlled release of drugs at the tumor site. Xu et al.<xref rid="bib277" ref-type="bibr"><sup>277</sup></xref> conjugated hemoglobin (Hb) with the photosensitizer Ce6 to construct a two-in-one nanoplatform loaded with Sorafenib (SRF@Hb-Ce6), and subsequently integrated amphiphilic MMP2-responsive peptide into the framework of the nanoplatform to guarantee drug-specific release. Under the influence of MMP, 70% of the drug could be released within 120 min (<xref rid="fig9" ref-type="fig">Fig. 9</xref>H and I). After laser irradiation at 150 mW/cm<sup>2</sup>, the PDT generated by the photosensitizer enhanced ferroptosis by recruiting immune cells to secrete IFN-<italic toggle="yes">&#947;</italic>. The results indicated that Sorafenib@Hb-Ce6 exhibited an excellent therapeutic effect <italic toggle="yes">in vivo</italic>, and the survival rate of breast cancer mice reached 100% within 40 days (<xref rid="fig9" ref-type="fig">Fig. 9</xref>J). Although the activity and quantity of enzymes do not undergo significant alterations before and after catalysis, it appears that enzyme-stimuli-responsive delivery systems are unable to directly eliminate abnormal enzymes. Nevertheless, due to the high specificity of enzymes, such delivery systems can still effectively exploit the characteristics of enzymes to achieve precise drug release, thereby exerting a significant therapeutic effect. However, the species-specific differences in esterase activity (<italic toggle="yes">e.g.</italic>, between preclinical models and humans) lead to inconsistent therapeutic outcomes with identical formulations, posing a major translational challenge for advancing enzyme-responsive delivery systems<xref rid="bib238" ref-type="bibr"><sup>238</sup></xref>.</p><p id="p0395">Given that the physiological environment of healthy tissues is highly complex, this may result in the accidental activation of the drug delivery system. For instance, acidic characteristics are not exclusive to the TME. The site of infection also possesses an acidic environment due to the accumulation of lactic acid, which might also trigger the release of active drugs and give rise to adverse toxicity<xref rid="bib234" ref-type="bibr"><sup>234</sup></xref><sup>,</sup><xref rid="bib235" ref-type="bibr"><sup>235</sup></xref>. By leveraging the multi-stimuli-responsive properties of certain materials or incorporating multiple materials, it is anticipated that the controlled drug release can be optimized. HA can not only bind to CD44 on the surface of cancer cells to exert a targeted effect, but also serve as a degradation site in response to stimulation by being degraded by hyaluronidase in the TME<xref rid="bib278" ref-type="bibr"><sup>278</sup></xref>. Zhang et al.<xref rid="bib239" ref-type="bibr"><sup>239</sup></xref> employed Fe<sup>3+</sup>, TA and HA to design and fabricate a novel pH/HAase double-stimulated smart nanoprobe, FeIIITA@HA (<xref rid="fig9" ref-type="fig">Fig. 9</xref>K and L). The precise diagnosis and treatment of squamous cell carcinoma were achieved. At the tumor site, HA gradually undergoes degradation under the action of HAase. Subsequently, FeIIITA is internalized by tumor cells, and the acidic state of the cellular lysosome further triggers protonation, leading to the release of Fe<sup>3+</sup> from the nanoprobe and triggering ferroptosis. The dual-stimuli-responsive delivery system enables a gradual release, significantly enhancing the specificity of tumor treatment (<xref rid="fig9" ref-type="fig">Fig. 9</xref>M).</p><p id="p0400">A controlled release delivery strategy exploiting the characteristics of the TME can be employed to regulate the microenvironment, exert a certain therapeutic effect, and does not require reliance on external stimulation, thereby being more conducive to delivery. Nevertheless, the conditions within the microenvironment are insufficient, and the response is inadequate. Some stimuli-response conditions sometimes exhibit a non-specific distribution. Even with the use of multi-responsive delivery strategies, complete prevention of drug leakage cannot be guaranteed. Additionally, as the complexity of the carrier increases, the design and manufacturing challenges of the system also grow accordingly. Not only that, but due to the heterogeneity of the tumor, it is challenging to ensure the complete activation of the material at the tumor site, making the realization of precisely controlled release highly difficult. In preclinical research, it is necessary to simultaneously optimize the two response thresholds and the synergy effect.</p></sec><sec id="sec3.3.2"><label>3.3.2</label><title>Exogenous stimuli-responsive delivery strategy</title><p id="p0405">In contrast to endogenous stimuli-responsive delivery, exogenous stimuli-responsive delivery requires external stimuli and responsive carriers. However, it offers advantages for precise tumor treatment, as it&#8217;s non-invasive and controllable. This review will focus specifically on exogenous stimulus-responsive delivery strategies related to photothermal therapy (PTT), photodynamic therapy (PDT), and sonodynamic therapy (SDT). These three modalities utilize either light or ultrasound as external stimuli to enhance ferroptosis while concurrently activating antitumor immunity through the generation of photothermal effects or ROS. Detailed discussions of each approach will follow in subsequent sections.</p><p id="p0410">Light is increasingly used in responsive drug delivery systems for tumor treatment. Given the spatiotemporal controllability of light, the light-stimuli-responsive drug delivery strategy exhibits higher selectivity and specificity in achieving on-demand drug release and activation<xref rid="bib240" ref-type="bibr"><sup>240</sup></xref>. Specific wavelengths of light (namely, ultraviolet, visible, and near-infrared) can modify the stability or structural degradation of responsive materials in light-stimuli-responsive drug delivery systems to release drugs at precise locations<xref rid="bib279" ref-type="bibr"><sup>279</sup></xref>. Besides the significant function of responsive drug release, light-responsive delivery systems are also closely associated with PTT and PDT. For PTT, materials with photothermal conversion capability can promote the ICD of cancer cells by generating high temperatures in the local tumor under the influence of light, which can significantly sensitize ferroptosis and immunotherapy. Chen et al.<xref rid="bib241" ref-type="bibr"><sup>241</sup></xref> developed MetaCell, a cellular Trojan horse, which utilizes living neutrophils to incorporate heat-sensitive liposomal bimetallic Fe-Cu-MOFs (Lip@Fe-Cu-MOFs). When the NIR laser stimulates the tumor area, a significant difference in inflammation is observed between the normal tissue and the tumor area. These differences facilitate the enhanced recruitment of MetaCell to the tumor site. Subsequently, Fe-Cu-MOFs, which possess significant photothermal conversion ability, can elevate the temperature and control the release of heat-sensitive liposomes for drug release. Experimental results indicate that Lip@Fe-Cu-MOF (500 &#956;g/mL) can increase to &#8764;50 &#176;C after 5 min of irradiation with 808 nm light (1.5 W/cm<sup>2</sup>), and 44.36% of the drug can be released within 1 h. Not only that, but there are multiple options for the utilization of light, and a second type of near-infrared light (NIR-II) can be employed for this purpose. This is because it exhibits greater tissue penetration and lower phototoxicity in comparison to NIR-I<xref rid="bib280" ref-type="bibr"><sup>280</sup></xref>. For instance, Yue utilizes NIR-II to activate dual-enzyme modified semiconductor polymer nanopreparations (SPHGA) to achieve controlled ferroptosis/immunotherapy/PPT therapy<xref rid="bib281" ref-type="bibr"><sup>281</sup></xref>. Under 1064 nm laser irradiation, the nanoparticles undergo photothermal conversion and structural disruption, releasing a ferroptosis inducer, Hb and an immune adjuvant, adenosine deaminase, to precisely regulate tumor suppression. In a subcutaneous bilateral 4T1 breast cancer mouse model, the ability to completely suppress the tumor and prevent recurrence was demonstrated. For PDT, the photosensitizer needs to be activated under the light to generate ROS, which can not only enable responsive delivery but also sensitize ferroptosis. Besides directly exerting cytotoxicity on tumor cells, PDT also demonstrates immunomodulatory properties, inducing ICD<xref rid="bib282" ref-type="bibr"><sup>282</sup></xref>. Wang et al.<xref rid="bib283" ref-type="bibr"><sup>283</sup></xref> have developed a multifunctional nanoplatform (CMArg@Lip), where the hydrophilic NO donor Arg is enveloped in a ROS-stimuli-responsive liposome through a hydrophobic interaction, and the hydrophobic photosensitizer Ce6 and the NRF2 inhibitor ML385 are located within the lipid bilayer of the nanoplatform. Under 650 nm light stimulation, Ce6 generates ROS and induces liposome depolymerization, facilitating the release of encapsulated drugs. CMArg@Lip has exhibited potent anti-tumor effects by disrupting the powerful antioxidant capacity of cancer cells, promoting the ICD of cancer cells, and activating the STING pathway.</p><p id="p0415">Ultrasound-stimuli-responsive delivery strategies are intimately associated with sonodynamic therapy (SDT)<xref rid="bib284" ref-type="bibr"><sup>284</sup></xref>. Likewise, SDT has demonstrated remarkable potential in inducing ICD and activating anti-tumor immunity<xref rid="bib243" ref-type="bibr"><sup>243</sup></xref>. Ding et al.<xref rid="bib242" ref-type="bibr"><sup>242</sup></xref> fabricated a semiconductor polymer nanotherapeutic agent (SPC<sub>Fe</sub>/siP). SPC<sub>Fe</sub>/siP integrates PD-L1 siRNA, ferroptosis-inducing Fe<sub>3</sub>O<sub>4</sub> nanoparticles, and a semiconductor polymer sonosensitizer within a singlet oxygen (<sup>1</sup>O<sub>2</sub>)-cleavable nanosystem. After the injection of the nanomedicine and subsequent ultrasound irradiation, SPC<sub>Fe</sub>/siP generates <sup>1</sup>O<sub>2</sub>
<italic toggle="yes">via</italic> the SDT effect of the semiconductor polymer, leading to precise and efficient liberation of Fe<sub>3</sub>O<sub>4</sub> nanoparticles and PD-L1 siRNA from SPC<sub>Fe</sub>/siP. This ultrasound-activated ferroptosis immunotherapy using SPC<sub>Fe</sub>/siP effectively suppressed the growth of orthotopic glioma in mouse models.</p><p id="p0420">Among the exogenous stimulus-responsive delivery strategies, the utilization of light sources for photoresponsive delivery systems is currently the most extensively developed. However, among several distinct types of light, such as ultraviolet, visible, and near-infrared light, short and medium-wave ultraviolet (200&#8210;320 nm) tend to induce more severe skin damage<xref rid="bib285" ref-type="bibr"><sup>285</sup></xref>. A considerable number of studies have demonstrated that even UVA with a wavelength of 337 nm can also cause harm to DNA<xref rid="bib279" ref-type="bibr"><sup>279</sup></xref><sup>,</sup><xref rid="bib286" ref-type="bibr"><sup>286</sup></xref>. In contrast, near-infrared light exhibits more prominent advantages in related clinical applications and is more conducive to clinical transformation.</p><p id="p0425">It is noteworthy that light/ultrasound-triggered drug release typically relies on metal-based sensitizers, which may pose potential biosafety risks<xref rid="bib287" ref-type="bibr"><sup>287</sup></xref>. For successful clinical translation, it is imperative to employ biocompatible materials or regulatory-approved sensitizers, such as FDA-certified ICG and iron oxide nanoparticles authorized for PTT in the European Union<xref rid="bib288" ref-type="bibr"><sup>288</sup></xref>. However, systems enabling stimulus-triggered release without added sensitizers simplify preparation, will enhance safety, and improve clinical potential. This aligns with approaches like light-triggered Fe<sup>2+</sup> release from ferrihydrite below 480 nm. Yang et al.<xref rid="bib289" ref-type="bibr"><sup>289</sup></xref> employed visible blue light at 450 nm for the release of Fe<sup>2+</sup>. Firstly, they fabricated PEG-coated ferrihydrite nanoparticles (PEG-Fns), which released 60&#8210;170 &#956;mol/L Fe<sup>2+</sup> within 90 min after blue light irradiation, significantly higher than the Fe<sup>2+</sup> in normal cells (2.4 &#177; 0.4 &#956;mol/L)<xref rid="bib290" ref-type="bibr"><sup>290</sup></xref>. Besides the release of Fe<sup>2+</sup>, PEG-Fns possesses photofenton activity and is capable of generating &#183;OH under blue light irradiation. The formation of Fe<sup>2+</sup> and &#183;OH initiates potent ferroptosis and PDT effects. The results of the <italic toggle="yes">in vivo</italic> study in mice demonstrated that this approach can induce the polarization of TAM from the tumor-promoting M2 type to the tumor-suppressing M1 type, and effectively alleviate lung metastasis. Therefore, the future direction should focus on developing light-responsive systems that do not require the introduction of photosensitizers.</p><p id="p0430">Compared to conventional injections, both endogenous and exogenous stimulus-responsive delivery systems enable precise drug release control to prevent burst release effects and prolong plasma half-life. While externally stimulated therapies, including PTT, PDT, and SDT, enhance tumor inhibition, endogenous systems such as pH-responsive carriers reduce immunotoxicity <italic toggle="yes">via</italic> tumor microenvironment pH normalization and impair tumor progression through redox balance disruption, synergistically boosting antitumor responses. However, clinical translation remains challenged by tumor microenvironment heterogeneity, limiting release precision, alongside complex manufacturing scale-up, high quality-control expenses, and deficient regulatory frameworks.</p></sec></sec><sec id="sec3.4"><label>3.4</label><title>Combination strategy</title><p id="p0435">In this review, we categorize the delivery strategies for ferroptosis-immunotherapy into three functional modules: co-delivery strategies, targeting strategies and stimuli-responsive release strategies. Each of these strategies independently contributes to the enhancement of ferroptosis or immune activation, thereby improving antitumor efficacy. Importantly, rather than relying on a single approach, recent studies commonly favor the integration of multiple strategies to maximize therapeutic efficacy. For example, combining targeting strategies with co-delivery has been widely explored: cRGD-mediated tumor targeting has been integrated with the co-delivery of aPD-L1 to simultaneously enhance delivery efficiency and immune activation<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref>. Similarly, biomimetic nanocarriers can serve dual roles by providing active targeting capabilities while functioning as ISAPIs themselves<xref rid="bib217" ref-type="bibr"><sup>217</sup></xref>. Moreover, stimuli-responsive strategies are often merged with co-delivery approaches; for instance, pH-sensitive nanocarriers have been developed to co-deliver NLG919, achieving precise release within the acidic tumor environment to boost immune responses<xref rid="bib210" ref-type="bibr"><sup>210</sup></xref>. However, it inevitably introduces greater complexity to the design and manufacturing processes, posing significant challenges for clinical translation.</p></sec></sec><sec id="sec4"><label>4</label><title>Conclusions and perspectives</title><p id="p0440">Ferroptosis-cancer immunotherapy shows remarkable advantages in cancer treatment. However, it is noteworthy that the crosstalk between ferroptosis and immunity is highly complex. Some studies have shown that ferroptosis in tumor cells may have negative effects on immune cells, such as excessive LPO, potentially impairing the function of DCs. Therefore, precise drug delivery strategies that can achieve ferroptosis-cancer immunotherapy while mitigating immune damage have been developed: (1) Immunostimulatory active pharmaceutical ingredients co-delivery directly stimulates the immune system and enhances synergistic effects, thereby augmenting anti-tumor efficacy while mitigating the side effects of ferroptosis on the immune. (2) Tumor-targeted delivery systems selectively accumulate therapeutic agents in malignant cells while preserving immune cell viability. (3) Stimuli-responsive release strategies utilize TME-specific cues to achieve controlled release at the lesion site or incorporate auxiliary therapies (<italic toggle="yes">e.g.</italic>, photo-, thermo-, or sono-therapy) to amplify therapeutic effects. Thus, implementing precise and efficient delivery strategies to enhance ferroptosis in tumor cells while minimizing immune system damage is essential for improving the efficacy of ferroptosis-cancer immunotherapy.</p><p id="p0445">However, formidable challenges persist during the transition from preclinical studies to clinical applications. In this section, we systematically analyze the underlying challenges hindering clinical translation and propose forward-looking strategies to overcome these obstacles (<xref rid="fig10" ref-type="fig">Fig. 10</xref>). (1) Complex mechanistic crosstalk between ferroptosis and antitumor immunity. It's widely believed that tumor cell ferroptosis, as ICD can activate APCs, subsequently initiating CD8<sup>+</sup>T cell responses. Activated CD8<sup>+</sup> T cells can secrete IFN-<italic toggle="yes">&#947;</italic> that sensitizes ferroptosis through dual pathways. However, critical knowledge gaps persist: T cells exhibit heightened ferroptosis susceptibility due to absent p53 suppressors, and the dose-response relationship between T-cell infiltration depth and ferroptosis sensitivity remains unquantified<xref rid="bib291" ref-type="bibr"><sup>291</sup></xref>. Critically, LPO accumulating on ferroptotic tumor cell membranes lacks cellular selectivity and may directly damage neighboring immune cells, compromising antitumor immunity. Additionally, the specificity of ferroptosis inducers and their efficacy in distinct tumor subtypes requires further validation. Therefore, future efforts should focus on developing more inhibitors of reductive systems (<italic toggle="yes">e.g.</italic>, targeting the system Xc<sup>&#8722;</sup>/GSH/GPX<sub>4</sub> axis) to reduce tumor ferroptosis resistance rather than directly enhancing LPO, integrating ISAPIs to directly potentiate immunity, simultaneously enhancing tumor-specific drug accumulation <italic toggle="yes">via</italic> targeting strategies, alongside achieving controlled release at the lesion site. Furthermore, interdisciplinary collaboration to integrate research advances across fields is essential, such as employing high-throughput screening to identify specific ferroptosis-inducing agents, leveraging single-cell sequencing and metabolomics to decode ferroptosis-immune crosstalk. (2) Biocompatibility concerns persist in ferroptosis-immunotherapy delivery systems. Although the three strategies enhance tumor-specific accumulation and spatiotemporal drug control, their complex material designs raise critical biosafety challenges. The core dilemma lies in the necessity for multi-functional modifications, such as targeting ligands, responsive linkers or photo/ultrasound-sensitive components, to achieve precise drug delivery. These modular additions may compromise biocompatibility through: (a) heterogeneous surface modifications destabilizing carriers, causing off-target organ accumulation; (b) interference with immune cell metabolic homeostasis; (c) insufficient toxicological analysis of multi-excipient formulations. Future investigations should focus on streamlined modular design with biocompatible materials with FDA-approved, incorporating systematic toxicology assessments of long-term biodistribution, immunogenicity, and metabolic stability. (3) The Lack of personalized therapeutic strategies targeting ferroptosis modulation with immunotherapy continues to limit synergistic efficacy in tumor treatment. Future research could propose a precision medicine framework that leverages patient-specific tumor genetic profiles and tumor microenvironment biomarkers, such as CD8<sup>+</sup> T-cell infiltration density and M2 macrophage prevalence to develop modular therapeutic toolkits, optimizing treatment regimens. (4) The development of standardized multidimensional evaluation frameworks for assessing therapeutic outcomes in oncology remains a formidable challenge. While the Response Evaluation Criteria in Solid Tumors (RECIST) provides an internationally recognized, quantitative framework for evaluating therapeutic efficacy in clinical trials, significant discrepancies exist in preclinical research due to inconsistent evaluation criteria across institutions and experimental designs. To address this limitation, future efforts should establish unified standards and protocols, strengthen preclinical quality requirements, foster interdisciplinary collaboration, and ensure scientific validity and practicality of strategies. (5) A persistent translational bottleneck also stems from the limited conventional preclinical models. Drug candidates demonstrating efficacy in rodent models frequently exhibit suboptimal therapeutic outcomes during clinical translation phases due to interspecies disparities in drug metabolism and tumor microenvironmental dynamics. To bridge this preclinical-clinical divide, next-generation model systems&#8212;such as humanized tumor organoid models-must be prioritized to enhance clinical correlation. Harness cutting-edge technologies to improve data quality, leveraging big data and AI for real-time monitoring and analysis of treatment responses to optimize therapeutic strategies. Foster interdisciplinary collaboration and deepen research through partnerships across the pharma industry.<fig id="fig10" position="float" orientation="portrait"><label>Figure 10</label><caption><p>Conclusion and perspectives of ferroptosis-cancer immunotherapy. The upper section lists the three delivery strategies, the left section outlines the formidable challenges, and the right section presents the corresponding forward-looking strategies.</p></caption><alt-text id="alttext0060">Figure 10</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr10.jpg"/></fig></p></sec><sec id="sec5"><title>Author contributions</title><p id="p0450">Lu Gan, Xincheng Lin and Ziqiao Zhong: Writing &#8211; original draft. Yichun Zheng, Xinyi Chen and Jun Chen: Visualization. Xiao Yue and Yingshan Liu revised the manuscript. Wenhao Wang, Ying Huang, Xin Pan and Chuanbin Wu: Writing &#8211; review &amp; editing, Supervision, Conceptualization. All of the authors have read and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Conflicts of interest</title><p id="p0455">The authors have no conflicts of interest to declare.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name></person-group><article-title>Hallmarks of cancer: new dimensions</article-title><source>Cancer Discov</source><volume>12</volume><year>2022</year><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">35022204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-21-1059</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><volume>71</volume><year>2021</year><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Thermal immuno-nanomedicine in cancer</article-title><source>Nat Rev Clin Oncol</source><volume>20</volume><year>2023</year><fpage>116</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">36604531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-022-00717-y</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.X.</given-names></name></person-group><article-title>Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4</article-title><source>Mol Cancer</source><volume>18</volume><year>2019</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">31690319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-019-1091-2</pub-id><pub-id pub-id-type="pmcid">PMC6833286</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Nishinakamura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shinya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Irie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sakihama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Naito</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade</article-title><source>Sci Transl Med</source><volume>17</volume><year>2025</year><object-id pub-id-type="publisher-id">eadk3160</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.adk3160</pub-id><pub-id pub-id-type="pmid">39937883</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>June</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Kawalekar</surname><given-names>O.U.</given-names></name><name name-style="western"><surname>Ghassemi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Milone</surname><given-names>M.C.</given-names></name></person-group><article-title>CAR T cell immunotherapy for human cancer</article-title><source>Science</source><volume>359</volume><year>2018</year><fpage>1361</fpage><lpage>1365</lpage><pub-id pub-id-type="pmid">29567707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aar6711</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="book" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Shigemori</surname><given-names>K.</given-names></name></person-group><part-title>Radiation-induced inflammatory responses in carcinogenesis and cardiac disease</part-title><year>2022</year><publisher-name>University of</publisher-name><publisher-loc>Oxford (United Kingdom)</publisher-loc></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Min</surname><given-names>Y.Z.</given-names></name></person-group><article-title>Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy</article-title><source>Acta Biomater</source><volume>171</volume><year>2023</year><fpage>482</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">37708924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2023.09.013</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>He</surname><given-names>Z.K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.S.</given-names></name></person-group><article-title>Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction</article-title><source>eLife</source><volume>8</volume><year>2019</year><object-id pub-id-type="publisher-id">e49020</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.49020</pub-id><pub-id pub-id-type="pmcid">PMC6879305</pub-id><pub-id pub-id-type="pmid">31767055</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Diaz</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Shiu</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Punt</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Pembrolizumab <italic toggle="yes">versus</italic> chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study</article-title><source>Lancet Oncol</source><volume>23</volume><year>2022</year><fpage>659</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">35427471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(22)00197-8</pub-id><pub-id pub-id-type="pmcid">PMC9533375</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Kumagai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>H.</given-names></name></person-group><article-title>Antitumour immunity regulated by aberrant ERBB family signalling</article-title><source>Nat Rev Cancer</source><volume>21</volume><year>2021</year><fpage>181</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">33462501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-020-00322-0</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.W.</given-names></name><etal/></person-group><article-title>Tumor-killing nanoreactors fueled by tumor debris can enhance radiofrequency ablation therapy and boost antitumor immune responses</article-title><source>Nat Commun</source><volume>12</volume><year>2021</year><fpage>4299</fpage><pub-id pub-id-type="pmid">34262038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-24604-9</pub-id><pub-id pub-id-type="pmcid">PMC8280226</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.Y.</given-names></name><etal/></person-group><article-title>Engineering autologous tumor cell vaccine to locally mobilize antitumor immunity in tumor surgical bed</article-title><source>Sci Adv</source><volume>6</volume><year>2020</year><object-id pub-id-type="publisher-id">eaba4024</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.aba4024</pub-id><pub-id pub-id-type="pmcid">PMC7304971</pub-id><pub-id pub-id-type="pmid">32596457</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Freitas-Cortez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Masrorpour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mahmud</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cancer cells avoid ferroptosis induced by immune cells <italic toggle="yes">via</italic> fatty acid binding proteins</article-title><source>Mol Cancer</source><volume>24</volume><year>2025</year><fpage>40</fpage><pub-id pub-id-type="pmid">39901247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-024-02198-2</pub-id><pub-id pub-id-type="pmcid">PMC11789333</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>G.L.</given-names></name><etal/></person-group><article-title>Engineered anti-cancer nanomedicine for synergistic ferroptosis-immunotherapy</article-title><source>Chem Eng J</source><volume>455</volume><year>2023</year><object-id pub-id-type="publisher-id">140688</object-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Ferroptosis signature shapes the immune profiles to enhance the response to immune checkpoint inhibitors in head and neck cancer</article-title><source>Adv Sci</source><volume>10</volume><year>2023</year><object-id pub-id-type="publisher-id">2204514</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202204514</pub-id><pub-id pub-id-type="pmcid">PMC10214241</pub-id><pub-id pub-id-type="pmid">37026630</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Q.S.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.L.</given-names></name></person-group><article-title>Ferroptosis to pyroptosis regulation by iron-based nanocatalysts for enhanced tumor immunotherapy</article-title><source>J Am Chem Soc</source><volume>146</volume><year>2024</year><fpage>32403</fpage><lpage>32414</lpage><pub-id pub-id-type="pmid">39531413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.4c08304</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.Y.</given-names></name></person-group><article-title>Ferroptosis: promising approach for cancer and cancer immunotherapy</article-title><source>Cancer Lett</source><volume>561</volume><year>2023</year><object-id pub-id-type="publisher-id">216152</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2023.216152</pub-id><pub-id pub-id-type="pmid">37023938</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Induction of tumor ferroptosis-dependent immunity <italic toggle="yes">via</italic> an injectable attractive pickering emulsion gel</article-title><source>Adv Mater</source><volume>35</volume><year>2023</year><object-id pub-id-type="publisher-id">2303542</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202303542</pub-id><pub-id pub-id-type="pmid">37192546</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>PAFAH2 suppresses synchronized ferroptosis to ameliorate acute kidney injury</article-title><source>Nat Chem Biol</source><volume>20</volume><year>2024</year><fpage>835</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">38287154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-023-01528-7</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.Y.</given-names></name><etal/></person-group><article-title>Nanoparticle-based MRI-guided tumor microenvironment heating <italic toggle="yes">via</italic> the synergistic effect of ferroptosis and inhibition of TGF-<italic toggle="yes">&#946;</italic> signaling</article-title><source>Adv Healthcare Mater</source><volume>12</volume><year>2023</year><object-id pub-id-type="publisher-id">2300176</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202300176</pub-id><pub-id pub-id-type="pmid">37093559</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Hangauer</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Viswanathan</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bole</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Matov</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition</article-title><source>Nature</source><volume>551</volume><year>2017</year><fpage>247</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">29088702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature24297</pub-id><pub-id pub-id-type="pmcid">PMC5933935</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Roh</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.</given-names></name></person-group><article-title>Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis</article-title><source>Redox Biol</source><volume>11</volume><year>2017</year><fpage>254</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">28012440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2016.12.010</pub-id><pub-id pub-id-type="pmcid">PMC5198738</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Mishima</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mour&#227;o</surname><given-names>A.S.D.</given-names></name><name name-style="western"><surname>Sennhenn</surname><given-names>P.</given-names></name><etal/></person-group><article-title>DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition</article-title><source>Nature</source><volume>619</volume><year>2023</year><fpage>E9</fpage><lpage>E18</lpage><pub-id pub-id-type="pmid">37407687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06269-0</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.X.</given-names></name></person-group><article-title>Targeting ferroptosis: paving new roads for drug design and discovery</article-title><source>Eur J Med Chem</source><volume>247</volume><year>2023</year><object-id pub-id-type="publisher-id">115015</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2022.115015</pub-id><pub-id pub-id-type="pmid">36543035</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Kryczek</surname><given-names>I.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bian</surname><given-names>Y.J.</given-names></name><etal/></person-group><article-title>CD8<sup>+</sup> T cells and fatty acids orchestrate tumor ferroptosis and immunity <italic toggle="yes">via</italic> ACSL4</article-title><source>Cancer Cell</source><volume>40</volume><year>2022</year><comment>365-78.e6</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2022.02.003</pub-id><pub-id pub-id-type="pmcid">PMC9007863</pub-id><pub-id pub-id-type="pmid">35216678</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name></person-group><article-title>The crosstalk between ferroptosis and anti-tumor immunity in the tumor microenvironment: molecular mechanisms and therapeutic controversy</article-title><source>Cancer Commun</source><volume>43</volume><year>2023</year><fpage>1071</fpage><lpage>1096</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cac2.12487</pub-id><pub-id pub-id-type="pmcid">PMC10565387</pub-id><pub-id pub-id-type="pmid">37718480</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Ping</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R.</given-names></name><etal/></person-group><article-title>PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8<sup>+</sup> T cell ferroptosis</article-title><source>Immunity</source><volume>57</volume><year>2024</year><comment>2122&#8211;39.e9</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2024.08.003</pub-id><pub-id pub-id-type="pmid">39208806</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.Z.</given-names></name><etal/></person-group><article-title>Ferroptosis in cancer therapy: mechanisms, small molecule inducers, and novel approaches</article-title><source>Drug Des Dev Ther</source><volume>18</volume><year>2024</year><fpage>2485</fpage><lpage>2529</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S472178</pub-id><pub-id pub-id-type="pmcid">PMC11198730</pub-id><pub-id pub-id-type="pmid">38919962</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Chiou</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.T.</given-names></name><etal/></person-group><article-title>Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis</article-title><source>Nat Commun</source><volume>13</volume><year>2022</year><fpage>1371</fpage><pub-id pub-id-type="pmid">35296660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-29018-9</pub-id><pub-id pub-id-type="pmcid">PMC8927306</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.C.</given-names></name></person-group><article-title>Recent progress in ferroptosis inducers for cancer therapy</article-title><source>Adv Mater</source><volume>31</volume><year>2019</year><object-id pub-id-type="publisher-id">1904197</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.201904197</pub-id><pub-id pub-id-type="pmid">31595562</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>B.Y.</given-names></name></person-group><article-title>The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions</article-title><source>Cancer Cell</source><volume>42</volume><year>2024</year><fpage>513</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">38593779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2024.03.011</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Efimova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Catanzaro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van der Meeren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Turubanova</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mishchenko</surname><given-names>T.A.</given-names></name><etal/></person-group><article-title>Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity</article-title><source>J Immunother Cancer</source><volume>8</volume><year>2020</year><object-id pub-id-type="publisher-id">e001369</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2020-001369</pub-id><pub-id pub-id-type="pmcid">PMC7668384</pub-id><pub-id pub-id-type="pmid">33188036</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Wiernicki</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maschalidi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pinney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adjemian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vanden Berghe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ravichandran</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity</article-title><source>Nat Commun</source><volume>13</volume><year>2022</year><fpage>3676</fpage><pub-id pub-id-type="pmid">35760796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-31218-2</pub-id><pub-id pub-id-type="pmcid">PMC9237053</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Green</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Gij&#243;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.K.</given-names></name><etal/></person-group><article-title>CD8<sup>+</sup> T cells regulate tumour ferroptosis during cancer immunotherapy</article-title><source>Nature</source><volume>569</volume><year>2019</year><fpage>270</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">31043744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1170-y</pub-id><pub-id pub-id-type="pmcid">PMC6533917</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Conche</surname><given-names>C.</given-names></name><name name-style="western"><surname>Finkelmeier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pe&#353;i&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>B&#246;ttger</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Kennel</surname><given-names>K.B.</given-names></name><etal/></person-group><article-title>Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade</article-title><source>Gut</source><volume>72</volume><year>2023</year><fpage>1774</fpage><lpage>1782</lpage><pub-id pub-id-type="pmid">36707233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2022-327909</pub-id><pub-id pub-id-type="pmcid">PMC10423492</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Lotze</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Zeh</surname><given-names>I.I.I.H.J.</given-names></name><etal/></person-group><article-title>Autophagy promotes ferroptosis by degradation of ferritin</article-title><source>Autophagy</source><volume>12</volume><year>2016</year><fpage>1425</fpage><lpage>1428</lpage><pub-id pub-id-type="pmid">27245739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2016.1187366</pub-id><pub-id pub-id-type="pmcid">PMC4968231</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Little</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Fels</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Koumenis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kridel</surname><given-names>S.J.</given-names></name></person-group><article-title>Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells</article-title><source>Cancer Res</source><volume>67</volume><year>2007</year><fpage>1262</fpage><lpage>1269</lpage><pub-id pub-id-type="pmid">17283163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-06-1794</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Dierge</surname><given-names>E.</given-names></name><name name-style="western"><surname>Debock</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guilbaud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corbet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mignolet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mignard</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Peroxidation of <italic toggle="yes">n</italic>-3 and <italic toggle="yes">n</italic>-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects</article-title><source>Cell Metab</source><volume>33</volume><year>2021</year><comment>1701-15.e5</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2021.05.016</pub-id><pub-id pub-id-type="pmid">34118189</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Lamperis</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Calvert</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Rink</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pandkar</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>CRISPR screen reveals a simultaneous targeted mechanism to reduce cancer cell selenium and increase lipid oxidation to induce ferroptosis</article-title><source>Proc Natl Acad Sci U S A</source><volume>122</volume><year>2025</year><object-id pub-id-type="publisher-id">e2502876122</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2502876122</pub-id><pub-id pub-id-type="pmcid">PMC12146712</pub-id><pub-id pub-id-type="pmid">40445760</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H.H.</given-names></name><etal/></person-group><article-title>Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs</article-title><source>Cancer Lett</source><volume>483</volume><year>2020</year><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">32067993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2020.02.015</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Zandkarimi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model</article-title><source>Cell Chem Biol</source><volume>26</volume><year>2019</year><comment>623&#8211;33.e9</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2019.01.008</pub-id><pub-id pub-id-type="pmcid">PMC6525071</pub-id><pub-id pub-id-type="pmid">30799221</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Montesdeoca</surname><given-names>N.</given-names></name><name name-style="western"><surname>Johannknecht</surname><given-names>L.</given-names></name><name name-style="western"><surname>Efanova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Heinen-Weiler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Karges</surname><given-names>J.</given-names></name></person-group><article-title>Ferroptosis inducing Co(III) polypyridine sulfasalazine complex for therapeutically enhanced anticancer therapy</article-title><source>Angew Chem Int Ed</source><volume>63</volume><year>2024</year><object-id pub-id-type="publisher-id">e202412585</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202412585</pub-id><pub-id pub-id-type="pmid">39136323</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Q.Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Intracellular magnetic hyperthermia sensitizes sorafenib to orthotopic hepatocellular carcinoma <italic toggle="yes">via</italic> amplified ferroptosis</article-title><source>ACS Nano</source><volume>18</volume><year>2024</year><fpage>29804</fpage><lpage>29819</lpage><pub-id pub-id-type="pmid">39431335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.4c09500</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>O'Connell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.F.</given-names></name></person-group><article-title>Long noncoding RNA NEAT1 promotes ferroptosis by modulating the miR-362-3p/MIOX axis as a ceRNA</article-title><source>Cell Death Differ</source><volume>29</volume><year>2022</year><fpage>1850</fpage><lpage>1863</lpage><pub-id pub-id-type="pmid">35338333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-022-00970-9</pub-id><pub-id pub-id-type="pmcid">PMC9433379</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.Z.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L.Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Intracellular delivery of glutathione peroxidase degrader induces ferroptosis <italic toggle="yes">in vivo</italic></article-title><source>Angew Chem Int Ed</source><volume>134</volume><year>2022</year><object-id pub-id-type="publisher-id">e202206277</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202206277</pub-id><pub-id pub-id-type="pmid">35924720</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Akiyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rahhal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ayoub</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ostermann</surname><given-names>L.B.</given-names></name><etal/></person-group><article-title>Therapeutic targeting of ferroptosis pathway in combination with mitochondrial oxidative stress induction in acute myeloid leukemia</article-title><source>Blood</source><volume>138</volume><year>2021</year><fpage>1162</fpage></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>W.J.</given-names></name></person-group><article-title>FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients <italic toggle="yes">via</italic> a nonferroptosis mechanism</article-title><source>Cell Death Differ</source><volume>31</volume><year>2024</year><fpage>497</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">38374229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-024-01263-z</pub-id><pub-id pub-id-type="pmcid">PMC11043371</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Dual-targeting nanozyme combined with aPD-L1-based immunotherapy for combating cancer recurrence and metastasis</article-title><source>Mater Today</source><volume>73</volume><year>2024</year><fpage>79</fpage><lpage>95</lpage></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Faust</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wenz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harms</surname><given-names>G.</given-names></name><name name-style="western"><surname>Greffrath</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>C.</given-names></name></person-group><article-title>Cell&#8211;cell contacts prevent t-BuOOH-triggered ferroptosis and cellular damage <italic toggle="yes">in vitro</italic> by regulation of intracellular calcium</article-title><source>Arch Toxicol</source><volume>98</volume><year>2024</year><fpage>2953</fpage><lpage>2969</lpage><pub-id pub-id-type="pmid">38814333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-024-03792-5</pub-id><pub-id pub-id-type="pmcid">PMC11324706</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Assembling ruthenium complexes to form ruthenosome unleashing ferritinophagy-mediated tumor suppression</article-title><source>ACS Nano</source><volume>19</volume><year>2025</year><fpage>10207</fpage><lpage>10219</lpage><pub-id pub-id-type="pmid">40040589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.4c17344</pub-id><pub-id pub-id-type="pmcid">PMC11925053</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Kudarha</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dhas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mutalik</surname><given-names>S.</given-names></name></person-group><article-title>Distinct features of iron based metal organic frameworks (MOFs) for ferroptosis mediated cancer therapy: a comprehensive review</article-title><source>Coord Chem Rev</source><volume>494</volume><year>2023</year><object-id pub-id-type="publisher-id">215330</object-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hern&#225;ndez Millares</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Synergistic effect of ferroptosis-inducing nanoparticles and x-ray irradiation combination therapy</article-title><source>Small</source><volume>20</volume><year>2024</year><object-id pub-id-type="publisher-id">2310873</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202310873</pub-id><pub-id pub-id-type="pmid">38279618</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Y.L.</given-names></name><etal/></person-group><article-title>Multienzyme-like reactivity cooperatively impairs glutathione peroxidase 4 and ferroptosis suppressor protein 1 pathways in triple-negative breast cancer for sensitized ferroptosis therapy</article-title><source>ACS Nano</source><volume>16</volume><year>2022</year><fpage>2381</fpage><lpage>2398</lpage><pub-id pub-id-type="pmid">35041395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.1c08664</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.X.</given-names></name><etal/></person-group><article-title>A &#8220;closed-loop&#8221; therapeutic strategy based on mutually reinforced ferroptosis and immunotherapy</article-title><source>Adv Funct Mater</source><volume>32</volume><year>2022</year><object-id pub-id-type="publisher-id">2111784</object-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ayton</surname><given-names>S.</given-names></name></person-group><article-title>Neuroferroptosis in health and diseases</article-title><source>Nat Rev Neurosci</source><volume>26</volume><year>2025</year><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41583-025-00930-5</pub-id><pub-id pub-id-type="pmid">40389615</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Hl</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Zj</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Zt</given-names></name><name name-style="western"><surname>Mao</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Ferroptosis: past, present and future</article-title><source>Cell Death Dis</source><volume>11</volume><year>2020</year><fpage>88</fpage><pub-id pub-id-type="pmid">32015325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-2298-2</pub-id><pub-id pub-id-type="pmcid">PMC6997353</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Pope</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>S.J.</given-names></name></person-group><article-title>Regulation of ferroptosis by lipid metabolism</article-title><source>Trends Cell Biol</source><volume>33</volume><year>2023</year><fpage>1077</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">37407304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcb.2023.05.003</pub-id><pub-id pub-id-type="pmcid">PMC10733748</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Dixon</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Olzmann</surname><given-names>J.A.</given-names></name></person-group><article-title>The cell biology of ferroptosis</article-title><source>Nat Rev Mol Cell Biol</source><volume>25</volume><year>2024</year><fpage>424</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">38366038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-024-00703-5</pub-id><pub-id pub-id-type="pmcid">PMC12187608</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Binnewies</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fearon</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Merad</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Understanding the tumor immune microenvironment (TIME) for effective therapy</article-title><source>Nat Med</source><volume>24</volume><year>2018</year><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">29686425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0014-x</pub-id><pub-id pub-id-type="pmcid">PMC5998822</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>De Visser</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>J.A.</given-names></name></person-group><article-title>The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth</article-title><source>Cancer Cell</source><volume>41</volume><year>2023</year><fpage>374</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">36917948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2023.02.016</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.H.</given-names></name></person-group><article-title>Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy</article-title><source>Nat Commun</source><volume>11</volume><year>2020</year><fpage>3637</fpage><pub-id pub-id-type="pmid">32686685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17380-5</pub-id><pub-id pub-id-type="pmcid">PMC7371635</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.Q.</given-names></name><etal/></person-group><article-title>Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2</article-title><source>Cell Death Differ</source><volume>28</volume><year>2021</year><fpage>1971</fpage><lpage>1989</lpage><pub-id pub-id-type="pmid">33432112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-020-00719-2</pub-id><pub-id pub-id-type="pmcid">PMC8185102</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>Q.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>D.L.</given-names></name></person-group><article-title>The release and activity of HMGB1 in ferroptosis</article-title><source>Biochem Biophys Res Commun</source><volume>510</volume><year>2019</year><fpage>278</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">30686534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2019.01.090</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.Z.</given-names></name><etal/></person-group><article-title>HMGB1 regulates erastin-induced ferroptosis <italic toggle="yes">via</italic> RAS&#8211;JNK/p38 signaling in HL-60/NRASQ61L cells</article-title><source>Am J Cancer Res</source><volume>9</volume><year>2019</year><fpage>730</fpage><pub-id pub-id-type="pmid">31105999</pub-id><pub-id pub-id-type="pmcid">PMC6511643</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Rothe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>F.</given-names></name><name name-style="western"><surname>Uderhardt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ipseiz</surname><given-names>N.</given-names></name><name name-style="western"><surname>R&#246;ssner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oskolkova</surname><given-names>O.</given-names></name><etal/></person-group><article-title>12/15-lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function</article-title><source>J Clin Investig</source><volume>125</volume><year>2015</year><fpage>1944</fpage><lpage>1954</lpage><pub-id pub-id-type="pmid">25844901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI78490</pub-id><pub-id pub-id-type="pmcid">PMC4463199</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Cubillos-Ruiz</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Silberman</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Rutkowski</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perales-Puchalt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Song</surname><given-names>M.</given-names></name><etal/></person-group><article-title>ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis</article-title><source>Cell</source><volume>161</volume><year>2015</year><fpage>1527</fpage><lpage>1538</lpage><pub-id pub-id-type="pmid">26073941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.05.025</pub-id><pub-id pub-id-type="pmcid">PMC4580135</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Aqbi</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sappal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Manjili</surname><given-names>M.H.</given-names></name></person-group><article-title>IFN-<italic toggle="yes">&#947;</italic> orchestrates tumor elimination, tumor dormancy, tumor escape, and progression</article-title><source>J Leukoc Biol</source><volume>103</volume><year>2018</year><fpage>1219</fpage><lpage>1223</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/JLB.5MIR0917-351R</pub-id><pub-id pub-id-type="pmcid">PMC6157004</pub-id><pub-id pub-id-type="pmid">29469956</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.L.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.Y.</given-names></name></person-group><article-title>Engineering macrophages for cancer immunotherapy and drug delivery</article-title><source>Adv Mater</source><volume>32</volume><year>2020</year><object-id pub-id-type="publisher-id">2002054</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202002054</pub-id><pub-id pub-id-type="pmid">32856350</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Kapralov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dar</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Tyurina</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Anthonymuthu</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death</article-title><source>Nat Chem Biol</source><volume>16</volume><year>2020</year><fpage>278</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">32080625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-019-0462-8</pub-id><pub-id pub-id-type="pmcid">PMC7233108</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Dar</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Anthonymuthu</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Ponomareva</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Souryavong</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Shurin</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Kapralov</surname><given-names>A.O.</given-names></name><etal/></person-group><article-title>A new thiol-independent mechanism of epithelial host defense against Pseudomonas aeruginosa: inos/no&#8231; sabotage of theft-ferroptosis</article-title><source>Redox Biol</source><volume>45</volume><year>2021</year><object-id pub-id-type="publisher-id">102045</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2021.102045</pub-id><pub-id pub-id-type="pmcid">PMC8227829</pub-id><pub-id pub-id-type="pmid">34167028</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Mikulska-Ruminska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Anthonymuthu</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Levkina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Kapralov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bay&#305;r</surname><given-names>H.</given-names></name><etal/></person-group><article-title>NO&#8231; represses the oxygenation of arachidonoyl PE by 15LOX/PEBP1: mechanism and role in ferroptosis</article-title><source>Int J Mol Sci</source><volume>22</volume><year>2021</year><fpage>5253</fpage><pub-id pub-id-type="pmid">34067535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22105253</pub-id><pub-id pub-id-type="pmcid">PMC8156958</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.J.</given-names></name><etal/></person-group><article-title>HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk</article-title><source>J Hematol Oncol</source><volume>15</volume><year>2022</year><fpage>2</fpage><pub-id pub-id-type="pmid">34991659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-021-01223-x</pub-id><pub-id pub-id-type="pmcid">PMC8740349</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Yee</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chih</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression</article-title><source>Nat Commun</source><volume>11</volume><year>2020</year><fpage>5424</fpage><pub-id pub-id-type="pmid">33110073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-19193-y</pub-id><pub-id pub-id-type="pmcid">PMC7591536</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.H.</given-names></name><etal/></person-group><article-title>Ferroptosis-induced immunomodulation with biometabolic MOF@ COF nanovaccine for self-boosting anti-tumor immunotherapy</article-title><source>Chem Eng J</source><volume>493</volume><year>2024</year><object-id pub-id-type="publisher-id">152675</object-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Q.B.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.L.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L.</given-names></name></person-group><article-title>Manganese porphyrin-based metal-organic framework for synergistic sonodynamic therapy and ferroptosis in hypoxic tumors</article-title><source>Theranostics</source><volume>11</volume><year>2021</year><fpage>1937</fpage><pub-id pub-id-type="pmid">33408790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.45511</pub-id><pub-id pub-id-type="pmcid">PMC7778611</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Vaccine adjuvants: putting innate immunity to work</article-title><source>Immunity</source><volume>33</volume><year>2010</year><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Dhanak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tummino</surname><given-names>P.J.</given-names></name></person-group><article-title>Small-molecule targets in immuno-oncology</article-title><source>Cell Chem Biol</source><volume>24</volume><year>2017</year><fpage>1148</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">28938090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2017.08.019</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>T.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>G.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>L.</given-names></name><etal/></person-group><article-title>An update on immunotherapy for solid tumors: a review</article-title><source>Ann Surg Oncol</source><volume>25</volume><year>2018</year><fpage>3404</fpage><lpage>3412</lpage><pub-id pub-id-type="pmid">30039324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-018-6658-4</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salunke</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics</article-title><source>Curr Opin Chem Biol</source><volume>70</volume><year>2022</year><object-id pub-id-type="publisher-id">102172</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbpa.2022.102172</pub-id><pub-id pub-id-type="pmid">35785601</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Hendry</surname><given-names>S.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Young</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Sturrock</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>W.A.</given-names></name><etal/></person-group><article-title>Comparison of four PD-L1 immunohistochemical assays in lung cancer</article-title><source>J Thorac Oncol</source><volume>13</volume><year>2018</year><fpage>367</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">29175115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2017.11.112</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Shou</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name></person-group><article-title>New advances in cancer therapy targeting TGF-<italic toggle="yes">&#946;</italic> signaling pathways</article-title><source>Mol Ther Oncolytics</source><volume>31</volume><year>2023</year><object-id pub-id-type="publisher-id">100755</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omto.2023.100755</pub-id><pub-id pub-id-type="pmcid">PMC10746361</pub-id><pub-id pub-id-type="pmid">38144669</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Batista-Duharte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Portuondo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Carlos</surname><given-names>I.Z.</given-names></name></person-group><article-title>Systemic immunotoxicity reactions induced by adjuvanted vaccines</article-title><source>Int Immunopharmacol</source><volume>20</volume><year>2014</year><fpage>170</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">24607449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2014.02.033</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Lynn</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Laga</surname><given-names>R.</given-names></name><name name-style="western"><surname>Darrah</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Balaci</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Dulcey</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title><italic toggle="yes">In vivo</italic> characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity</article-title><source>Nat Biotechnol</source><volume>33</volume><year>2015</year><fpage>1201</fpage><lpage>1210</lpage><pub-id pub-id-type="pmid">26501954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.3371</pub-id><pub-id pub-id-type="pmcid">PMC5842712</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Tomai</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Vasilakos</surname><given-names>J.P.</given-names></name></person-group><article-title>TLR-7 and-8 agonists as vaccine adjuvants</article-title><source>Expert Rev Vaccines</source><volume>10</volume><year>2011</year><fpage>405</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">21506636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.11.26</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Bachmann</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>G.T.</given-names></name></person-group><article-title>Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns</article-title><source>Nat Rev Immunol</source><volume>10</volume><year>2010</year><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">20948547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2868</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Picece</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>E.A.</given-names></name></person-group><article-title>Designing spatial and temporal control of vaccine responses</article-title><source>Nat Rev Mater</source><volume>7</volume><year>2022</year><fpage>174</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">34603749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41578-021-00372-2</pub-id><pub-id pub-id-type="pmcid">PMC8477997</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>Injectable microenvironment-responsive hydrogels with redox-activatable supramolecular prodrugs mediate ferroptosis-immunotherapy for postoperative tumor treatment</article-title><source>Acta Biomater</source><volume>169</volume><year>2023</year><fpage>289</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">37544392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2023.08.002</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>T.Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z.W.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.J.</given-names></name><etal/></person-group><article-title>Tumor microenvironment mediated spermidine-metal-immunopeptide nanocomplex for boosting ferroptotic immunotherapy of lymphoma</article-title><source>ACS Nano</source><volume>17</volume><year>2023</year><fpage>10925</fpage><lpage>10937</lpage><pub-id pub-id-type="pmid">37219600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c02803</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H.H.</given-names></name><etal/></person-group><article-title>Responsive and traceless assembly of iron nanoparticles and 131I labeled radiopharmaceuticals for ferroptosis enhanced radio-immunotherapy</article-title><source>Biomaterials</source><volume>313</volume><year>2025</year><object-id pub-id-type="publisher-id">122795</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2024.122795</pub-id><pub-id pub-id-type="pmid">39232333</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Oxygen-boosted biomimetic nanoplatform for synergetic phototherapy/ferroptosis activation and reversal of immune-suppressed tumor microenvironment</article-title><source>Biomaterials</source><volume>290</volume><year>2022</year><object-id pub-id-type="publisher-id">121832</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2022.121832</pub-id><pub-id pub-id-type="pmid">36228518</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.C.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name></person-group><article-title>A self-assembling nanoplatform for pyroptosis and ferroptosis enhanced cancer photoimmunotherapy</article-title><source>Light Sci Appl</source><volume>14</volume><year>2025</year><fpage>16</fpage><pub-id pub-id-type="pmid">39743555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41377-024-01673-1</pub-id><pub-id pub-id-type="pmcid">PMC11693763</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.J.</given-names></name><etal/></person-group><article-title>Self-driven nanoprodrug platform with enhanced ferroptosis for synergistic photothermal-IDO immunotherapy</article-title><source>Biomaterials</source><volume>299</volume><year>2023</year><object-id pub-id-type="publisher-id">122157</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2023.122157</pub-id><pub-id pub-id-type="pmid">37196407</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.R.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A dihydroartemisinin-loaded nanoreactor motivates anti-cancer immunotherapy by synergy-induced ferroptosis to activate cGAS/STING for reprogramming of macrophage</article-title><source>Adv Healthcare Mater</source><volume>12</volume><year>2023</year><object-id pub-id-type="publisher-id">2301561</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202301561</pub-id><pub-id pub-id-type="pmid">37567571</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.W.</given-names></name><etal/></person-group><article-title>Radiotherapy-sensitized cancer immunotherapy <italic toggle="yes">via</italic> cGAS&#8211;STING immune pathway by activatable nanocascade reaction</article-title><source>J Nanobiotechnol</source><volume>22</volume><year>2024</year><fpage>234</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-024-02502-8</pub-id><pub-id pub-id-type="pmcid">PMC11080188</pub-id><pub-id pub-id-type="pmid">38724978</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.X.</given-names></name></person-group><article-title>Light-triggered nanozymes remodel the tumor hypoxic and immunosuppressive microenvironment for ferroptosis-enhanced antitumor immunity</article-title><source>ACS Nano</source><volume>18</volume><year>2024</year><fpage>12261</fpage><lpage>12275</lpage><pub-id pub-id-type="pmid">38683132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.4c00844</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Morad</surname><given-names>G.</given-names></name><name name-style="western"><surname>Helmink</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wargo</surname><given-names>J.A.</given-names></name></person-group><article-title>Hallmarks of response, resistance, and toxicity to immune checkpoint blockade</article-title><source>Cell</source><volume>184</volume><year>2021</year><fpage>5309</fpage><lpage>5337</lpage><pub-id pub-id-type="pmid">34624224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.09.020</pub-id><pub-id pub-id-type="pmcid">PMC8767569</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Hurov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lahdenranta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Upadhyaya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haines</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Repash</surname><given-names>E.</given-names></name><etal/></person-group><article-title>BT7480, a novel fully synthetic bicycle tumor-targeted immune cell agonist&#8482; (Bicycle TICA&#8482;) induces tumor localized CD137 agonism</article-title><source>J Immunother Cancer</source><volume>9</volume><year>2021</year><object-id pub-id-type="publisher-id">e002883</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-002883</pub-id><pub-id pub-id-type="pmcid">PMC8562524</pub-id><pub-id pub-id-type="pmid">34725211</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>F.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.J.</given-names></name></person-group><article-title>Prognostic value of immune checkpoint molecules in breast cancer</article-title><source>Biosci Rep</source><volume>40</volume><year>2020</year><object-id pub-id-type="publisher-id">BSR20201054</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20201054</pub-id><pub-id pub-id-type="pmcid">PMC7340863</pub-id><pub-id pub-id-type="pmid">32602545</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nat Rev Cancer</source><volume>12</volume><year>2012</year><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">22437870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmcid">PMC4856023</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>J.-C.D.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Lorenz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Structural and functional analysis of the costimulatory receptor programmed death-1</article-title><source>Immunity</source><volume>20</volume><year>2004</year><fpage>337</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">15030777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1074-7613(04)00051-2</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.H.</given-names></name></person-group><article-title>PD-1/PD-L1 pathway: current researches in cancer</article-title><source>Am J Cancer Res</source><volume>10</volume><year>2020</year><fpage>727</fpage><pub-id pub-id-type="pmid">32266087</pub-id><pub-id pub-id-type="pmcid">PMC7136921</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Azuma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yagita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lanier</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>B70 antigen is a second ligand for CTLA-4 and CD28</article-title><source>Nature</source><volume>366</volume><year>1993</year><fpage>76</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">7694153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/366076a0</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>M.C.</given-names></name></person-group><article-title>Advances and prospects of biomarkers for immune checkpoint inhibitors</article-title><source>Cell Rep Med</source><volume>5</volume><year>2024</year><object-id pub-id-type="publisher-id">101621</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2024.101621</pub-id><pub-id pub-id-type="pmcid">PMC11293349</pub-id><pub-id pub-id-type="pmid">38906149</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.Y.</given-names></name><etal/></person-group><article-title>Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer</article-title><source>J Exp Clin Cancer Res</source><volume>40</volume><year>2021</year><fpage>184</fpage><pub-id pub-id-type="pmid">34088360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-021-01987-7</pub-id><pub-id pub-id-type="pmcid">PMC8178863</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Minor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alcedo</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Battaglia</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Snider</surname><given-names>N.T.</given-names></name></person-group><article-title>Cell type-and tissue-specific functions of ecto-5&#8242;-nucleotidase (CD73)</article-title><source>Am J Physiol Cell Physiol</source><volume>317</volume><year>2019</year><fpage>C1079</fpage><lpage>C1092</lpage><pub-id pub-id-type="pmid">31461341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpcell.00285.2019</pub-id><pub-id pub-id-type="pmcid">PMC6957383</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.L.</given-names></name><etal/></person-group><article-title>Discovery of novel 5-(pyridazin-3-yl) pyrimidine-2,4(1<italic toggle="yes">H</italic>,3<italic toggle="yes">H</italic>)-dione derivatives as potent and orally bioavailable inhibitors targeting ecto-5&#8242;-nucleotidase</article-title><source>J Med Chem</source><volume>67</volume><year>2024</year><fpage>18491</fpage><lpage>18511</lpage><pub-id pub-id-type="pmid">39385716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.4c01793</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Vijayan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>M.J.</given-names></name></person-group><article-title>Targeting immunosuppressive adenosine in cancer</article-title><source>Nat Rev Cancer</source><volume>17</volume><year>2017</year><fpage>709</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">29059149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc.2017.86</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Achyut</surname><given-names>B.R.</given-names></name><etal/></person-group><article-title>CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint</article-title><source>Nat Commun</source><volume>11</volume><year>2020</year><fpage>515</fpage><pub-id pub-id-type="pmid">31980601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-14060-x</pub-id><pub-id pub-id-type="pmcid">PMC6981126</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Zaiatz-Bittencourt</surname><given-names>V.</given-names></name><name name-style="western"><surname>Finlay</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Gardiner</surname><given-names>C.M.</given-names></name></person-group><article-title>Canonical TGF-<italic toggle="yes">&#946;</italic> signaling pathway represses human NK cell metabolism</article-title><source>J Immunol</source><volume>200</volume><year>2018</year><fpage>3934</fpage><lpage>3941</lpage><pub-id pub-id-type="pmid">29720425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1701461</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Brandes</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ohura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wahl</surname><given-names>S.M.</given-names></name></person-group><article-title>Type I transforming growth factor-beta receptors on neutrophils mediate chemotaxis to transforming growth factor-beta</article-title><source>J Immunol</source><volume>147</volume><year>1991</year><fpage>1600</fpage><lpage>1606</lpage><pub-id pub-id-type="pmid">1652608</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Huh</surname><given-names>C.-G.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Geiser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lyght</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flanders</surname><given-names>K.C.</given-names></name><etal/></person-group><article-title>Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death</article-title><source>Proc Natl Acad Sci U S A</source><volume>90</volume><year>1993</year><fpage>770</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">8421714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.90.2.770</pub-id><pub-id pub-id-type="pmcid">PMC45747</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Gorelik</surname><given-names>L.</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>R.A.</given-names></name></person-group><article-title>Immune-mediated eradication of tumors through the blockade of transforming growth factor-<italic toggle="yes">&#946;</italic> signaling in T cells</article-title><source>Nat Med</source><volume>7</volume><year>2001</year><fpage>1118</fpage><lpage>1122</lpage><pub-id pub-id-type="pmid">11590434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1001-1118</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T.Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>M.F.</given-names></name><etal/></person-group><article-title>Targeting HIC1/TGF-<italic toggle="yes">&#946;</italic> axis-shaped prostate cancer microenvironment restrains its progression</article-title><source>Cell Death Dis</source><volume>13</volume><year>2022</year><fpage>624</fpage><pub-id pub-id-type="pmid">35853880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-022-05086-z</pub-id><pub-id pub-id-type="pmcid">PMC9296670</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Willingham</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Volkmer</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Gentles</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Sahoo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dalerba</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>The CD47-signal regulatory protein alpha (SIRP<italic toggle="yes">&#945;</italic>) interaction is a therapeutic target for human solid tumors</article-title><source>Proc Natl Acad Sci U S A</source><volume>109</volume><year>2012</year><fpage>6662</fpage><lpage>6667</lpage><pub-id pub-id-type="pmid">22451913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1121623109</pub-id><pub-id pub-id-type="pmcid">PMC3340046</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Alizadeh</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Myklebust</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate Non-Hodgkin lymphoma</article-title><source>Cell</source><volume>142</volume><year>2010</year><fpage>699</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">20813259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2010.07.044</pub-id><pub-id pub-id-type="pmcid">PMC2943345</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Richter</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Bhansali</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>M.E.</given-names></name></person-group><article-title>Mechanistic determinants of biotherapeutics absorption following SC administration</article-title><source>AAPS J</source><volume>14</volume><year>2012</year><fpage>559</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">22619041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-012-9367-0</pub-id><pub-id pub-id-type="pmcid">PMC3385825</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Frokjaer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Otzen</surname><given-names>D.E.</given-names></name></person-group><article-title>Protein drug stability: a formulation challenge</article-title><source>Nat Rev Drug Discov</source><volume>4</volume><year>2005</year><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">15803194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd1695</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F.Y.</given-names></name><etal/></person-group><article-title>Engineering nanoparticles to locally activate T cells in the tumor microenvironment</article-title><source>Sci Immunol</source><volume>4</volume><year>2019</year><object-id pub-id-type="publisher-id">eaau6584</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.aau6584</pub-id><pub-id pub-id-type="pmid">31300478</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>L.C.M.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>AC-y</given-names></name><name name-style="western"><surname>Chau</surname><given-names>Y.</given-names></name></person-group><article-title>Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month <italic toggle="yes">in vivo</italic> study</article-title><source>Transl Vis Sci Technol</source><volume>4</volume><year>2015</year><fpage>5</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/tvst.4.2.5</pub-id><pub-id pub-id-type="pmcid">PMC4356035</pub-id><pub-id pub-id-type="pmid">25774331</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Hanagata</surname><given-names>N.</given-names></name></person-group><article-title>Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system</article-title><source>Int J Nanomed</source><volume>7</volume><year>2012</year><fpage>2181</fpage><lpage>2195</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S30197</pub-id><pub-id pub-id-type="pmcid">PMC3356174</pub-id><pub-id pub-id-type="pmid">22619554</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Ngamcherdtrakul</surname><given-names>W.</given-names></name><name name-style="western"><surname>Reda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zaidan</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Bejan</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>In situ tumor vaccination with nanoparticle co-delivering CpG and STAT3 siRNA to effectively induce whole-body antitumor immune response</article-title><source>Adv Mater</source><volume>33</volume><year>2021</year><object-id pub-id-type="publisher-id">2100628</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202100628</pub-id><pub-id pub-id-type="pmcid">PMC8424660</pub-id><pub-id pub-id-type="pmid">34118167</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>L.R.</given-names></name><etal/></person-group><article-title>Red blood cell membrane-camouflaged nanoparticles loaded with AIEgen and Poly (I:C) for enhanced tumoral photodynamic-immunotherapy</article-title><source>Natl Sci Rev</source><volume>8</volume><year>2021</year><object-id pub-id-type="publisher-id">nwab039</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nsr/nwab039</pub-id><pub-id pub-id-type="pmcid">PMC8288176</pub-id><pub-id pub-id-type="pmid">34691671</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Dauletbaev</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cammisano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herscovitch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lands</surname><given-names>L.C.</given-names></name></person-group><article-title>Stimulation of the RIG-I/MAVS pathway by polyinosinic: polycytidylic acid upregulates IFN-<italic toggle="yes">&#946;</italic> in airway epithelial cells with minimal costimulation of IL-8</article-title><source>J Immunol</source><volume>195</volume><year>2015</year><fpage>2829</fpage><lpage>2841</lpage><pub-id pub-id-type="pmid">26283481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1400840</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Alexopoulou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>R.A.</given-names></name></person-group><article-title>Recognition of double-stranded RNA and activation of NF-<italic toggle="yes">&#954;</italic>B by toll-like receptor 3</article-title><source>Nature</source><volume>413</volume><year>2001</year><fpage>732</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">11607032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35099560</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>D.W.</given-names></name><etal/></person-group><article-title>Immunotherapy of malignant glioma by noninvasive administration of TLR9 agonist CpG nano-immunoadjuvant</article-title><source>Adv Sci</source><volume>9</volume><year>2022</year><object-id pub-id-type="publisher-id">2103689</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202103689</pub-id><pub-id pub-id-type="pmcid">PMC9069387</pub-id><pub-id pub-id-type="pmid">35253404</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Transforming &#8220;cold&#8221; tumors into &#8220;hot&#8221; ones <italic toggle="yes">via</italic> tumor-microenvironment-responsive siRNA micelleplexes for enhanced immunotherapy</article-title><source>Matter</source><volume>5</volume><year>2022</year><fpage>2285</fpage><lpage>2305</lpage></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.R.</given-names></name><etal/></person-group><article-title>Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer</article-title><source>Acta Biomater</source><volume>99</volume><year>2019</year><fpage>307</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">31513911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2019.08.046</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Targeted anti-cancer therapy: co-delivery of VEGF siRNA and phenethyl isothiocyanate (PEITC) <italic toggle="yes">via</italic> cRGD-modified lipid nanoparticles for enhanced anti-angiogenic efficacy</article-title><source>Asian J Pharm Sci</source><volume>19</volume><year>2024</year><object-id pub-id-type="publisher-id">100891</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajps.2024.100891</pub-id><pub-id pub-id-type="pmcid">PMC10990863</pub-id><pub-id pub-id-type="pmid">38584690</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Shamshiripour</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rahnama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nikoobakht</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rad</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Moradi</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Ahmadvand</surname><given-names>D.</given-names></name></person-group><article-title>Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis <italic toggle="yes">in vitro</italic></article-title><source>J Control Release</source><volume>369</volume><year>2024</year><fpage>128</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">38522817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2024.03.042</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>F.N.</given-names></name><etal/></person-group><article-title>Synchronous targeted delivery of TGF-<italic toggle="yes">&#946;</italic> siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment</article-title><source>Biomaterials</source><volume>301</volume><year>2023</year><object-id pub-id-type="publisher-id">122253</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2023.122253</pub-id><pub-id pub-id-type="pmid">37536040</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Vargason</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Anselmo</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S.</given-names></name></person-group><article-title>The evolution of commercial drug delivery technologies</article-title><source>Nat Biomed Eng</source><volume>5</volume><year>2021</year><fpage>951</fpage><lpage>967</lpage><pub-id pub-id-type="pmid">33795852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-021-00698-w</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Holmgaard</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Zamarin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gasmi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Munn</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner</article-title><source>Cell Rep</source><volume>13</volume><year>2015</year><fpage>412</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">26411680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2015.08.077</pub-id><pub-id pub-id-type="pmcid">PMC5013825</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Brenk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scheler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Takikawa</surname><given-names>O.</given-names></name><name name-style="western"><surname>H&#228;cker</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4<sup>+</sup> CD25<sup>+</sup> Foxp3<sup>+</sup> T regulatory cells</article-title><source>J Immunol</source><volume>183</volume><year>2009</year><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">19535644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0803277</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Cheong</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name></person-group><article-title>Targeting the IDO1/TDO2&#8211;KYN&#8211;AhR pathway for cancer immunotherapy&#8211;challenges and opportunities</article-title><source>Trends Pharmacol Sci</source><volume>39</volume><year>2018</year><fpage>307</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">29254698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2017.11.007</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.X.</given-names></name><etal/></person-group><article-title>The mechanism of STING autoinhibition and activation</article-title><source>Mol Cell</source><volume>83</volume><year>2023</year><comment>1502&#8211;18.e10</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2023.03.029</pub-id><pub-id pub-id-type="pmid">37086726</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Universal STING mimic boosts antitumour immunity <italic toggle="yes">via</italic> preferential activation of tumour control signalling pathways</article-title><source>Nat Nanotechnol</source><volume>19</volume><year>2024</year><fpage>856</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">38480836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-024-01624-2</pub-id><pub-id pub-id-type="pmcid">PMC11948844</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Doshi</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Cantin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prickett</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Mele</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Amiji</surname><given-names>M.</given-names></name></person-group><article-title>Systemic nano-delivery of low-dose STING agonist targeted to CD103<sup>+</sup> dendritic cells for cancer immunotherapy</article-title><source>J Control Release</source><volume>345</volume><year>2022</year><fpage>721</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">35378213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.03.054</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Benoit-Lizon</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jacquin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roussey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dal Zuffo</surname><given-names>L.</given-names></name><etal/></person-group><article-title>CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of TH1 and TH9 cells</article-title><source>J Immunother Cancer</source><volume>10</volume><year>2022</year><object-id pub-id-type="publisher-id">e003459</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-003459</pub-id><pub-id pub-id-type="pmcid">PMC8804688</pub-id><pub-id pub-id-type="pmid">35091453</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Jing</surname><given-names>W.</given-names></name><name name-style="western"><surname>McAllister</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vonderhaar</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Palen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Riese</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Gershan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models</article-title><source>J Immunother Cancer</source><volume>7</volume><year>2019</year><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">31036082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-019-0573-5</pub-id><pub-id pub-id-type="pmcid">PMC6489306</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer</article-title><source>J Immunother Cancer</source><volume>9</volume><year>2021</year><object-id pub-id-type="publisher-id">e002195</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2020-002195</pub-id><pub-id pub-id-type="pmcid">PMC8215239</pub-id><pub-id pub-id-type="pmid">34145029</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Xian</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.N.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.X.</given-names></name></person-group><article-title>Ionizable STING-activating nanoadjuvants enhance tumor immunogenicity and potentiate immunotherapy efficacy in solid tumors</article-title><source>Cancer Res</source><volume>84</volume><year>2024</year><fpage>3044</fpage><lpage>3057</lpage><pub-id pub-id-type="pmid">38990727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-23-3511</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Ultrathin clay nanoparticles-mediated mutual reinforcement of ferroptosis and cancer immunotherapy</article-title><source>Adv Mater</source><volume>36</volume><year>2024</year><object-id pub-id-type="publisher-id">2309562</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202309562</pub-id><pub-id pub-id-type="pmid">37939375</pub-id></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Novel photo-STING agonists delivered by erythrocyte efferocytosis-mimicking pattern to repolarize tumor-associated macrophages for boosting anticancer immunotherapy</article-title><source>Adv Mater</source><volume>36</volume><year>2024</year><object-id pub-id-type="publisher-id">2410937</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202410937</pub-id><pub-id pub-id-type="pmid">39380354</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Radiotherapy-sensitized cancer immunotherapy <italic toggle="yes">via</italic> cGAS&#8211;STING immune pathway by activatable nanocascade reaction</article-title><source>J Nanobiotechnol</source><volume>22</volume><year>2024</year><fpage>234</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-024-02502-8</pub-id><pub-id pub-id-type="pmcid">PMC11080188</pub-id><pub-id pub-id-type="pmid">38724978</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Van Herck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z.F.</given-names></name><name name-style="western"><surname>Deswarte</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Potent and prolonged innate immune activation by enzyme-responsive imidazoquinoline TLR7/8 agonist prodrug vesicles</article-title><source>J Am Chem Soc</source><volume>142</volume><year>2020</year><fpage>12133</fpage><lpage>12139</lpage><pub-id pub-id-type="pmid">32524819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.0c01928</pub-id><pub-id pub-id-type="pmcid">PMC7116109</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>Turco</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pfleiderer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hunger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Horvat</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Karimian-Jazi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schregel</surname><given-names>K.</given-names></name><etal/></person-group><article-title>T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles</article-title><source>Nat Commun</source><volume>14</volume><year>2023</year><fpage>771</fpage><pub-id pub-id-type="pmid">36774352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-36321-6</pub-id><pub-id pub-id-type="pmcid">PMC9922247</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Ya</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>X.T.</given-names></name><etal/></person-group><article-title>Spatial isolation of single copper (i) sites for cascade enzyme-like catalysis and simultaneous ferroptosis/cuproptosis boosted immunotherapy</article-title><source>Explorations</source><volume>5</volume><year>2025</year><object-id pub-id-type="publisher-id">20240275</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/EXP.20240275</pub-id><pub-id pub-id-type="pmcid">PMC12199402</pub-id><pub-id pub-id-type="pmid">40585770</pub-id></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Rodell</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Arlauckas</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Cuccarese</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Garris</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy</article-title><source>Nat Biomed Eng</source><volume>2</volume><year>2018</year><fpage>578</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">31015631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-018-0236-8</pub-id><pub-id pub-id-type="pmcid">PMC6192054</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Phuengkham</surname><given-names>H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Y.T.</given-names></name></person-group><article-title>A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy</article-title><source>Adv Mater</source><volume>31</volume><year>2019</year><object-id pub-id-type="publisher-id">1903242</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.201903242</pub-id><pub-id pub-id-type="pmid">31490604</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Bahmani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luk</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Haushalter</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>DeTeresa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Previti</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors</article-title><source>Nat Commun</source><volume>12</volume><year>2021</year><fpage>1999</fpage><pub-id pub-id-type="pmid">33790276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-22311-z</pub-id><pub-id pub-id-type="pmcid">PMC8012593</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Hijacking endogenous iron and GSH <italic toggle="yes">via</italic> a polyvalent ferroptosis agonist to enhance tumor immunotherapy</article-title><source>Adv Funct Mater</source><volume>33</volume><year>2023</year><object-id pub-id-type="publisher-id">2303195</object-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>R.Z.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.R.</given-names></name><etal/></person-group><article-title>Topology regulation of nanomedicine for autophagy-augmented ferroptosis and cancer immunotherapy</article-title><source>Sci Bull</source><volume>68</volume><year>2023</year><fpage>77</fpage><lpage>94</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scib.2022.12.030</pub-id><pub-id pub-id-type="pmid">36621435</pub-id></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.G.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Biomimetic chiral nanotopography for manipulating immunological response</article-title><source>Adv Funct Mater</source><volume>34</volume><year>2024</year><object-id pub-id-type="publisher-id">2313157</object-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.L.</given-names></name><etal/></person-group><article-title>Autologous tumoral esterase-driven therapeutic polymers sequentially orchestrated antigen-induction, STING activation and anti-angiogenesis for systemic cancer immune therapy</article-title><source>Biomaterials</source><volume>320</volume><year>2025</year><object-id pub-id-type="publisher-id">123260</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2025.123260</pub-id><pub-id pub-id-type="pmid">40138966</pub-id></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Munoz-Wolf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Oleszycka</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>H.B.</given-names></name><etal/></person-group><article-title>The vaccine adjuvant chitosan promotes cellular immunity <italic toggle="yes">via</italic> DNA sensor cGAS&#8211;STING-dependent induction of type I interferons</article-title><source>Immunity</source><volume>44</volume><year>2016</year><fpage>597</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">26944200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2016.02.004</pub-id><pub-id pub-id-type="pmcid">PMC4852885</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Turley</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>McEntee</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>O'Grady</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mu&#241;oz-Wolf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Chitin-derived polymer deacetylation regulates mitochondrial reactive oxygen species dependent cGAS&#8211;STING and NLRP3 inflammasome activation</article-title><source>Biomaterials</source><volume>275</volume><year>2021</year><object-id pub-id-type="publisher-id">120961</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.120961</pub-id><pub-id pub-id-type="pmid">34171753</pub-id></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tuo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Z.Y.</given-names></name><etal/></person-group><article-title>Ferroptosis-enhanced immunotherapy with an injectable dextran-chitosan hydrogel for the treatment of malignant ascites in hepatocellular carcinoma</article-title><source>Adv Sci</source><volume>10</volume><year>2023</year><object-id pub-id-type="publisher-id">2300517</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202300517</pub-id><pub-id pub-id-type="pmcid">PMC10369279</pub-id><pub-id pub-id-type="pmid">37132587</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.D.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarcinoma</article-title><source>J Nanobiotechnol</source><volume>22</volume><year>2024</year><fpage>353</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-024-02646-7</pub-id><pub-id pub-id-type="pmcid">PMC11191229</pub-id><pub-id pub-id-type="pmid">38902759</pub-id></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Kaparakis-Liaskos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferrero</surname><given-names>R.L.</given-names></name></person-group><article-title>Immune modulation by bacterial outer membrane vesicles</article-title><source>Nat Rev Immunol</source><volume>15</volume><year>2015</year><fpage>375</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">25976515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3837</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Bacterial outer membrane vesicles as a platform for biomedical applications: an update</article-title><source>J Control Release</source><volume>323</volume><year>2020</year><fpage>253</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">32333919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2020.04.031</pub-id></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>O.Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>N.T.H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Bacterial outer membrane vesicles suppress tumor by interferon-<italic toggle="yes">&#947;</italic>-mediated antitumor response</article-title><source>Nat Commun</source><volume>8</volume><year>2017</year><fpage>626</fpage><pub-id pub-id-type="pmid">28931823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-00729-8</pub-id><pub-id pub-id-type="pmcid">PMC5606984</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.Z.</given-names></name><etal/></person-group><article-title>Surface mineralization of engineered bacterial outer membrane vesicles to enhance tumor photothermal/immunotherapy</article-title><source>ACS Nano</source><volume>18</volume><year>2024</year><fpage>1357</fpage><lpage>1370</lpage><pub-id pub-id-type="pmid">38164903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c05714</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Shangguan</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>P.P.</given-names></name><etal/></person-group><article-title>Metal ions-anchored bacterial outer membrane vesicles for enhanced ferroptosis induction and immune stimulation in targeted antitumor therapy</article-title><source>J Nanobiotechnol</source><volume>22</volume><year>2024</year><fpage>474</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-024-02747-3</pub-id><pub-id pub-id-type="pmcid">PMC11311927</pub-id><pub-id pub-id-type="pmid">39123234</pub-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>Irradiated microparticles suppress prostate cancer by tumor microenvironment reprogramming and ferroptosis</article-title><source>J Nanobiotechnol</source><volume>22</volume><year>2024</year><fpage>225</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-024-02496-3</pub-id><pub-id pub-id-type="pmcid">PMC11070086</pub-id><pub-id pub-id-type="pmid">38705987</pub-id></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X.T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W.F.</given-names></name><etal/></person-group><article-title>Design strategies of tumor-targeted delivery systems based on 2D nanomaterials</article-title><source>Small Methods</source><volume>6</volume><year>2022</year><object-id pub-id-type="publisher-id">2200853</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smtd.202200853</pub-id><pub-id pub-id-type="pmid">36161304</pub-id></element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miyasaki</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>E.J.</given-names></name></person-group><article-title>Engineered nanomaterials that exploit blood&#8210;brain barrier dysfunction for delivery to the brain</article-title><source>Adv Drug Deliv Rev</source><volume>197</volume><year>2023</year><object-id pub-id-type="publisher-id">114820</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.114820</pub-id><pub-id pub-id-type="pmid">37054953</pub-id></element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Adilijiang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Z.Q.</given-names></name><etal/></person-group><article-title>Recent advances in targeted drug delivery strategy for enhancing oncotherapy</article-title><source>Pharmaceutics</source><volume>15</volume><year>2023</year><fpage>2233</fpage><pub-id pub-id-type="pmid">37765202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15092233</pub-id><pub-id pub-id-type="pmcid">PMC10534854</pub-id></element-citation></ref><ref id="bib169"><label>169</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Subhan</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Yalamarty</surname><given-names>S.S.K.</given-names></name><name name-style="western"><surname>Filipczak</surname><given-names>N.</given-names></name><name name-style="western"><surname>Parveen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V.P.</given-names></name></person-group><article-title>Recent advances in tumor targeting <italic toggle="yes">via</italic> EPR effect for cancer treatment</article-title><source>J Personalized Med</source><volume>11</volume><year>2021</year><fpage>571</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm11060571</pub-id><pub-id pub-id-type="pmcid">PMC8234032</pub-id><pub-id pub-id-type="pmid">34207137</pub-id></element-citation></ref><ref id="bib170"><label>170</label><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name name-style="western"><surname>Golombek</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>May</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Theek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Appold</surname><given-names>L.</given-names></name><name name-style="western"><surname>Drude</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kiessling</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Tumor targeting <italic toggle="yes">via</italic> EPR: strategies to enhance patient responses</article-title><source>Adv Drug Deliv Rev</source><volume>130</volume><year>2018</year><fpage>17</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">30009886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2018.07.007</pub-id><pub-id pub-id-type="pmcid">PMC6130746</pub-id></element-citation></ref><ref id="bib171"><label>171</label><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>Fe-MnO<sub>2</sub> nanosheets loading dihydroartemisinin for ferroptosis and immunotherapy</article-title><source>Biomed Pharmacother</source><volume>161</volume><year>2023</year><object-id pub-id-type="publisher-id">114431</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.114431</pub-id><pub-id pub-id-type="pmid">36827713</pub-id></element-citation></ref><ref id="bib172"><label>172</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonnet-Delpon</surname><given-names>D.</given-names></name><name name-style="western"><surname>B&#233;gu&#233;</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meunier</surname><given-names>B.</given-names></name></person-group><article-title>Alkylation of manganese (II) tetraphenylporphyrin by antimalarial fluorinated artemisinin derivatives</article-title><source>Bioorg Med Chem Lett</source><volume>13</volume><year>2003</year><fpage>1059</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">12643911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0960-894x(03)00076-3</pub-id></element-citation></ref><ref id="bib173"><label>173</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>F.Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Inhalable biomineralized liposomes for cyclic Ca<sup>2+</sup>-burst-centered endoplasmic reticulum stress enhanced lung cancer ferroptosis therapy</article-title><source>ACS Nano</source><volume>17</volume><year>2023</year><fpage>5486</fpage><lpage>5502</lpage><pub-id pub-id-type="pmid">36883602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c10830</pub-id></element-citation></ref><ref id="bib174"><label>174</label><element-citation publication-type="journal" id="sref174"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Y.</given-names></name></person-group><article-title>The role of erastin in ferroptosis and its prospects in cancer therapy</article-title><source>OncoTargets Ther</source><volume>13</volume><year>2020</year><fpage>5429</fpage><lpage>5441</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S254995</pub-id><pub-id pub-id-type="pmcid">PMC7295539</pub-id><pub-id pub-id-type="pmid">32606760</pub-id></element-citation></ref><ref id="bib175"><label>175</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Q.Q.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Du</surname><given-names>H.H.</given-names></name></person-group><article-title>Erastin-induced ferroptosis causes physiological and pathological changes in healthy tissues of mice</article-title><source>Mol Med Rep</source><volume>24</volume><year>2021</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2021.12352</pub-id><pub-id pub-id-type="pmcid">PMC8383038</pub-id><pub-id pub-id-type="pmid">34396451</pub-id></element-citation></ref><ref id="bib176"><label>176</label><element-citation publication-type="journal" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Weichselbaum</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.B.</given-names></name></person-group><article-title>Nanoparticles synergize ferroptosis and cuproptosis to potentiate cancer immunotherapy</article-title><source>Adv Sci</source><volume>11</volume><year>2024</year><object-id pub-id-type="publisher-id">2310309</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202310309</pub-id><pub-id pub-id-type="pmcid">PMC11187894</pub-id><pub-id pub-id-type="pmid">38477411</pub-id></element-citation></ref><ref id="bib177"><label>177</label><element-citation publication-type="journal" id="sref177"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Piao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>S.Q.</given-names></name><etal/></person-group><article-title>The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives</article-title><source>Adv Drug Deliv Rev</source><volume>191</volume><year>2022</year><object-id pub-id-type="publisher-id">114614</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2022.114614</pub-id><pub-id pub-id-type="pmid">36347432</pub-id></element-citation></ref><ref id="bib178"><label>178</label><element-citation publication-type="journal" id="sref178"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>K.Y.</given-names></name></person-group><article-title>Tumor therapy: targeted drug delivery systems</article-title><source>J Mater Chem B</source><volume>4</volume><year>2016</year><fpage>6758</fpage><lpage>6772</lpage><pub-id pub-id-type="pmid">32263571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c6tb01743f</pub-id></element-citation></ref><ref id="bib179"><label>179</label><element-citation publication-type="journal" id="sref179"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.W.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.L.</given-names></name><etal/></person-group><article-title>Recent advances in hyaluronic acid-based nanomedicines: preparation and application in cancer therapy</article-title><source>Carbohydr Polym</source><volume>292</volume><year>2022</year><object-id pub-id-type="publisher-id">119662</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carbpol.2022.119662</pub-id><pub-id pub-id-type="pmid">35725165</pub-id></element-citation></ref><ref id="bib180"><label>180</label><element-citation publication-type="journal" id="sref180"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.L.</given-names></name></person-group><article-title>Development and application of hyaluronic acid in tumor targeting drug delivery</article-title><source>Acta Pharm Sin B</source><volume>9</volume><year>2019</year><fpage>1099</fpage><lpage>1112</lpage><pub-id pub-id-type="pmid">31867159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2019.06.004</pub-id><pub-id pub-id-type="pmcid">PMC6900560</pub-id></element-citation></ref><ref id="bib181"><label>181</label><element-citation publication-type="journal" id="sref181"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>M.J.</given-names></name></person-group><article-title><italic toggle="yes">In vivo</italic> pharmacokinetics, biodistribution and the anti-tumor effect of cyclic RGD-modified doxorubicin-loaded polymers in tumor-bearing mice</article-title><source>Colloid Surf B-Biointerfaces</source><volume>146</volume><year>2016</year><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.colsurfb.2016.05.054</pub-id><pub-id pub-id-type="pmid">27244048</pub-id></element-citation></ref><ref id="bib182"><label>182</label><element-citation publication-type="journal" id="sref182"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Liposomes with cyclic RGD peptide motif triggers acute immune response in mice</article-title><source>J Control Release</source><volume>293</volume><year>2019</year><fpage>201</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">30527753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2018.12.003</pub-id></element-citation></ref><ref id="bib183"><label>183</label><element-citation publication-type="journal" id="sref183"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Q.W.</given-names></name><etal/></person-group><article-title>cRGD enables rapid phagocytosis of liposomal vancomycin for intracellular bacterial clearance</article-title><source>J Control Release</source><volume>344</volume><year>2022</year><fpage>202</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">35235809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.02.030</pub-id></element-citation></ref><ref id="bib184"><label>184</label><element-citation publication-type="journal" id="sref184"><person-group person-group-type="author"><name name-style="western"><surname>Khoshnejad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Parhiz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shuvaev</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Dmochowski</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Muzykantov</surname><given-names>V.R.</given-names></name></person-group><article-title>Ferritin-based drug delivery systems: hybrid nanocarriers for vascular immunotargeting</article-title><source>J Control Release</source><volume>282</volume><year>2018</year><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">29522833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2018.02.042</pub-id><pub-id pub-id-type="pmcid">PMC6008199</pub-id></element-citation></ref><ref id="bib185"><label>185</label><element-citation publication-type="journal" id="sref185"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X.Y.</given-names></name></person-group><article-title>Ferritin drug carrier (FDC) for tumor targeting therapy</article-title><source>J Control Release</source><volume>311-312</volume><year>2019</year><fpage>288</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">31494184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2019.09.002</pub-id></element-citation></ref><ref id="bib186"><label>186</label><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name name-style="western"><surname>Kesharwani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Halwai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jha</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Al Mughram</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Almujri</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Almalki</surname><given-names>W.H.</given-names></name><etal/></person-group><article-title>Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers</article-title><source>Mol Cancer</source><volume>23</volume><year>2024</year><fpage>244</fpage><pub-id pub-id-type="pmid">39482651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-024-02163-z</pub-id><pub-id pub-id-type="pmcid">PMC11526716</pub-id></element-citation></ref><ref id="bib187"><label>187</label><element-citation publication-type="journal" id="sref187"><person-group person-group-type="author"><name name-style="western"><surname>Sudimack</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.J.</given-names></name></person-group><article-title>Targeted drug delivery <italic toggle="yes">via</italic> the folate receptor</article-title><source>Adv Drug Deliv Rev</source><volume>41</volume><year>2000</year><fpage>147</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">10699311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-409x(99)00062-9</pub-id></element-citation></ref><ref id="bib188"><label>188</label><element-citation publication-type="journal" id="sref188"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Le</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>T.X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.M.</given-names></name><etal/></person-group><article-title>Cell membrane camouflaged nanoparticles: a new biomimetic platform for cancer photothermal therapy</article-title><source>Int J Nanomed</source><volume>14</volume><year>2019</year><fpage>4431</fpage><lpage>4448</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S200284</pub-id><pub-id pub-id-type="pmcid">PMC6588714</pub-id><pub-id pub-id-type="pmid">31354269</pub-id></element-citation></ref><ref id="bib189"><label>189</label><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.S.</given-names></name></person-group><article-title>Multifunctional biomedical materials derived from biological membranes</article-title><source>Adv Mater</source><volume>34</volume><year>2022</year><object-id pub-id-type="publisher-id">2107406</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202107406</pub-id><pub-id pub-id-type="pmid">34739155</pub-id></element-citation></ref><ref id="bib190"><label>190</label><element-citation publication-type="journal" id="sref190"><person-group person-group-type="author"><name name-style="western"><surname>Behera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Padhi</surname><given-names>S.</given-names></name></person-group><article-title>Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: a review</article-title><source>Environ Chem Lett</source><volume>18</volume><year>2020</year><fpage>1557</fpage><lpage>1567</lpage></element-citation></ref><ref id="bib191"><label>191</label><element-citation publication-type="journal" id="sref191"><person-group person-group-type="author"><name name-style="western"><surname>Ouyang</surname><given-names>Q.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>M.</given-names></name></person-group><article-title>Hyaluronic acid receptor-mediated nanomedicines and targeted therapy</article-title><source>Small Methods</source><volume>8</volume><year>2024</year><object-id pub-id-type="publisher-id">2400513</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smtd.202400513</pub-id><pub-id pub-id-type="pmid">39039982</pub-id></element-citation></ref><ref id="bib192"><label>192</label><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>F.Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Open pocket and tighten holes: inhalable lung cancer-targeted nanocomposite for enhanced ferroptosis-apoptosis synergetic therapy</article-title><source>Chem Eng J</source><volume>458</volume><year>2023</year><object-id pub-id-type="publisher-id">141487</object-id></element-citation></ref><ref id="bib193"><label>193</label><element-citation publication-type="journal" id="sref193"><person-group person-group-type="author"><name name-style="western"><surname>Chi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>Dual-responsive multifunctional &#8220;core&#8211;shell&#8221; magnetic nanoparticles promoting Fenton reaction for tumor ferroptosis therapy</article-title><source>Int J Pharm</source><volume>622</volume><year>2022</year><object-id pub-id-type="publisher-id">121898</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2022.121898</pub-id><pub-id pub-id-type="pmid">35688287</pub-id></element-citation></ref><ref id="bib194"><label>194</label><element-citation publication-type="journal" id="sref194"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chuan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Engineering MMP-2 activated nanoparticles carrying B7-H3 bispecific antibodies for ferroptosis-enhanced glioblastoma immunotherapy</article-title><source>ACS Nano</source><volume>17</volume><year>2023</year><fpage>9126</fpage><lpage>9139</lpage><pub-id pub-id-type="pmid">37097811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c12217</pub-id></element-citation></ref><ref id="bib195"><label>195</label><element-citation publication-type="journal" id="sref195"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abourehab</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.S.</given-names></name><name name-style="western"><surname>Kesharwani</surname><given-names>P.</given-names></name><etal/></person-group><article-title>New opportunities for RGD-engineered metal nanoparticles in cancer</article-title><source>Mol Cancer</source><volume>22</volume><year>2023</year><fpage>87</fpage><pub-id pub-id-type="pmid">37226188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01784-0</pub-id><pub-id pub-id-type="pmcid">PMC10210367</pub-id></element-citation></ref><ref id="bib196"><label>196</label><element-citation publication-type="journal" id="sref196"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.Y.</given-names></name></person-group><article-title>Integrin targeted delivery of chemotherapeutics</article-title><source>Theranostics</source><volume>1</volume><year>2011</year><fpage>189</fpage><pub-id pub-id-type="pmid">21547159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno/v01p0189</pub-id><pub-id pub-id-type="pmcid">PMC3086622</pub-id></element-citation></ref><ref id="bib197"><label>197</label><element-citation publication-type="journal" id="sref197"><person-group person-group-type="author"><name name-style="western"><surname>Pachane</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Selistre-de-Araujo</surname><given-names>H.S.</given-names></name></person-group><article-title>The role of <italic toggle="yes">&#945;v&#946;</italic>3 integrin in cancer therapy resistance</article-title><source>Biomedicines</source><volume>12</volume><year>2024</year><fpage>1163</fpage><pub-id pub-id-type="pmid">38927370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines12061163</pub-id><pub-id pub-id-type="pmcid">PMC11200931</pub-id></element-citation></ref><ref id="bib198"><label>198</label><element-citation publication-type="journal" id="sref198"><person-group person-group-type="author"><name name-style="western"><surname>Kapp</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Rechenmacher</surname><given-names>F.</given-names></name><name name-style="western"><surname>Neubauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maltsev</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Cavalcanti-Adam</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Zarka</surname><given-names>R.</given-names></name><etal/></person-group><article-title>A comprehensive evaluation of the activity and selectivity profile of ligands for RGD-binding integrins</article-title><source>Sci Rep</source><volume>7</volume><year>2017</year><object-id pub-id-type="publisher-id">39805</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep39805</pub-id><pub-id pub-id-type="pmcid">PMC5225454</pub-id><pub-id pub-id-type="pmid">28074920</pub-id></element-citation></ref><ref id="bib199"><label>199</label><element-citation publication-type="journal" id="sref199"><person-group person-group-type="author"><name name-style="western"><surname>Asati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>V.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>V.</given-names></name></person-group><article-title>RGD peptide as a targeting moiety for theranostic purpose: an update study</article-title><source>Int J Pept Res Therapeut</source><volume>25</volume><year>2019</year><fpage>49</fpage><lpage>65</lpage></element-citation></ref><ref id="bib200"><label>200</label><element-citation publication-type="journal" id="sref200"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.Z.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.L.</given-names></name></person-group><article-title>Renal clearable ultrasmall single-crystal Fe nanoparticles for highly selective and effective ferroptosis therapy and immunotherapy</article-title><source>J Am Chem Soc</source><volume>143</volume><year>2021</year><fpage>15812</fpage><lpage>15823</lpage><pub-id pub-id-type="pmid">34473493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.1c07471</pub-id></element-citation></ref><ref id="bib201"><label>201</label><element-citation publication-type="journal" id="sref201"><person-group person-group-type="author"><name name-style="western"><surname>Patten</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name></person-group><article-title>Fibronectin in development and wound healing</article-title><source>Adv Drug Deliv Rev</source><volume>170</volume><year>2021</year><fpage>353</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">32961203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2020.09.005</pub-id></element-citation></ref><ref id="bib202"><label>202</label><element-citation publication-type="journal" id="sref202"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Fibronectin-coated metal&#8211;phenolic networks for cooperative tumor chemo-/chemodynamic/immune therapy <italic toggle="yes">via</italic> enhanced ferroptosis-mediated immunogenic cell death</article-title><source>ACS Nano</source><volume>16</volume><year>2022</year><fpage>984</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">35023715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.1c08585</pub-id></element-citation></ref><ref id="bib203"><label>203</label><element-citation publication-type="journal" id="sref203"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>C.Y.</given-names></name><etal/></person-group><article-title>Factors influencing the immunogenicity and immunotoxicity of cyclic RGD peptide-modified nanodrug delivery systems</article-title><source>Mol Pharm</source><volume>17</volume><year>2020</year><fpage>3281</fpage><lpage>3290</lpage><pub-id pub-id-type="pmid">32786957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.0c00394</pub-id></element-citation></ref><ref id="bib204"><label>204</label><element-citation publication-type="journal" id="sref204"><person-group person-group-type="author"><name name-style="western"><surname>Javid</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oryani</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rezagholinejad</surname><given-names>N.</given-names></name><name name-style="western"><surname>Esparham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tajaldini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karimi-Shahri</surname><given-names>M.</given-names></name></person-group><article-title>RGD peptide in cancer targeting: benefits, challenges, solutions, and possible integrin&#8211;RGD interactions</article-title><source>Cancer Med</source><volume>13</volume><year>2024</year><object-id pub-id-type="publisher-id">e6800</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.6800</pub-id><pub-id pub-id-type="pmcid">PMC10832341</pub-id><pub-id pub-id-type="pmid">38349028</pub-id></element-citation></ref><ref id="bib205"><label>205</label><element-citation publication-type="journal" id="sref205"><person-group person-group-type="author"><name name-style="western"><surname>Trinder</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>E.</given-names></name></person-group><article-title>Transferrin receptor 2: a new molecule in iron metabolism</article-title><source>Int J Biochem Cell Biol</source><volume>35</volume><year>2003</year><fpage>292</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">12531241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1357-2725(02)00258-3</pub-id></element-citation></ref><ref id="bib206"><label>206</label><element-citation publication-type="journal" id="sref206"><person-group person-group-type="author"><name name-style="western"><surname>Lodhi</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Bukhari</surname><given-names>S.M.H.</given-names></name><name name-style="western"><surname>Sabir</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Samra</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Butt</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Probing transferrin receptor overexpression in gastric cancer mice models</article-title><source>ACS Omega</source><volume>6</volume><year>2021</year><fpage>29893</fpage><lpage>29904</lpage><pub-id pub-id-type="pmid">34778662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsomega.1c04382</pub-id><pub-id pub-id-type="pmcid">PMC8587131</pub-id></element-citation></ref><ref id="bib207"><label>207</label><element-citation publication-type="journal" id="sref207"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>M.M.</given-names></name></person-group><article-title>Cargo loading within ferritin nanocages in preparation for tumor-targeted delivery</article-title><source>Nat Protoc</source><volume>16</volume><year>2021</year><fpage>4878</fpage><lpage>4896</lpage><pub-id pub-id-type="pmid">34497386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41596-021-00602-5</pub-id></element-citation></ref><ref id="bib208"><label>208</label><element-citation publication-type="journal" id="sref208"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Niemi</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Lebr&#243;n</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bj&#246;rkman</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Binding and uptake of H-ferritin are mediated by human transferrin receptor-1</article-title><source>Proc Natl Acad Sci U S A</source><volume>107</volume><year>2010</year><fpage>3505</fpage><lpage>3510</lpage><pub-id pub-id-type="pmid">20133674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0913192107</pub-id><pub-id pub-id-type="pmcid">PMC2840523</pub-id></element-citation></ref><ref id="bib209"><label>209</label><element-citation publication-type="journal" id="sref209"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>L.Y.</given-names></name><etal/></person-group><article-title>Intrinsic tumor-targeted murine Ferritin nanocage co-delivers GPX4 and FSP1 inhibitors for synergistic ferroptosis-immunotherapy</article-title><source>Nano Today</source><volume>58</volume><year>2024</year><object-id pub-id-type="publisher-id">102411</object-id></element-citation></ref><ref id="bib210"><label>210</label><element-citation publication-type="journal" id="sref210"><person-group person-group-type="author"><name name-style="western"><surname>Zuo</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>T.X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.H.</given-names></name><etal/></person-group><article-title>pH-Sensitive molecular-switch-containing polymer nanoparticle for breast cancer therapy with ferritinophagy-cascade ferroptosis and tumor immune activation</article-title><source>Adv Healthcare Mater</source><volume>10</volume><year>2021</year><object-id pub-id-type="publisher-id">2100683</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202100683</pub-id><pub-id pub-id-type="pmid">34535975</pub-id></element-citation></ref><ref id="bib211"><label>211</label><element-citation publication-type="journal" id="sref211"><person-group person-group-type="author"><name name-style="western"><surname>Sudimack</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.J.</given-names></name></person-group><article-title>Targeted drug delivery <italic toggle="yes">via</italic> the folate receptor</article-title><source>Adv Drug Deliv Rev</source><volume>41</volume><year>2000</year><fpage>147</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">10699311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-409x(99)00062-9</pub-id></element-citation></ref><ref id="bib212"><label>212</label><element-citation publication-type="journal" id="sref212"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q.Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.H.</given-names></name></person-group><article-title>Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma</article-title><source>J Nanobiotechnol</source><volume>21</volume><year>2023</year><fpage>383</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-02146-0</pub-id><pub-id pub-id-type="pmcid">PMC10585872</pub-id><pub-id pub-id-type="pmid">37858186</pub-id></element-citation></ref><ref id="bib213"><label>213</label><element-citation publication-type="journal" id="sref213"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.W.</given-names></name><name name-style="western"><surname>Hiew</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Nanomedicines for targeted pulmonary delivery: receptor-mediated strategy and alternatives</article-title><source>Nanoscale</source><volume>16</volume><year>2024</year><fpage>2820</fpage><lpage>2833</lpage><pub-id pub-id-type="pmid">38289362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3nr05487j</pub-id></element-citation></ref><ref id="bib214"><label>214</label><element-citation publication-type="journal" id="sref214"><person-group person-group-type="author"><name name-style="western"><surname>Sebak</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>El-Shenawy</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>El-Safy</surname><given-names>S.</given-names></name><name name-style="western"><surname>El-Shazly</surname><given-names>M.</given-names></name></person-group><article-title>From passive targeting to personalized nanomedicine: multidimensional insights on nanoparticles' interaction with the tumor microenvironment</article-title><source>Curr Pharm Biotechnol</source><volume>22</volume><year>2021</year><fpage>1444</fpage><lpage>1465</lpage><pub-id pub-id-type="pmid">33308126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389201021666201211103856</pub-id></element-citation></ref><ref id="bib215"><label>215</label><element-citation publication-type="journal" id="sref215"><person-group person-group-type="author"><name name-style="western"><surname>Rios de la Rosa</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pingrajai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pelliccia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spadea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lallana</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gennari</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Binding and internalization in receptor-targeted carriers: the complex role of CD44 in the uptake of hyaluronic acid-based nanoparticles (siRNA delivery)</article-title><source>Adv Healthcare Mater</source><volume>8</volume><year>2019</year><object-id pub-id-type="publisher-id">1901182</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201901182</pub-id><pub-id pub-id-type="pmid">31738017</pub-id></element-citation></ref><ref id="bib216"><label>216</label><element-citation publication-type="journal" id="sref216"><person-group person-group-type="author"><name name-style="western"><surname>Patra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rengan</surname><given-names>A.K.</given-names></name></person-group><article-title>Cancer cell membrane cloaked nanocarriers: a biomimetic approach towards cancer theranostics</article-title><source>Mater Today Commun</source><volume>33</volume><year>2022</year><object-id pub-id-type="publisher-id">104289</object-id></element-citation></ref><ref id="bib217"><label>217</label><element-citation publication-type="journal" id="sref217"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.Y.</given-names></name><etal/></person-group><article-title>Cancer cell membrane biomimetic mesoporous silica nanotheranostics for enhanced ferroptosis-mediated immuogenic cell death on gastric cancer</article-title><source>Chem Eng J</source><volume>455</volume><year>2023</year><object-id pub-id-type="publisher-id">140868</object-id></element-citation></ref><ref id="bib218"><label>218</label><element-citation publication-type="journal" id="sref218"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.Q.</given-names></name><etal/></person-group><article-title>Microenvironment-driven sequential ferroptosis, photodynamic therapy, and chemotherapy for targeted breast cancer therapy by a cancer-cell-membrane-coated nanoscale metal-organic framework</article-title><source>Biomaterials</source><volume>283</volume><year>2022</year><object-id pub-id-type="publisher-id">121449</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2022.121449</pub-id><pub-id pub-id-type="pmid">35247637</pub-id></element-citation></ref><ref id="bib219"><label>219</label><element-citation publication-type="journal" id="sref219"><person-group person-group-type="author"><name name-style="western"><surname>Dash</surname><given-names>P.</given-names></name><name name-style="western"><surname>Piras</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Dash</surname><given-names>M.</given-names></name></person-group><article-title>Cell membrane coated nanocarriers-an efficient biomimetic platform for targeted therapy</article-title><source>J Control Release</source><volume>327</volume><year>2020</year><fpage>546</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">32911013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2020.09.012</pub-id></element-citation></ref><ref id="bib220"><label>220</label><element-citation publication-type="journal" id="sref220"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pereira-Silva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peixoto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Veiga</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hamblin</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Macrophage cell membrane-cloaked nanoplatforms for biomedical applications</article-title><source>Small Methods</source><volume>6</volume><year>2022</year><object-id pub-id-type="publisher-id">2200289</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smtd.202200289</pub-id><pub-id pub-id-type="pmid">35768282</pub-id></element-citation></ref><ref id="bib221"><label>221</label><element-citation publication-type="journal" id="sref221"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.F.</given-names></name><name name-style="western"><surname>Kam</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Surface-engineered chlorella alleviated hypoxic tumor microenvironment for enhanced chemotherapy and immunotherapy of first-line drugs</article-title><source>Mater Today</source><volume>58</volume><year>2022</year><fpage>57</fpage><lpage>70</lpage></element-citation></ref><ref id="bib222"><label>222</label><element-citation publication-type="journal" id="sref222"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.D.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.Z.</given-names></name><name name-style="western"><surname>Ai</surname><given-names>X.Z.</given-names></name><etal/></person-group><article-title>White blood cell membrane-coated nanoparticles: recent development and medical applications</article-title><source>Adv Healthcare Mater</source><volume>11</volume><year>2022</year><object-id pub-id-type="publisher-id">2101349</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202101349</pub-id><pub-id pub-id-type="pmid">34468090</pub-id></element-citation></ref><ref id="bib223"><label>223</label><element-citation publication-type="journal" id="sref223"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Su</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>K.X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.Y.</given-names></name><etal/></person-group><article-title>Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy</article-title><source>Acta Biomater</source><volume>144</volume><year>2022</year><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">35314366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2022.03.030</pub-id></element-citation></ref><ref id="bib224"><label>224</label><element-citation publication-type="journal" id="sref224"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Biomimetic nanoarchitectonics with chitosan nanogels for collaborative induction of ferroptosis and anticancer immunity for cancer therapy</article-title><source>Adv Healthcare Mater</source><volume>13</volume><year>2024</year><object-id pub-id-type="publisher-id">2302752</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202302752</pub-id><pub-id pub-id-type="pmid">37975280</pub-id></element-citation></ref><ref id="bib225"><label>225</label><element-citation publication-type="journal" id="sref225"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q.L.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>D.H.</given-names></name><etal/></person-group><article-title>Cell membrane-coated nanomaterials for cancer therapy</article-title><source>Mater Today Bio</source><volume>20</volume><year>2023</year><object-id pub-id-type="publisher-id">100633</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mtbio.2023.100633</pub-id><pub-id pub-id-type="pmcid">PMC10148189</pub-id><pub-id pub-id-type="pmid">37128288</pub-id></element-citation></ref><ref id="bib226"><label>226</label><element-citation publication-type="journal" id="sref226"><person-group person-group-type="author"><name name-style="western"><surname>Oroojalian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Beygi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baradaran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mokhtarzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shahbazi</surname><given-names>M.A.</given-names></name></person-group><article-title>Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy</article-title><source>Small</source><volume>17</volume><year>2021</year><object-id pub-id-type="publisher-id">2006484</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202006484</pub-id><pub-id pub-id-type="pmid">33577127</pub-id></element-citation></ref><ref id="bib227"><label>227</label><element-citation publication-type="journal" id="sref227"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira-Faria</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yousefiasl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mac&#225;rio-Soares</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pereira-Silva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peixoto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zafar</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Stem cell membrane-coated abiotic nanomaterials for biomedical applications</article-title><source>J Control Release</source><volume>351</volume><year>2022</year><fpage>174</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">36103910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.09.012</pub-id></element-citation></ref><ref id="bib228"><label>228</label><element-citation publication-type="journal" id="sref228"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>N.-H.</given-names></name><name name-style="western"><surname>You</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taghizadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taghizadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name></person-group><article-title>Cell membrane-cloaked nanotherapeutics for targeted drug delivery</article-title><source>Int J Mol Sci</source><volume>23</volume><year>2022</year><fpage>2223</fpage><pub-id pub-id-type="pmid">35216342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23042223</pub-id><pub-id pub-id-type="pmcid">PMC8879543</pub-id></element-citation></ref><ref id="bib229"><label>229</label><element-citation publication-type="journal" id="sref229"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z.X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.Q.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.Z.</given-names></name></person-group><article-title>Nanoparticle-Based drug delivery strategies for targeted therapy to hypoxic solid tumors</article-title><source>Chem Eng J</source><volume>502</volume><year>2024</year><object-id pub-id-type="publisher-id">158081</object-id></element-citation></ref><ref id="bib230"><label>230</label><element-citation publication-type="journal" id="sref230"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ming</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.T.</given-names></name><etal/></person-group><article-title>A pH and glutathione-responsive carbon monoxide-driven nano-herb delivery system for enhanced immunotherapy in colorectal cancer</article-title><source>J Control Release</source><volume>376</volume><year>2024</year><fpage>659</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">39442888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2024.10.043</pub-id></element-citation></ref><ref id="bib231"><label>231</label><element-citation publication-type="journal" id="sref231"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A dual heat shock protein down-regulation strategy using PDA/Cu/ICG/R controlled by NIR &#8220;switch&#8221; enhances mild-photothermal therapy effect</article-title><source>Adv Healthcare Mater</source><volume>12</volume><year>2023</year><object-id pub-id-type="publisher-id">2300929</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202300929</pub-id><pub-id pub-id-type="pmid">37300324</pub-id></element-citation></ref><ref id="bib232"><label>232</label><element-citation publication-type="journal" id="sref232"><person-group person-group-type="author"><name name-style="western"><surname>Baryakova</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Pogostin</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>K.J.</given-names></name></person-group><article-title>Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems</article-title><source>Nat Rev Drug Discov</source><volume>22</volume><year>2023</year><fpage>387</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">36973491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-023-00670-0</pub-id><pub-id pub-id-type="pmcid">PMC10041531</pub-id></element-citation></ref><ref id="bib233"><label>233</label><element-citation publication-type="journal" id="sref233"><person-group person-group-type="author"><name name-style="western"><surname>Peralta</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lontos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nieves-Rosado</surname><given-names>H.</given-names></name><name name-style="western"><surname>Spahr</surname><given-names>K.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism</article-title><source>Nat Immunol</source><volume>25</volume><year>2024</year><fpage>2297</fpage><lpage>2307</lpage><pub-id pub-id-type="pmid">39516648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-024-01999-3</pub-id><pub-id pub-id-type="pmcid">PMC11588660</pub-id></element-citation></ref><ref id="bib234"><label>234</label><element-citation publication-type="journal" id="sref234"><person-group person-group-type="author"><name name-style="western"><surname>Pucino</surname><given-names>V.</given-names></name><name name-style="western"><surname>Certo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bulusu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cucchi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Goldmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pontarini</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Lactate buildup at the site of chronic inflammation promotes disease by inducing CD4<sup>+</sup> T cell metabolic rewiring</article-title><source>Cell Metab</source><volume>30</volume><year>2019</year><comment>1055-74.e8</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2019.10.004</pub-id><pub-id pub-id-type="pmcid">PMC6899510</pub-id><pub-id pub-id-type="pmid">31708446</pub-id></element-citation></ref><ref id="bib235"><label>235</label><element-citation publication-type="journal" id="sref235"><person-group person-group-type="author"><name name-style="western"><surname>Chai</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Polymyxin b-polysaccharide polyion nanocomplex with improved biocompatibility and unaffected antibacterial activity for acute lung infection management</article-title><source>Adv Healthcare Mater</source><volume>9</volume><year>2020</year><object-id pub-id-type="publisher-id">1901542</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201901542</pub-id><pub-id pub-id-type="pmid">31898875</pub-id></element-citation></ref><ref id="bib236"><label>236</label><element-citation publication-type="journal" id="sref236"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.X.</given-names></name><etal/></person-group><article-title>Adipocyte-derived glutathione promotes obesity-related breast cancer by regulating the SCARB2&#8211;ARF1&#8211;mTORC1 complex</article-title><source>Cell Metab</source><volume>37</volume><year>2025</year><fpage>692</fpage><lpage>707.e9</lpage><pub-id pub-id-type="pmid">39442522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2024.09.013</pub-id></element-citation></ref><ref id="bib237"><label>237</label><element-citation publication-type="journal" id="sref237"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>A study of glutathione status in the blood and tissues of patients with breast cancer</article-title><source>Cell Biochem Funct</source><volume>24</volume><year>2006</year><fpage>555</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">16142688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbf.1275</pub-id></element-citation></ref><ref id="bib238"><label>238</label><element-citation publication-type="journal" id="sref238"><person-group person-group-type="author"><name name-style="western"><surname>Fontaine</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Hann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Santi</surname><given-names>D.V.</given-names></name></person-group><article-title>Species-specific optimization of PEG&#8764; SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft</article-title><source>Cancer Chemother Pharmacol</source><volume>84</volume><year>2019</year><fpage>729</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">31321449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-019-03903-5</pub-id></element-citation></ref><ref id="bib239"><label>239</label><element-citation publication-type="journal" id="sref239"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Dual-stimuli responsive smart nanoprobe for precise diagnosis and synergistic multi-modalities therapy of superficial squamous cell carcinoma</article-title><source>J Nanobiotechnol</source><volume>21</volume><year>2023</year><fpage>4</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-022-01759-1</pub-id><pub-id pub-id-type="pmcid">PMC9808965</pub-id><pub-id pub-id-type="pmid">36597067</pub-id></element-citation></ref><ref id="bib240"><label>240</label><element-citation publication-type="journal" id="sref240"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>K.Y.</given-names></name></person-group><article-title>Near-infrared photoactivatable semiconducting polymer nanoblockaders for metastasis-inhibited combination cancer therapy</article-title><source>Adv Mater</source><volume>31</volume><year>2019</year><object-id pub-id-type="publisher-id">1905091</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.201905091</pub-id><pub-id pub-id-type="pmid">31566279</pub-id></element-citation></ref><ref id="bib241"><label>241</label><element-citation publication-type="journal" id="sref241"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.R.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>X.H.</given-names></name></person-group><article-title>Cellular Trojan Horse initiates bimetallic Fe&#8211;Cu MOF-mediated synergistic cuproptosis and ferroptosis against malignancies</article-title><source>Sci Adv</source><volume>10</volume><year>2024</year><object-id pub-id-type="publisher-id">eadk3201</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adk3201</pub-id><pub-id pub-id-type="pmcid">PMC11006215</pub-id><pub-id pub-id-type="pmid">38598629</pub-id></element-citation></ref><ref id="bib242"><label>242</label><element-citation publication-type="journal" id="sref242"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.Y.</given-names></name><etal/></person-group><article-title>Neutrophil-based Trojan horse containing polymer nano-therapeutics for sono-activatable ferroptosis-immunotherapy of orthotopic glioma</article-title><source>Nano Today</source><volume>57</volume><year>2024</year><object-id pub-id-type="publisher-id">102398</object-id></element-citation></ref><ref id="bib243"><label>243</label><element-citation publication-type="journal" id="sref243"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.H.</given-names></name></person-group><article-title>Harnessing nanomaterials for cancer sonodynamic immunotherapy</article-title><source>Adv Mater</source><volume>35</volume><year>2023</year><object-id pub-id-type="publisher-id">2211130</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202211130</pub-id><pub-id pub-id-type="pmid">36881527</pub-id></element-citation></ref><ref id="bib244"><label>244</label><element-citation publication-type="journal" id="sref244"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.H.</given-names></name></person-group><article-title>Tumor microenvironment-induced structure changing drug/gene delivery system for overcoming delivery-associated challenges</article-title><source>J Control Release</source><volume>323</volume><year>2020</year><fpage>203</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">32320817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2020.04.026</pub-id></element-citation></ref><ref id="bib245"><label>245</label><element-citation publication-type="journal" id="sref245"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V.P.</given-names></name></person-group><article-title>Stimulus-responsive nanopreparations for tumor targeting</article-title><source>Integr Biol</source><volume>5</volume><year>2013</year><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c2ib20135f</pub-id><pub-id pub-id-type="pmcid">PMC3521849</pub-id><pub-id pub-id-type="pmid">22869005</pub-id></element-citation></ref><ref id="bib246"><label>246</label><element-citation publication-type="journal" id="sref246"><person-group person-group-type="author"><name name-style="western"><surname>Koppenol</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Bounds</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>C.V.</given-names></name></person-group><article-title>Otto Warburg's contributions to current concepts of cancer metabolism</article-title><source>Nat Rev Cancer</source><volume>11</volume><year>2011</year><fpage>325</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">21508971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3038</pub-id></element-citation></ref><ref id="bib247"><label>247</label><element-citation publication-type="journal" id="sref247"><person-group person-group-type="author"><name name-style="western"><surname>Corbet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Feron</surname><given-names>O.</given-names></name></person-group><article-title>Tumour acidosis: from the passenger to the driver's seat</article-title><source>Nat Rev Cancer</source><volume>17</volume><year>2017</year><fpage>577</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">28912578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc.2017.77</pub-id></element-citation></ref><ref id="bib248"><label>248</label><element-citation publication-type="journal" id="sref248"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Voelkl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meidenbauer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ammer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Edinger</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Inhibitory effect of tumor cell-derived lactic acid on human T cells</article-title><source>Blood</source><volume>109</volume><year>2007</year><fpage>3812</fpage><lpage>3819</lpage><pub-id pub-id-type="pmid">17255361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2006-07-035972</pub-id></element-citation></ref><ref id="bib249"><label>249</label><element-citation publication-type="journal" id="sref249"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Grichuk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pantoja</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Faubert</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Severely polarized extracellular acidity around tumour cells</article-title><source>Nat Biomed Eng</source><volume>8</volume><year>2024</year><fpage>787</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">38438799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-024-01178-7</pub-id><pub-id pub-id-type="pmcid">PMC12192457</pub-id></element-citation></ref><ref id="bib250"><label>250</label><element-citation publication-type="journal" id="sref250"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Tumor-microenvironment-activatable polymer nano-immunomodulator for precision cancer photoimmunotherapy</article-title><source>Adv Mater</source><volume>34</volume><year>2022</year><object-id pub-id-type="publisher-id">2106654</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202106654</pub-id><pub-id pub-id-type="pmid">34854147</pub-id></element-citation></ref><ref id="bib251"><label>251</label><element-citation publication-type="journal" id="sref251"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Ran</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Low molecular weight heparin-coated and dendrimer-based core-shell nanoplatform with enhanced immune activation and multiple anti-metastatic effects for melanoma treatment</article-title><source>Theranostics</source><volume>9</volume><year>2019</year><fpage>337</fpage><pub-id pub-id-type="pmid">30809278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.29026</pub-id><pub-id pub-id-type="pmcid">PMC6376190</pub-id></element-citation></ref><ref id="bib252"><label>252</label><element-citation publication-type="journal" id="sref252"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>N.</given-names></name><etal/></person-group><article-title>A pH-responsive biomimetic drug delivery nanosystem for targeted chemo-photothermal therapy of tumors</article-title><source>Nano Res</source><volume>15</volume><year>2022</year><fpage>4274</fpage><lpage>4284</lpage></element-citation></ref><ref id="bib253"><label>253</label><element-citation publication-type="journal" id="sref253"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.G.</given-names></name></person-group><article-title>Enhanced therapeutic siRNA to tumor cells by a pH-sensitive agmatine&#8211;chitosan bioconjugate</article-title><source>ACS Appl Mater Interfaces</source><volume>7</volume><year>2015</year><fpage>8114</fpage><lpage>8124</lpage><pub-id pub-id-type="pmid">25832629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.5b00851</pub-id></element-citation></ref><ref id="bib254"><label>254</label><element-citation publication-type="journal" id="sref254"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>An oxidative stress nanoamplifier to enhance the efficacy of cisplatin in head and neck cancer</article-title><source>Angew Chem Int Ed</source><volume>64</volume><year>2025</year><object-id pub-id-type="publisher-id">e202421481</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202421481</pub-id><pub-id pub-id-type="pmid">39876759</pub-id></element-citation></ref><ref id="bib255"><label>255</label><element-citation publication-type="journal" id="sref255"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>pH responsive and zwitterionic micelle for enhanced cellular uptake and antitumor performance</article-title><source>Biomater Adv</source><volume>167</volume><year>2025</year><object-id pub-id-type="publisher-id">214082</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioadv.2024.214082</pub-id><pub-id pub-id-type="pmid">39486242</pub-id></element-citation></ref><ref id="bib256"><label>256</label><element-citation publication-type="journal" id="sref256"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem</article-title><source>Nat Commun</source><volume>9</volume><year>2018</year><fpage>3390</fpage><pub-id pub-id-type="pmid">30139933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-05906-x</pub-id><pub-id pub-id-type="pmcid">PMC6107580</pub-id></element-citation></ref><ref id="bib257"><label>257</label><element-citation publication-type="journal" id="sref257"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.Z.</given-names></name><etal/></person-group><article-title>Stimuli-responsive antibacterial materials: molecular structures, design principles, and biomedical applications</article-title><source>Adv Sci</source><volume>9</volume><year>2022</year><object-id pub-id-type="publisher-id">2104843</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202104843</pub-id><pub-id pub-id-type="pmcid">PMC9069201</pub-id><pub-id pub-id-type="pmid">35224893</pub-id></element-citation></ref><ref id="bib258"><label>258</label><element-citation publication-type="journal" id="sref258"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.L.</given-names></name><etal/></person-group><article-title>Preparation and application of pH-responsive drug delivery systems</article-title><source>J Control Release</source><volume>348</volume><year>2022</year><fpage>206</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">35660634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.05.056</pub-id></element-citation></ref><ref id="bib259"><label>259</label><element-citation publication-type="journal" id="sref259"><person-group person-group-type="author"><name name-style="western"><surname>I&#351;&#305;klan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Polat</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis and characterization of thermo/pH-sensitive pectin-graft-poly(dimethylaminoethyl methacrylate) coated magnetic nanoparticles</article-title><source>Int J Biol Macromol</source><volume>164</volume><year>2020</year><fpage>4499</fpage><lpage>4515</lpage><pub-id pub-id-type="pmid">32898537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2020.09.002</pub-id></element-citation></ref><ref id="bib260"><label>260</label><element-citation publication-type="journal" id="sref260"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>G.T.</given-names></name></person-group><article-title>Mechanisms of drug release in pH-sensitive micelles for tumour targeted drug delivery system: a review</article-title><source>Int J Pharm</source><volume>535</volume><year>2018</year><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">29113804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2017.11.003</pub-id></element-citation></ref><ref id="bib261"><label>261</label><element-citation publication-type="journal" id="sref261"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Zi</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Z.L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.Y.</given-names></name><etal/></person-group><article-title>pH-Responsive nanoparticles based on cholesterol/imidazole modified oxidized-starch for targeted anticancer drug delivery</article-title><source>Carbohydr Polym</source><volume>233</volume><year>2020</year><object-id pub-id-type="publisher-id">115858</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carbpol.2020.115858</pub-id><pub-id pub-id-type="pmid">32059909</pub-id></element-citation></ref><ref id="bib262"><label>262</label><element-citation publication-type="journal" id="sref262"><person-group person-group-type="author"><name name-style="western"><surname>Ovais</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pramanik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Raza</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Designing stimuli-responsive upconversion nanoparticles that exploit the tumor microenvironment</article-title><source>Adv Mater</source><volume>32</volume><year>2020</year><object-id pub-id-type="publisher-id">2000055</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202000055</pub-id><pub-id pub-id-type="pmid">32227413</pub-id></element-citation></ref><ref id="bib263"><label>263</label><element-citation publication-type="journal" id="sref263"><person-group person-group-type="author"><name name-style="western"><surname>Valavanidis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vlachogianni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fiotakis</surname><given-names>C.</given-names></name></person-group><article-title>8-Hydroxy-2&#8242;-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis</article-title><source>J Environ Sci Health Part C Toxicol Carcinogen</source><volume>27</volume><year>2009</year><fpage>120</fpage><lpage>139</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10590500902885684</pub-id><pub-id pub-id-type="pmid">19412858</pub-id></element-citation></ref><ref id="bib264"><label>264</label><element-citation publication-type="journal" id="sref264"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Duvall</surname><given-names>C.L.</given-names></name></person-group><article-title>Poly (PS<italic toggle="yes">-b</italic>-DMA) micelles for reactive oxygen species triggered drug release</article-title><source>J Control Release</source><volume>162</volume><year>2012</year><fpage>591</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">22889714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2012.07.042</pub-id><pub-id pub-id-type="pmcid">PMC3572905</pub-id></element-citation></ref><ref id="bib265"><label>265</label><element-citation publication-type="journal" id="sref265"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y.Q.</given-names></name><etal/></person-group><article-title>Free-blockage mesoporous anticancer nanoparticles based on ROS-responsive wetting behavior of nanopores</article-title><source>Small</source><volume>13</volume><year>2017</year><object-id pub-id-type="publisher-id">1701942</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.201701942</pub-id><pub-id pub-id-type="pmid">28841777</pub-id></element-citation></ref><ref id="bib266"><label>266</label><element-citation publication-type="journal" id="sref266"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D.X.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Composite hydrogel for spatiotemporal lipid intervention of tumor milieu</article-title><source>Adv Mater</source><volume>35</volume><year>2023</year><object-id pub-id-type="publisher-id">2211579</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202211579</pub-id><pub-id pub-id-type="pmid">36637436</pub-id></element-citation></ref><ref id="bib267"><label>267</label><element-citation publication-type="journal" id="sref267"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Therapeutic nanocarriers with hydrogen peroxide-triggered drug release for cancer treatment</article-title><source>Biomacromolecules</source><volume>14</volume><year>2013</year><fpage>1627</fpage><lpage>1636</lpage><pub-id pub-id-type="pmid">23510441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bm4002574</pub-id></element-citation></ref><ref id="bib268"><label>268</label><element-citation publication-type="journal" id="sref268"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>F.</given-names></name><etal/></person-group><article-title>GSH-depleted PtCu3 nanocages for chemodynamic-enhanced sonodynamic cancer therapy</article-title><source>Adv Funct Mater</source><volume>30</volume><year>2020</year><object-id pub-id-type="publisher-id">1907954</object-id></element-citation></ref><ref id="bib269"><label>269</label><element-citation publication-type="journal" id="sref269"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Z.H.</given-names></name><etal/></person-group><article-title>Reversing cold tumors to hot: an immunoadjuvant-functionalized metal-organic framework for multimodal imaging-guided synergistic photo-immunotherapy</article-title><source>Bioact Mater</source><volume>6</volume><year>2021</year><fpage>312</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">32954050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2020.08.005</pub-id><pub-id pub-id-type="pmcid">PMC7475520</pub-id></element-citation></ref><ref id="bib270"><label>270</label><element-citation publication-type="journal" id="sref270"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Di</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.S.</given-names></name></person-group><article-title>Preparation of disulfide/trisulfide core-cross-linked polycarbonate nanocarriers for intracellular reduction-triggered drug release</article-title><source>ACS Macro Lett</source><volume>13</volume><year>2024</year><fpage>1433</fpage><lpage>1441</lpage><pub-id pub-id-type="pmid">39383241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsmacrolett.4c00443</pub-id></element-citation></ref><ref id="bib271"><label>271</label><element-citation publication-type="journal" id="sref271"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Su</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.F.</given-names></name><etal/></person-group><article-title>Rigid shell decorated nanodevice with Fe/H<sub>2</sub>O<sub>2</sub> supply and glutathione depletion capabilities for potentiated ferroptosis and synergized immunotherapy</article-title><source>Adv Funct Mater</source><volume>33</volume><year>2023</year><object-id pub-id-type="publisher-id">2215022</object-id></element-citation></ref><ref id="bib272"><label>272</label><element-citation publication-type="journal" id="sref272"><person-group person-group-type="author"><name name-style="western"><surname>Wijewantha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eikanger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Antony</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Potts</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Enhancing anti-tumorigenic efficacy of eugenol in human colon cancer cells using enzyme-responsive nanoparticles</article-title><source>Cancers</source><volume>15</volume><year>2023</year><fpage>1145</fpage><pub-id pub-id-type="pmid">36831488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15041145</pub-id><pub-id pub-id-type="pmcid">PMC9953800</pub-id></element-citation></ref><ref id="bib273"><label>273</label><element-citation publication-type="journal" id="sref273"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>L.Q.</given-names></name><name name-style="western"><surname>Han</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A hyaluronidase-responsive nanoparticle-based drug delivery system for targeting colon cancer cells</article-title><source>Cancer Res</source><volume>76</volume><year>2016</year><fpage>7208</fpage><lpage>7218</lpage><pub-id pub-id-type="pmid">27742685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-16-1681</pub-id><pub-id pub-id-type="pmcid">PMC5161640</pub-id></element-citation></ref><ref id="bib274"><label>274</label><element-citation publication-type="journal" id="sref274"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cong</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name></person-group><article-title>Application and design of esterase-responsive nanoparticles for cancer therapy</article-title><source>Drug Deliv</source><volume>26</volume><year>2019</year><fpage>416</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">30929527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10717544.2019.1588424</pub-id><pub-id pub-id-type="pmcid">PMC6450553</pub-id></element-citation></ref><ref id="bib275"><label>275</label><element-citation publication-type="journal" id="sref275"><person-group person-group-type="author"><name name-style="western"><surname>Janczy-Cempa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mazuryk</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kania</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brindell</surname><given-names>M.</given-names></name></person-group><article-title>Significance of specific oxidoreductases in the design of hypoxia-activated prodrugs and fluorescent turn off&#8211;on probes for hypoxia imaging</article-title><source>Cancers</source><volume>14</volume><year>2022</year><fpage>2686</fpage><pub-id pub-id-type="pmid">35681666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14112686</pub-id><pub-id pub-id-type="pmcid">PMC9179281</pub-id></element-citation></ref><ref id="bib276"><label>276</label><element-citation publication-type="journal" id="sref276"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.Z.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.C.</given-names></name><etal/></person-group><article-title>Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1</article-title><source>Genome Med</source><volume>12</volume><year>2020</year><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-020-00780-z</pub-id><pub-id pub-id-type="pmcid">PMC7523356</pub-id><pub-id pub-id-type="pmid">32988398</pub-id></element-citation></ref><ref id="bib277"><label>277</label><element-citation publication-type="journal" id="sref277"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Q.L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.K.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.Y.</given-names></name><etal/></person-group><article-title>Enhanced ferroptosis by oxygen-boosted phototherapy based on a 2-in-1 nanoplatform of ferrous hemoglobin for tumor synergistic therapy</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>3414</fpage><lpage>3425</lpage><pub-id pub-id-type="pmid">32155051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.9b09426</pub-id></element-citation></ref><ref id="bib278"><label>278</label><element-citation publication-type="journal" id="sref278"><person-group person-group-type="author"><name name-style="western"><surname>Bourguignon</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Bikle</surname><given-names>D.</given-names></name></person-group><article-title>Selective hyaluronan&#8211;CD44 signaling promotes miRNA-21 expression and interacts with vitamin D function during cutaneous squamous cell carcinomas progression following UV irradiation</article-title><source>Front Immunol</source><volume>6</volume><year>2015</year><fpage>224</fpage><pub-id pub-id-type="pmid">26029210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2015.00224</pub-id><pub-id pub-id-type="pmcid">PMC4429634</pub-id></element-citation></ref><ref id="bib279"><label>279</label><element-citation publication-type="journal" id="sref279"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Hydrogel local drug delivery systems for postsurgical management of tumors: <italic toggle="yes">status Quo</italic> and perspectives</article-title><source>Mater Today Bio</source><volume>29</volume><year>2024</year><object-id pub-id-type="publisher-id">101308</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mtbio.2024.101308</pub-id><pub-id pub-id-type="pmcid">PMC11550774</pub-id><pub-id pub-id-type="pmid">39525397</pub-id></element-citation></ref><ref id="bib280"><label>280</label><element-citation publication-type="journal" id="sref280"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.W.</given-names></name><etal/></person-group><article-title>Reprogramming the tumor microenvironment through second-near-infrared-window photothermal genome editing of PD-L1 mediated by supramolecular gold nanorods for enhanced cancer immunotherapy</article-title><source>Adv Mater</source><volume>33</volume><year>2021</year><object-id pub-id-type="publisher-id">2006003</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202006003</pub-id><pub-id pub-id-type="pmid">33538047</pub-id></element-citation></ref><ref id="bib281"><label>281</label><element-citation publication-type="journal" id="sref281"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>X.M.</given-names></name><etal/></person-group><article-title>Dual-enzyme decorated semiconducting polymer nanoagents for second near-infrared photoactivatable ferroptosis-immunotherapy</article-title><source>Mater Horiz</source><volume>11</volume><year>2024</year><fpage>2406</fpage><lpage>2419</lpage><pub-id pub-id-type="pmid">38440840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3mh01844j</pub-id></element-citation></ref><ref id="bib282"><label>282</label><element-citation publication-type="journal" id="sref282"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>I.-C.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name></person-group><article-title>Light-triggered photodynamic nanomedicines for overcoming localized therapeutic efficacy in cancer treatment</article-title><source>Adv Drug Deliv Rev</source><volume>186</volume><year>2022</year><object-id pub-id-type="publisher-id">114344</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2022.114344</pub-id><pub-id pub-id-type="pmid">35580813</pub-id></element-citation></ref><ref id="bib283"><label>283</label><element-citation publication-type="journal" id="sref283"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>A NRF2 regulated and the immunosuppressive microenvironment reversed nanoplatform for cholangiocarcinoma photodynamic-gas therapy</article-title><source>Adv Sci</source><volume>11</volume><year>2024</year><object-id pub-id-type="publisher-id">2307143</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202307143</pub-id><pub-id pub-id-type="pmcid">PMC11005733</pub-id><pub-id pub-id-type="pmid">38308097</pub-id></element-citation></ref><ref id="bib284"><label>284</label><element-citation publication-type="journal" id="sref284"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A pH responsive nanocomposite for combination sonodynamic-immunotherapy with ferroptosis and calcium ion overload <italic toggle="yes">via</italic> SLC7A11/ACSL4/LPCAT3 pathway</article-title><source>Explorations</source><volume>5</volume><year>2025</year><object-id pub-id-type="publisher-id">20240002</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/EXP.20240002</pub-id><pub-id pub-id-type="pmcid">PMC11875445</pub-id><pub-id pub-id-type="pmid">40040833</pub-id></element-citation></ref><ref id="bib285"><label>285</label><element-citation publication-type="journal" id="sref285"><person-group person-group-type="author"><name name-style="western"><surname>Che</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>B.O.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>S.I.</given-names></name></person-group><article-title>Protective effects of grape stem extract against UVB-induced damage in C57BL mice skin</article-title><source>J Photochem Photobiol, B</source><volume>173</volume><year>2017</year><fpage>551</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">28697472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jphotobiol.2017.06.042</pub-id></element-citation></ref><ref id="bib286"><label>286</label><element-citation publication-type="journal" id="sref286"><person-group person-group-type="author"><name name-style="western"><surname>Kielbassa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roza</surname><given-names>L.</given-names></name><name name-style="western"><surname>Epe</surname><given-names>B.</given-names></name></person-group><article-title>Wavelength dependence of oxidative DNA damage induced by UV and visible light</article-title><source>Carcinogenesis</source><volume>18</volume><year>1997</year><fpage>811</fpage><lpage>816</lpage><pub-id pub-id-type="pmid">9111219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/18.4.811</pub-id></element-citation></ref><ref id="bib287"><label>287</label><element-citation publication-type="journal" id="sref287"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name></person-group><article-title>Optimizing photosensitizers with type I and type II ROS generation through modulating triplet lifetime and intersystem crossing efficiency</article-title><source>Adv Funct Mater</source><volume>35</volume><year>2025</year><object-id pub-id-type="publisher-id">2414542</object-id></element-citation></ref><ref id="bib288"><label>288</label><element-citation publication-type="journal" id="sref288"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Hanyu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Nagatsu</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Marriage of black phosphorus and Cu<sup>2+</sup> as effective photothermal agents for PET-guided combination cancer therapy</article-title><source>Nat Commun</source><volume>11</volume><year>2020</year><fpage>2778</fpage><pub-id pub-id-type="pmid">32513979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-16513-0</pub-id><pub-id pub-id-type="pmcid">PMC7280494</pub-id></element-citation></ref><ref id="bib289"><label>289</label><element-citation publication-type="journal" id="sref289"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Blue light-triggered Fe<sup>2+</sup>-release from monodispersed ferrihydrite nanoparticles for cancer iron therapy</article-title><source>Biomaterials</source><volume>271</volume><year>2021</year><object-id pub-id-type="publisher-id">120739</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.120739</pub-id><pub-id pub-id-type="pmid">33690102</pub-id></element-citation></ref><ref id="bib290"><label>290</label><element-citation publication-type="journal" id="sref290"><person-group person-group-type="author"><name name-style="western"><surname>Tenopoulou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kurz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Doulias</surname><given-names>P.-T.</given-names></name><name name-style="western"><surname>Galaris</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brunk</surname><given-names>U.T.</given-names></name></person-group><article-title>Does the calcein-AM method assay the total cellular &#8216;labile iron pool&#8217;or only a fraction of it?</article-title><source>Biochem J</source><volume>403</volume><year>2007</year><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">17233627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BJ20061840</pub-id><pub-id pub-id-type="pmcid">PMC1874234</pub-id></element-citation></ref><ref id="bib291"><label>291</label><element-citation publication-type="journal" id="sref291"><person-group person-group-type="author"><name name-style="western"><surname>Tyurin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Balasubramanian</surname><given-names>K.</given-names></name><name name-style="western"><surname>Winnica</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tyurina</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Vikulina</surname><given-names>A.</given-names></name><name name-style="western"><surname>He</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic &#8216;eat-me&#8217; signals: cleavage and inhibition of phagocytosis by Lp-PLA2</article-title><source>Cell Death Differ</source><volume>21</volume><year>2014</year><fpage>825</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">24464221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cdd.2014.1</pub-id><pub-id pub-id-type="pmcid">PMC3978307</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p id="p0460">This work was supported by <funding-source id="gs1">National Natural Science Foundation of China</funding-source> (No. <award-id award-type="grant" rid="gs1">82073774</award-id>), <funding-source id="gs2">Science and Technology Projects in Guangzhou</funding-source> (No. <award-id award-type="grant" rid="gs2">202102070001</award-id>), <funding-source id="gs3">Jinan University Scientific and Technological Association Youth Science and Technology Talent Cultivation Program</funding-source> (No. <award-id award-type="grant" rid="gs3">21624223</award-id>, China), &#8220;Master Mentor Plan&#8221; of <funding-source id="gs4">Jinan University</funding-source> (No. <award-id award-type="grant" rid="gs4">YDXS2406</award-id>), the Outstanding Innovative Talents Cultivation Funded Programs for Doctoral Students of <funding-source id="gs5">Jinan University</funding-source> (No. <award-id award-type="grant" rid="gs5">2024CXB026</award-id>, China) and Special Funds for the <funding-source id="gs6">Cultivation of Guangdong College Students' Scientific and Technological Innovation</funding-source> (&#8220;Climbing Program&#8221; Special Funds) (No. <award-id award-type="grant" rid="gs6">pdjh2025bk037</award-id>, China).</p></ack><fn-group><fn id="d36e794"><p id="ntpara0010a">Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.</p></fn></fn-group></back></article></pmc-articleset>